Clinical Development
CTL019
Oncology Clinical Trial Protocol CCTL019C2201 / [STUDY_ID_REMOVED]
A phase II, single arm, multicenter trial to determine the 
efficac y and safety of CTL019 in adult patients w ith 
relapsed or refractor y diffuse large B -cell ly mphoma 
(DLBCL)
Document type Amended Protocol Version
EUDRACT number 2014 -003060 -20
Version number 06 (Clean )
Development phase II
Document status Final
Release date 15-Apr-2021
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis

Novartis Confidential Page 2
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 7
List of figures ...................................................................................................................... 8
List of abbreviations ............................................................................................................ 9
Glossary  of terms ............................................................................................................... 14
Amendment 6 (15 -Apr-2021) ............................................................................................ 15
Summary  of previous amendments ................................................................................... 18
Protocol summary :
............................................................................................................. 38
1Background ........................................................................................................................ 44
1.1 Overview of disease pathogenesis, epidemiology
 and current treatment .............. 44
1.1.1 Historical experie nce with retroviral gene therapies ............................. 45
1.2 Introduction to investigational treatment(s) and other study  treatment(s) ............. 47
1.2.1 Overview of CTL019 ............................................................................ 47
2Rationale ............................................................................................................................ 52
2.1 Study  rationale and purpose ................................................................................... 52
2.2 Rationale for the stud y design ................................ ................................ ............... 54
2.2.1 Rationale for l ymphodepletion .............................................................. 56
2.3 Rationale for dose and regimen selection .............................................................. 56
2.4
Rationale for choice of combination drugs............................................................ 58
2.5 Rationale for choice of comparators drugs ............................................................ 59
3Objectives and endpoints ................................................................................................... 59
4Study  design ...................................................................................................................... 63
4.1 Description of stud y design ................................................................................... 63
4.1.1
Leukapheresis assessment..................................................................... 64
4.2 Definition of end of the study ................................................................................ 65
4.3 Early study termination .......................................................................................... 65
5Population .......................................................................................................................... 66
5.1 Patient population .................................................................................................. 66
5.2 Inclusion criteria .................................................................................................... 66
5.3 Exclusion criteria ................................................................................................... 68
6Treatment ........................................................................................................................... 69
6.1 Study  treatment ...................................................................................................... 69
6.1.1 Dosing regimen ..................................................................................... 70
6.1.2 Ancillary  treatments .............................................................................. 74
6.1.3
Rescue medication ................................................................................ 74

Novartis Confidential Page 3
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
6.1.4 Guidelines for continuation of treatment .............................................. 74
6.1.5 Treatment duration ................................................................................ 74
6.2 Dose escalation guidelines ..................................................................................... 74
6.2.1 Starting dose rationale ........................................................................... 74
6.2.2 Provisional dose levels .......................................................................... 75
6.2.3
Guidelines for dose escalation and determination of 
MTD/RP2D/RDE ................................ ................................ .................. 75
6.2.4 Definitions of dose limiting toxicities (DL Ts) in a phase II study .......75
6.2.5 Criteria for dis continuing a patient’s participa tionin the study............. 85
6.2.6 Concomitant Therap y............................................................................ 85
6.2.7 Prohibited concomitant therap y
............................................................ 86
6.3 Dose modifications ................................................................................................ 87
6.3.1 Dose modification and dose delay ........................................................ 87
6.3.2 Follow -up for toxicities ......................................................................... 87
6.4 Patient numbering, treatment assignment or randomization ................................. 89
6.4.1
Patient numbering ................................................................................. 89
6.4.2 Treatment assignment ........................................................................... 90
6.4.3 Treatment blinding ................................................................................ 90
90
91
91
91
92
7
Visit schedule and assessments ......................................................................................... 92
7.1 Study  flow and 
visit schedule ................................................................................ 92
7.1.1 Screening phase ................................................................................... 109
7.1.2 Pre-
treatment phase............................................................................. 111
7.1.3 Treatment and primary  follow -up phase ............................................. 112
7.1.4 Secondary  follow -up phase ................................ ................................ .117
7.1.5 Survival follow -up phase .................................................................... 118
7.1.6 Long -term fo llow-
up........................................................................... 118
7.1.7 Discontinuation of study  treatment ..................................................... 118
7.1.8 Withdrawal of consent ........................................................................ 118
7.1.9 Follow up for safet y evaluations ......................................................... 119
7.1.10 Lost to follow -
up................................................................................. 119
7.2 Assessment ty pes................................................................................................. 119

Novartis Confidential Page 4
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
7.2.1 Efficacy  assessments ........................................................................... 119
7.2.2 Safety  and tolerability  assessments ..................................................... 121
7.2.3 Cellular Kinetics and Pharmacokinetics ............................................. 125
131
133
134
134
8Safety  monitoring and reporting ...................................................................................... 136
8.1 Adverse events ..................................................................................................... 136
8.1.1
Definitions........................................................................................... 136
8.1.2
Reporting............................................................................................. 136
8.1.3 Laboratory  test abnormalities .............................................................. 138
8.1.4
Adverse events of special interest....................................................... 139
8.2 Serious adverse events ......................................................................................... 139
8.2.1
Definitions........................................................................................... 139
8.2.2
Reporting............................................................................................. 139
8.3 Emergency  unblinding of treatment assignment ................................................. 142
8.4 Contraception ....................................................................................................... 142
8.5 Pregnancies .......................................................................................................... 143
8.6 Warnings and precautions .................................................................................... 143
8.7 Data Monitoring Committee ................................................................................ 143
8.8 Steering Committee ............................................................................................. 144
8.9 Independent Review Committee (I RC)............................................................... 144
8.10 Follow -up of Secondary  Malignancy .................................................................. 144
9Data collection and management ..................................................................................... 145
9.1 Data confidentiality ............................................................................................. 145
9.2 Site monitoring .................................................................................................... 145
9.3
Data collection..................................................................................................... 146
9.4 Database management and quality  control .......................................................... 146
10Statistical methods and data anal ysis.............................................................................. 146
10.1 Analy sis sets ........................................................................................................ 146
10.1.1 Screened Set ........................................................................................ 147
10.1.2 Enrolled Set ......................................................................................... 147
10.1.3 Full Anal ysis Set ................................................................................. 147
10.1.4 Safety  Set
............................................................................................ 147

Novartis Confidential Page 5
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
10.1.5 Per- Protocol Set ................................ ................................ .................. 147
10.1.6 Pharmacokinetic anal ysis set............................................................... 147
10.2 Patient demographics/other baseline characteristics ........................................... 148
10.3 Treatments (stud y treatment, concom itant therapies, compliance) ..................... 148
10.4 Primary  objective ................................................................................................. 148
10.4.1 Variabl e
............................................................................................... 148
10.4.2 Statistical hy pothesis, model, and method of analy sis........................ 151
10.4.3 Handling of missing values/censoring/discontinuations ..................... 151
10.4.4 Supportive analy ses............................................................................. 151
10.5 Secondary  objectives ........................................................................................... 152
10.5.1 Key secondary  objective(s) ................................................................. 152
10.5.2 Other secondary  efficacy objectives ................................................... 152
10.5.3 Safety  objectives ................................................................................. 154
10.5.4 Pharmacokinetics ................................................................................ 157
158
158
160
160
160
160
161
161
161
10.7 Interim anal ysis.................................................................................................... 161
10.8
Sample size calculation........................................................................................ 162
10.9 Power for anal ysis of key secondary  variables
.................................................... 162
11Ethical considerations and administrative procedures .................................................... 163
11.1 Regulatory
 and ethical compliance ...................................................................... 163
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... 163
11.3 Informed consent procedures ............................................................................... 163
11.4 Discontinuation of the study ................................................................................ 163
11.5 Publication of study  protocol and results ............................................................. 164
11.6 Study  documentation, record keeping and retention of documents
..................... 164
11.7 Confidentiality  of study  documents and patient records ..................................... 165
11.8
Audits and inspections......................................................................................... 165
11.9 Financial disclosures ............................................................................................ 165

Novartis Confidential Page 6
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
12Protocol adherence ................................ ................................ ................................ .......... 165
12.1 Amendments to the protocol ................................................................................ 165
13References (available upon request) ................................................................................ 166
14Appendices ...................................................................................................................... 174
 
174
176
177
180
183
187
193
194
195
14.2 Appendix 2: Eligibility  based on serologi
c markers for hepatitis B infection .... 196
14.3 Appendix 3: CTL 019 modified data reporting – Treatment and Primary  
Follow Up Phase .................................................................................................. 196
14.3.1
Adverse event (AE) and serious adverse event (SAE) reporting........ 197
14.3.2 Concomitant medication an d laboratory  reporting ............................. 198
14.4 Appendix 4: CTL 019 modified data reporting – Secondary  Follow Up Phase ...200
14.5 Appendix 5 : Liver event and Laboratory  trigger Definitions and Follow-up 
Requirements ....................................................................................................... 200
14.5.1 Liver Event and Laboratory  Trigger Definitions ................................ 200
14.5.2 Follow Up Requirements for L iver Laboratory  Triggers -ALT, 
AST, TBL ............................................................................................ 201
14.6 Append ix 6: Specific Renal Alert Criteria and Actions and Event Follow -up
....202
14.6.1 Specific Renal Alert Criteria and Actions ........................................... 202
14.6.2 Follow up of renal events .................................................................... 203

Novartis Confidential Page 7
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
List of tables
Table 1-1 Summary  of ongoing human studies as of January  2015 ...................... 52
Table 3-1 Objectives and related endpoints .......................................................... 60
Table 6
-1 CTL 019 therapy  associated grading for cy tokine release s yndrome: 
The Penn Grading Scale for Cy tokine Release S yndrome (PGS -
CRS) ...................................................................................................... 79
Table 6
-2 High dose vasopressor use .................................................................... 80
Table 6
-3 Concomitant medication reporting b y study period .............................. 86
Table 7-1 Primary  visit evaluation sch edule ......................................................... 93
Table 7
-2 Secondary  follow -up visit evaluation schedule (for patients who 
end their primary  follow up before M60) ................................ ........... 107
Table 7
-3 Imaging or disease assessment collection plan ................................... 121
Table 7
-4 ECOG Performance status grade ........................................................ 122
Table 7
-5 Local clinical laboratory  parameters collection plan .......................... 123
Table 7-6 Central clinical laboratory  parameters collection plan ........................ 123
Table 7-7 CTL 019 pharmacokinetics by  q-PCR in peripheral blood collection 
log................................ ................................ ................................ ........ 125
Table 7-8 CTL 019 pharmacokinetics by  flow cytometry  in peripheral blood 
collection log....................................................................................... 126
Table 7
-9 CTL 019 pharmacokinetics by q-PCR in bone marrow aspirate 
collection log....................................................................................... 127
Table 7
-10 CTL 019 pharmacokinetics by  flow cytometry  in bone marrow 
aspirate collection log ......................................................................... 127
Table 7
-11 CTL 019 pharmacokinetics by  q-PCR in CSF biopsy  or other tissue 
log........................................................................................................ 128
Table 7
-12 Immunogenicit y serum sample collection log .................................... 128
Table 7
-13 Imm unogenicit y whole blood sample collection log .......................... 128
Table 7-14  CTL 019 Pharmacokinetics (PK),  in 
treated patients during CRS ............................................. 129
Table 7
-15  CTL 019 PK  in reated 
patients during CRS ................................ ................................ ............ 130
131
131
133
Table 10-1 Overall response assessment ............................................................... 149
Table 10
-2 Noncompartmental pharmacokinetic parameters ................................ 157
Table 10-3 Simulated scenarios for i nterim and final analy sis............................. 162
176

Novartis Confidential Page 8
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
177
184
191
192
List of figures
Figure 1 -1 CTL 019 chimeric antigen receptor design............................................ 48
Figure 2 -
1 Mechanisms of actions of rituximab, ibrutinib and CTL 019 in B 
lymphocy tes:......................................................................................... 53
Figure 2 -
2 Expected flow of patients in CTL 019C2201 ........................................ 55
Figure 4 -
1 CTL 019C2201 study  design ................................................................. 64
Figure 6 -
1 CRS Management Algorithm................................................................ 78

Novartis Confidential Page 9
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
List of abbreviations
ABC Activated B -cell
ADCC Antibody -dependent cell -mediated cytotoxicity
AE Adverse Event
AESI Adverse events of special interest
ALC Absolute Lymphocyte Count
ALL Acute Lymphoblastic Leukemia
ALT Alanine aminotransferase/glutamic pyruvic transaminase/SGPT
aPTT Activated partial thromboplastin time
ASH American Society of Hematology
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/SGOT
ATC Anatomical Therapeutic Chemical
ATG Anti-Thymocyte Globulin
AUC Area Under the Curve
BCR B cell receptor
BiPAP Bilateral Positive Airway Pressure
BTK Bruton’s Tyrosine kinase
BUN Blood Urea Nitrogen
CAR Chimeric antigen receptor
CBC Complete Blood Count
CCG CRF Completion Guidelines
CD19 CART CD 19 redirected autologous T cells
CFR Code of Federal Regulations
CGD Chronic granulomatous disease
CGTU Cell and Gene Therapies Unit
CI Confidence Interval
CIF Cumulative incidence function
Clast Last observable concentration
CLL Chronic Lymphocytic Leukemia
cm Centimeter
Cmax Maximum concentration
CMR Complete Metabolic Response
CMV Cytomegalovirus
CNS Central Nervous System
CPAP Continuous Positive Airway Pressure
CR Complete Response
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
CRS Cytokine Release Syndrome
CSF Cerebral spinal fluid
CSP Clinical Study Protocol
CSR Clinical Study Report
CT Computed tomography
CTC Common toxicity criteria

Novartis Confidential Page 10
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
CTCAE Common Terminology Criteria for Adverse Events
CTL Cytotoxic T -lymphocyte
CVPF Cell and Vaccine Production Facility
DFS Disease free survival
DLBCL Diffuse large B- cell lymphoma
DLT Dose Limiting Toxicity
DMC Data monitoring committee
DNA Deoxyribonucleic acid
DOR Duration of Response
DS&E Drug Safety and Epidemiology
EBV Epstein -Barr Virus
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic case report form
EDC Electronic data capture
EFS Event free survival
eGFR Estimated Glomerular Filtration Rate
EMA European Medicines Agency
ESMO European Society for Medical Oncology
FAS Full analysis set
FDA Food & Drug Administration
FDG Fluorodeoxyglucose
FFP Fresh frozen plasma
FISH Fluorescence in situ hybridization
FL Follicular Lymphoma
FLOW Flowcytometry
FPFV First Patient First Visit
GC Germinal center- like
GCP Good Clinical Practice
G-CSF Granulocyte colony stimulating factor
GI Gastrointestinal
GM-CSF Granulocyte macrophage -colony stimulating factor
GVHD Graft versus Host Disease
HA Health Authority
HBcAb Hepatitis B core Antibody
HBsAb Hepatitis B surface Antibody
HBsAg Hepatitis B surface Antigen
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HIPAA Health Insurance Portability and Accountability Act
HIV Human immunodeficiency virus
HRQoL Health Relates Quality of Life
HSCT Hematopoietic stem cell transplantation (refers to both allogenic SCT and autologous SCT)
i.v. Intravenous(ly)

Novartis Confidential Page 11
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
IB Investigator Brochure
ICF Informed consent form
ICH International Conference on Harmonization
ICU Intensive Care Unit
IEC Independent Ethics Committee
Ig Immunoglobulin
IHC Immunohistochemistry
IN Investigator Notification
INR International Normalized Ratio
IPI International Prognostic Index
IRB Institutional Review Board
IRC Independent Review Committee
IRT Interactive Response Technology
IUD Intrauterine Device
IWRS Interactive W eb Response System
JCV John Cunningham Virus
kg Kilogram
KM Kaplan Meier
LDH Lactate dehydrogenase
LDi Longest transverse diameter of a lesion
LFT Liver function tests
LLOQ Lower Limit of Quantification
LOQ Limit of Quantification
LPLV Last Patient Last Visit
LSS Lymphoma specific survival
LTFU Long Term Follow Up
LTR Long terminal repeat
LVEF Left Ventricular Ejection Fraction
MAP Master Analysis Plan
MAS Macrophage Activation Syndrome
MCHC Mean Corpuscular Hemoglobin Concentration
MCL Mantle Cell Lymphoma
MCV Mean Corpuscular Volume
MedDRA Medical Dictionary for Regulatory Authorities
MHC Major histocompatibility complex
mL milliliter
MNC Mononuclear cell
MRI Magnetic Resonance Imaging 
mRNA Messenger RNA
MTD Maximum Tolerated Dose
MUGA Multiple Uptake Gated Acquisition
NCCN National Comprehensive Cancer Network
NE Norepinephrine Equivalent

Novartis Confidential Page 12
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
NHL Non-Hodgkin’s Lymphoma
NK Natural Killer cell
NMR No Metabolic Response
NOS Not otherwise specified
O2 Oxygen
ORR Overall Response Rate
OS Overall Survival
PAS Pharmacokinetic analysis set
PCR Polymerase Chain Reaction
PD Progressive disease
PD Pharmacodynamics
PE Physical Examination
PET Positron emission tomography
PFS Progression Free Survival
PGS -CRS The Penn Grading Scale for Cytokine Release Syndrome
PHI Protected Health Information
PI3K Phosphoinositide 3 -kinase
PK Pharmacokinetics
PMBCL Primary mediastinal large cell lymphoma
PMD Progressive Metabolic Disease
PML Progressive Multifocal Leukoencephalopathy
PPD Product of Perpendicular Diameters
PPS Per Protocol Set
PR Partial Response
PT Preferred Term
PT Prothrombin time
PTLD Post-transplant lymphoproliferative disorders
qPCR Quantitative Polymerase Chain Reaction
r/r Relapsed or refractory
RAP Report and Analysis Plan
RCL Replication competent lentivirus
RCR Replication competent retrovirus
RD Relapsed Disease
RDE Recommended dose for expansion
REB Research Ethics Board
RNA Ribonucleic acid
RP2D Recommended phase two dose 
SAE Serious Adverse Event
SC Steering Committee
scFv Single chain variable fragment
SCID-X1 X-linked Severe Combined Immunodeficiency
SCT Stem cell transplantation
SD Stable Disease
SDi Shortest axis perpendicular to LDi

Novartis Confidential Page 13
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
SGOT Serum glutamic -oxaloacetic transaminase
SGPT Serum glutamic -pyruvic transaminase
SOC System Organ Class
SPD Sum of the product of the diameters
SUSAR Suspected unexpected serious adverse reactions
SUV Standard Uptake Value
TCR T cell receptors
Tlast Time of last observable concentration
TLS Tumor lysis syndrome
Tmax Time to peak concentration
TNC Total nucleated cells
TNF Tumor Necrosis Factor
TTF Time to treatment failure
TTP Time to progression
TTR Time to Response
ULN Upper Limit of Normal
ULOQ Upper Limit of Quantification
UNK Unknown
UPENN University of Pennsylvania
VASST Vasopressin and Septic Shock Trial
VH Heavy Chain Variable Domain
VL Light Chain Variable Domain
VSV-G Vesicular Stomatitis Virus, Glycoprotein
WAS Wiskott -Aldrich syndrome
WBC White blood cells
WHO World Health Organization
WOCBP Women of child bearing potential

Novartis Confidential Page 14
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biologic Samples A biological specimen including, for example, blood (plasma, serum), saliva, 
tissue, urine, stool, etc. taken from a study subject or patient
Cohort A group of newly enrolled patients treated at a specific dose and regimen 
(i.e.treatment group) at the same time
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Final Enrollment Point/time of patient entry into the study when the following have been confirmed:
A.ICF signed
B.Local patient elig ibility confirmed
C.Apheresis product reviewed and accepted for manufacturing
Investigational drug The study treatment whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is synonymous with 
“inve stigational new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indication/ap proved dosage, or that are 
tested in a fixed combination. Investigational treatment generally does not include 
other study treatments administered as concomitant background therapy required 
or allowed by the protocol when used in within approved indication /dosage
MAP Master analysis plan documents project standards in the statistical methods which 
will be used within the individual clinical trial RAP documentation
Subject Number A unique identifying number assigned to each subject who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional 
segments such as screening, baseline, titration, washout, etc.
Premature patient 
withdrawalPoint/time when the patient exits from the study prior to the planned completi on of 
all study treatment administration and/or assessments; at this time all study 
treatment administration is discontinued and no further assessments are planned, 
unless the patient will be followed for progression and/or survival
RAP Report and analysi s plan is a regulatory document which provides evidence of 
preplanned analyses
Stage related to study 
timelineA major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatmen t, etc.
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient (subject) as part of the required study procedures, including
lymphodepleting chemotherapy.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatment combination; study treatme nt in this case 
refers to the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when a patient permanently stops taking study treatment for any 
reason
Variable Identifier used in the data analys is; derived directly or indirectly from data 
collected using specified assessments at specified timepoints
Withdrawal of Consent Withdrawal of consent occurs only when a patient does not want to participate in 
the study any longer, and does not want any further visits or assessments, and 
does not want any further study related contact

Novartis Confidential Page 15
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Amendment 6 (15 -Apr-2021)
Amendment Rationale 
At the time of this amendment, enrollment to the Main Cohort and Cohort A has been completed. 
A total of 167 patients were enrolled in the study  and 115 patients were infused with CTL019 
(99 patients infused in the Main Cohort and 16 patients infused in Cohort A). The last patient 
was infused on 20 -Feb-2018.
As of April 15th, 2021, there are 24 patients on study  in the treatme nt and primary  follow -up 
phase; there are 8 patients on study  in the secondary  follow -up phase; and there are 3patients 
in Survival Follow -up. The rest of the patients are off-study . This amendment 6 will apply  to 
all countries that still have patients on study  and in survival follow -up.
The main purpose of this amendment is to:
Change the required follow -
up time of a newborn after live birth from 6 months to 12 
months following pregnancy  of a female patient or the partner of any male patient. This 
additional safet y monitoring is not due to any new safet y concern or emerging data, but is 
taken on a precautionary  basis and aligns with current Novartis internal guidelines.
Update t he protocol safety  language to reflect the current Novartis CTL019 progr am safet y 
language; this includes updates to the Potential Toxi cities S ection as well as updates to the 
highl y effective contraceptive methods in a newly  added Contraception Section. Some of 
the changes to the Toxicity Section include deletion of Febrile neutropenia, and addition of 
neurological adverse reactions, viral reactivation, hematological disorders including 
cytopenias and other changes.
Add the requirement for urine or serum pregnancy  testing at 
allstudy  visits to align with 
standard CTL019 moni toring requirements .Changes to the Visit Evaluation Schedule have 
been made starting at Month 30 and after because all remaining patients are past Month 30 
follow -up.
Add language about secondary  malignancies and follow up to align with the CTL019 
program standard language.
Specify  that blood samples for RCL  testing are banked beyond month 12, as long as all 
samples through Month 12 were negative .
Given that enrollment is complete, no changes have been made to the inclusion/exclusion 
criteria , the cytokine release syndrome (CRS) management algorithm and CRS grading scale . 
Changes to the Visit Evaluation Schedule have been made starting at Month 30 and after 
because all remai ning patients are past Month 30 follow -up. The only change to the Visit 
Evaluation Schedule is addition of serum or urine pregnancy  testing. The contraceptive methods 
included for WOCBP & males in the inclusion criteria are obsolete and are replaced by those 
outlined in the newly  added Contraception section .

Novartis Confidential Page 16
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions .
Section 6.2.4.2 General toxicity  management considerations : The following sent ence has been 
added: Patients treated with CTL 019should not donate blood, organs, tissues, sperm, oocy tes 
and cells.
Section 6.2.4.2.1 Expected Toxicities: This section has been updated as per the most updated 
standard program safety language . Febrile Reaction has been deleted. Neurological Adverse 
Reactions, Viral Reactivation and Hematological disorders including cytopenias have 
been 
added.
Section 6.2.4.2.2 Potential Toxicities: This section has been updated as per the most updated 
standard p
rogram s afety language.
Section 6.3.2.1 Liver safety  monitoring : Table 6-4 and 6-5 have been deleted and replaced by 
Appendix 5 which contains updated information based on standard program safet y language.
Section 6.3.2.2 Follow up on potential drug -induced liver inj ury (DILI) cases : This section has 
been added based on standard program safet y language .
Section 6.3.2.3 Renal safet y monitoring : This section has been added based on standard 
program s afety language .
Section 6.3.3 Anticipated risks and safet y concerns :This section has been deleted.
Table 7.1 Pri mary  Visit Evaluation Schedule : Serum or urine pregnancy testing has been added 
in the Treatment and Primary  Follow -up Phase and in the Secondary Follow -up Phase as per 
standard program safety language. Pregnanci es has also been added to the Treatment and 
Primary  Follow -up Phase. Changes to the Visit Evaluation Schedule have been made starting 
at Month 30 and after because all remaining patients are past Month 30 follow -up.
Section 7.1.3 Treatment and primary  follow -up phase : Section has been updated to reflect the 
addition of urine or serum pregnancy testing added at M30, M36, M42, M48, and M54.
Section 7.1.3.1 End of treatment and primary  follow -up (EOT) visit (M60 ±14d) including 
premature withdrawal : Secti on has been updated to reflect the addition of serum pregnancy 
testing added at M60.
Section 7.1.4 Secondary  follow -up phase : Section has been updated to reflect the addition of 
urine or serum pregnancy  testing added atM30, M36, M42, M48, and M54. Section has been 
updated to reflect the addition of serum pregnancy testing at M60.
Table 7.5Local clinical laboratory  parameters collection plan: Updated urine and serum 
pregnancy  testing requirement per standard program safet y language.
Table 7.7CTL019 pharmacokinetics by q-PCR in peripheral blood collection log: A note has 
been added to clarify  that if RCL  blood samples test are negative through Month 12, all samples 
taken after Month 12 will be stored for potential future testing.
Section 8.1.2 Report ing: The following statement has been deleted: infections: defined as 
bacterial, viral, fungal, or parasitic.

Novartis Confidential Page 17
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 8.2.1 Definitions of SAEs : Section updated to add that All malignant neoplasms 
(secondary  malignancies, not disease progression of the study indication) will be assessed as 
serious under “medicall y significant.”
Section 8.2.2.3 Month 12 to Month 60: The following sentence has been deleted: ‘Defined as 
bacterial, viral, fungal, or parasite infections’.
Section 8.4 Contraception: The Contraception Section has been added. The contraceptive 
measures outlined in this section for WOCBP and sexually  active males are the effective ones 
and they replace those presented in the Inclusion Criteria section. Since enrol lment is complete, 
changes to the inclusion criteria have not been made.
Section 8.5 Pregnancies
: Section updated per standard program safet y language. In case of live 
birth the newborn will be followed up until 12 months of age (and not 6 months). 
Section 8.10 Follow -up of secondary  malignancy  language has been added as per program 
standard language. 
Section 11.3 Informed Consent Procedures :Section has been updated as per program standard 
language. 
Section 14.3.1 The following sentence has been deleted: ‘Defined as bacterial, viral, fu ngal, or 
parasite infections’. 
Appendix 5:Liver event and Laboratory  trigger Definitions and Follow -up Requirements : 
Appendix 5 has been added with the most updated Liver event and Laboratory  trigger 
Definitions and Follow -up Requirements
Appendix 6: Specific Renal Alert Criteria and Actions and Event Follow -up: Appendix 6 has 
been added with the most updated Specific Renal Alert Criteria and Actions and Event Follow -
up
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities , where required .
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation .

Novartis Confidential Page 18
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Summary  of previous amendments
Amendment 5 (09 -Mar-2017)
Amendment rati onale
At the time of this amendment, 144 patients have been enrolled and 95 patients have been 
treated (92 patients treated in the main cohort (US manufacturing) and 3 patients treated in 
cohort A (EU manufacturing)). Screening and enrollment to the main cohort was completed. 
Japanese patients are enrolled only in the main cohort. At the time of enrollment completion in 
the main cohort, there were 3 Japanese patients enrolled, treated and they are in primary  follow -
up.
A minimum of 9 Japanese patients must be treated in the study , in order to evaluate the safety 
and efficacy  of CTL019 in the Japanese patient population. This number of Japanese patients 
is not based on statistical considerations. It will allow the generation of a reasonable data 
package to su pport a marketing authorization for CTL 019 in Japan. Consequently  the protocol 
is amended in order to allow the enrollment of additional Japanese patients.
With this amendment 5, approximately  10 additional Japanese patients will be enrolled in the 
main cohort to allow at least 6 additional patients to be treated to ensure a minimum of 9 and 
maximum of 13 Japanese patients treated with CTL 019. The additional Japanese patients will 
be infused with CTL019 manufactured at the Novartis manufacturing facility  inMorris Plains, 
USA.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions .
Protocol summary  was updated to be consistent with other sections of the document.
Section 2.2 Rationale for the study  design: Approximately  10 Japanese patients will beadded 
to the pr evious population, in order to have at least 6 patients treated.
Section 4.1 Description of study  design: The description has been updated to include the 
additional Japanese patients.
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities , where required .
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation only in Japan.

Novartis Confidential Page 19
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Amendment 4 (07 -Jul-2016)
Amendment rationale
At the time of this amendment, 72 patients have been enrolled and 29patients have been treated.
The study  has been amended to use PET-CT at baseline and month 3 for primary  analysis of 
response. PET-CT at these time points had already  been part of the protocol. With the wide 
acceptance of metabolic imaging using FDG -PET for staging and response asses sment of 
lymphomas and the recommendations by the International Malignant Lym phomas Imaging 
Working Group (Cheson et al 2014) t his change is considered to improve the diagnostic qualit y 
and clinical meaningfulness of the endpoint of ORR in this trial. I n the proof of concept study 
performed at the University  of Penns ylvania metabolic response at month 1 and month 3 
correlated with duration of response .Novartis has revi sed 
its guideline for efficacy evaluation in DLBCL and FLstudies in version 2 to integrate PET, 
accordingl y. No new imaging assessments were introduced as PET-CT at baseline and at Month 
3 was alread y implemented in the original protocol.
Under the protoc olversion 03,
patients with manufactured cell numbers falling below the target 
dose and acceptable dose ranges for this study  were eligible to receive CTL019 therapy  if the 
product meets all other manufacturing release criteria. Preliminary  dose expansion analy ses 
suggest that these very low doses show only minimal in vivo expansion and patients are very 
unlikely  to derive clinical benefit. Consequently , CTL019 doses lower than the protocol 
specified range will no longer be releas ed.
One additional study  cohort was added :
Cohort A aims to assess efficacy  and safet y and characterize the invivo cellular PK profile
ofCTL 019 manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, German y
.
The CRS treatment algorithm was up dated with additional details to support trial investigators 
on appropriate CRS management .
In addition several clarifications have been implemented to ensure protocol adherence.
The changes implemented in this amendment are not impacting the study  population of the trial.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Protocol summary  was updated to be consistent with other sections of the document.
Section 2.2 Rationale for the study  design: One cohort hasbeen added to the previous 
population (main cohort) to assess the clinical profile of CTL019 manufactured at Fraunhofer 
Institut für Zelltherapie .
Table 3 -1 Objective and related endpoints: Primary  objective was clarified as being applicable 
for the main study  cohort only .
Table 3-1 Objectives and related endpoints: PK parameters were updated for the 
characterization of the in vivo cellular PK profile.

Novartis Confidential Page 20
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 3-1 Objectives and related endpoints: Objectives and endpoints have been added for the 
new cohort.
 
 
 
 
 
Section 4.1 Desc ription of study  design: Reference to the response guidance was updated to 
refer to the and the section was updated according to the .
Section 4.1 Description of study  design: Clarification was made that the treatment stagger ing 
for new site s is to be considered from infusion rather than from enrollment.
Section 4.1 Description of study design: One cohort ha sbeen added to the previous population 
(main cohort) to assess the clinical profile of CTL019 manufactured at Fraunhofer Institut für 
Zelltherapie .
Section 4.1.1 Leukapheresis assessment: Wording was updated to remove the cryopreserved 
aspect of the leukapheresis and that the product should be accepted for manufacturing before 
shipment to the manufacturing facility .
Section 5.1 Patient population: Figures regarding the patients to be enrolled and treated have 
been moved to the stud y design rationale section (section 2.2).
Section 5.2 Inclusion Criteria: Reference to the Cheson Response Criteria was updated to be 
consistent with other sections of the document.
Section 5.2 I nclusion Criteria: Inclusion criterion 10 language was clarified regarding IUDs
Section 5.2 Inclusion Criteria: Inclusion criterion 11 contraception requirement for male patient 
with sterile female partner w as clarified
Section 5.3 Exclusion criteria: exclusion criterion 7 was further clarified regarding the 
investigational drug washout period.
Section 5.3 Exclusion criteria: exclusion criterion 8 was further clarified regarding the excluded 
medications.
Section 6.1.1 Dosing regimen: CTL 019 product will nolonger be released for infusion if the 
dose is lower than the specified dose range.
Section 
6.1.1.1 Lymphodepleting chemotherapy : Timeframe for the lymphodepleting
chemotherap y in relation to CTL 019 infusion was clarified to be consistent with section 7.1.2.
Section 6.1.1.1 Lymphodepleting chemotherap y: The need for a negative pregnancy  test was 
clarified.

Novartis Confidential Page 21
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 6.1.1.2 CTL 019 Infusion: Criteria for prior therapies that have to be met prior to 
CTL 019 infusion were clarified and rescue medication that should be available at site was 
further specified.
Section 6.1.3 Rescue medication: Rescue medication that should be available at site was further 
specified.
Section 6.2.4.2.1 Expected toxicities: Wording regarding Cytokine Release Syndrome (CRS) 
and CRS Management Algorithm were updated.
Section 6.2.4.2.2 Potential toxicities: Additional information on prevention of hepatitis B 
reactivation was added
Table 6-1 CTL019 therapy  associated grading for cytokine release syndrome: The Penn 
Grading Scale for C ytokine Release S yndrome (PGS -CRS) was updated.
Section 6.2.6 Concomitant Therap y:Data collection for adverse events and concomitant 
medications per stud y period was clarified.
Section 6.2.7 Prohibited concom itant therapy : Wording on excluded medications was clarified 
to be consistent with other sections of the protocol.
Table 6-5Liver Event Follow Up Requirements: Wording was clarified to be consistent with 
study  treatment.
Section 6.4.2 Treatment assignment
: Wording was clarified.
Section 6.5.2 Drug supply  and storage: Reference to the Investigation Product Handling Manual 
was added.
Section 6.5.3 Study  drug compliance and accountability : Reference to the responsible Qualit y 
Department was updated.
Section 6.5.4 Study drug disposal and destruction: Wording regarding unused CTL019 product 
was updated.
Table 7-1Primary  visit evaluation schedule: Lymphodepleting Chemotherapy  visit column 
changed to reflect time window of -W2 to -
D5; IRT Registration was clarif ied to be required at 
infusion instead of pre -infusion; B-symptoms was changed from infusion to lymphodepleting 
chemotherap y visit to align with baseline imaging; Wording was added to clarify  requirements 
for baseline imaging within 4 weeks of infusion; Wording was added to clarify  D28 bone 
marrow biops y onl y needed if CR and prior bone marrow in volvement; Flow cy tometry  before 
leukapheresis and on leukapheresis product changed to central ; Clarification made that 
pregnancy  test prior to lymphodepleting therapy can be urine or serum; Serum immunoglobulin 
added at pre-infusion visit and at end of treatment visit;  
CTL 019 pharmacokinetics by flow cytometry  was 
added at Month 18 and Month 60;  
 
Table 7-2 Secondary  follow -up visit evaluation schedule: Removed mentioning of local 
assessment for flow cytometry  in peripheral blood ; Surviv al follow -up phase was further 
specified as after stud y completion.

Novartis Confidential Page 22
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 7.1.1 Screening phase: Assessments during the screening phase were updated to clarify 
accepted assessments performed during screening for study  CTL019B2206 or performed as part 
of clinical routine.
Section 7.1.1.1 Criteria for repeating screening procedures prior to CTL019 infusion: Criteria 
to repeat screening procedures were clarified.
Section 7.1.1.2 Eligibility  screening and enrollment: Enrollment process was clarified and 
confi rmation of infusion in I RT was added.
Section 7.1.2 Pre-treatment phase: Timing of lymphodepleting chemotherapy  visit was clarified 
and assessments to be performed during this visit were further specified. Baseline PET-CT 
assessment was moved to Lymphodepl eting chemotherap y visit to further stress the assessment 
should be performed as closely  before CTL019 infusion as possible.
Section 7.1.3 Infusion visit (D1): B symptom assessment was removed from the infusion visit 
to align with the baseline imaging asse ssment. Target dose was clarified to be 5 x 108CTL 019 
transduced cells.
Section 7.1.3 Post-infusion visit (D28 ±7d): Bone marrow biops y in patients with CR was 
clarified to be onl y required if the patient had prior bone marrow involvement
Section 7.2.1 Efficacy  Assessments: Reference to the response guidance was updated to refer 
to the .
Section 7.2.1 Efficacy  Assessments: Clarification was made that imaging used to determine 
eligibility  must be submitted to the I RC.
Section 7.2.1 Efficacy  Assessments: Criteria for use of imaging that was taken prior to ICF was 
updated to refer to 8 weeks before screening instead of treatment
Section 7.2.1 Efficacy  Assessments: Clarification was made that imaging used to determine 
eligibility  must be submitt edto the I RC.
Section 
7.2.1 Efficacy  Assessments: Wording was added to allow for imaging assessments to 
be completed at any time due to investigator’s discretion. Recommendation was made to assess 
disease status with PET- CT if progression prior to 3 months
Table 7-3 Imaging or disease assessment collection plan: Wording was updated to allow for 
baseline scan within 4 weeks of CTL019 infusion, without regard to l ymphodepleting therapy
Section 7.2.2.2 Vital Signs: Requirement for triplicate bl ood pressure was removed
Table 7-5 Local laboratory  parameters collection plan: Flow cytometry  of peripheral blood B 
cell and T 
cell levels (secondary  follow -up), and flow cytometry  on peripheral blood and 
leukapheresis product was removed to be added as a central assessment
Table 7-6 Central clinical laboratory  parameters collection plan: Clarification was made that 
flow cytometry  refers to B and T cells. Flow cy tometry  on peripheral blood and leukapheresis 
product was added. Serum immunoglobulin levels wa s added for secondary  follow -
up only
Table 7-7 CTL019 pharmacokinetics by q-PCR in peripheral blood collection log: Clarification 
was made on scheduled time point relative to dosing in order to align with visit evaluation 
schedule . Unscheduled time point a t time of relapse added

Novartis Confidential Page 23
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 7-8 CTL019 pharmacokinetics by flow cytometry  in peripheral blood collection log: 
Clarification was made on scheduled time point relative to dosing in order to align with visit 
evaluation schedule . Unscheduled time point at ti me of relapse added
Table 7-12 Immunogenicity  serum sample collection log: Unscheduled time point at time of 
relapse added
Table 7-13 Immunogenicity  whole blood sample collection log: Unscheduled time point at time 
of relapse added
Table 7-14  CTL019 Pharmacokinetics (PK),  
treated patients during CRS: Additional time point added at D3 after second dose. Time points 
added related to 3rddoses and more
Table 7-15  CTL019 PK  treated patients during 
CRS: New table added
 
 
 
Table 7
-17, Table 7 -18: Table numbers updated due to new table .
 
Section 8.1.2 Reporting : Wording on modified data capture for inpatient/in hospital events
clarified and reference made to new appendices 3 and 4.
Section 8.2.2.4 Post -treatment protocol: SAE reporting procedure was updated.
Section 8.4 Pregnancies: Requirement for male use of contracept ion was added to this section 
as per inclusion criteria 11. L anguage on IUDs was clarified.
Section 10 Statistical methods and data analy sis: Primary  anal ysis clarified to be performed on 
patients in the main cohort and changed from 6 months to 3 months.
Section 10.1.2 Enrolled Set: Wording updated to specify  apheresis product only has to be 
accepted for manufacturing .
Section 10.1.4 Safety  Set: Wording removed stating that the safet y set contains the same 
patients as the full anal ysis set.
Section 10.1.5 P er-Protocol Set: Clarification was made that missing or incomplete 
documentation of disease is referring to baseline assessments. Distinction was made between 
target dose and minimum dose.
Section 10.2 Patient demographics/other baseline characteristics: Updated due to addition of 
new cohort.

Novartis Confidential Page 24
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 10.3 Treatments (study treatment, concomitant therapies, compliance): Updated due to 
addition of new cohort.
Section 10.4 Primary  Objective: Addition of wording to clarify  that the primary  objective is 
related to the main cohort .
Section 10.4.1 Variable: Changes were made to Table 10-1 and the text to describe how to 
incorporate PET into the overall response assessment as per the .
Section 
10.4.3 Handling of missing values/censoring/discontinuatio ns: Updated reference to 
Novartis guideline for efficacy  evaluation in DLBCL and FL studies based on  
.
Section 10.5.2 Other secondary  efficacy  objectives: Updated due to addition of new cohort.
Section 10.5.2.7 Efficacy in cohort A: Se condary  objectives relating to cohort Awere added .
Section 10.5.3.4 Immunogenicity updated to be consistent at program level. Section 10.5.3.6 
Safety  subgroup analysis: Wording was added to clarify  that AEs will also be summarized 
separately for cohort A.
 
Section 10.5.4 Pharmacokinetics: Wording regarding descriptive statistics of key PK 
parameters for cohort A was added .
Table 10-2 Noncompartmental pharmacokinetic parameters updated to be consistent at program 
level.
 
 
Section 
10.7 Interim Analy sis: Wording was updated to specify  that the Interim Anal ysis will 
be performed on patients in the main cohort when approximately  50 patients have received 
CTL 019 infusion and have completed 3 months from study  day 1  infusion or discontinued 
earlier .
Section 10.8 Sample size calculation: Wording was updated to specify  that sample size 
calculation was performed for the main cohort .
Section 14 Appendix 1: Guidelines for efficacy  evaluation in diffuse large B cell lymphoma 
and follicular lymphoma studies (based on Cheson response criteria) were updated to include 
.
Section 14 Appendix 2: Eligibility  based on serologic markers for hepatitis B infection: 
Wording below table was updated for consistency and table was re -ordered for clarit y
Section 14.3 Appendix 3: CTL019 modified data reporting –Treatment and Primary  Follow 
Up Phase was added to provide further guidance.

Novartis Confidential Page 25
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 14.4 Appendix 4: CTL 019 modified data reporting – Secondary  Follow Up Phase was 
added to provide further guidance .
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 26
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Amendment 3 (18-Dec-2015)
Amendment rationale
The PET-CT was specified to be performed within 4 weeks of infusion but prior to start of 
lymphodepleti ngtherapy . During the startup of the trial it became evident that the baseline PET-
CT required at screening may often be too far out from the actual CTL 019 infusion to serve as 
a valid baseline for s
ubsequent response assessments.
In addition, it was clarified that at least one sentinel vial must be shipped together with the 
leukapheresis product .
Changes to the protocol
Protocol summary  was updated to be consistent w ith other sections of the document.
Section 4.1 Description of study  design: Wording was added to clarify  the interpretation of the 
Day 28 imaging assessment.
Section 4.1.1 Leukapheresis assessment: The timing of leukapheresis was clarified and wording 
wasadded regarding shipment of a sample sentinel vial.
Section 5.2 Inclusion criteria: Criterion 8.e. was further specified to define an absolute number 
of CD3+ cells >150/mm3.In addition, a note regarding the apheresis product was removed.
Section 5.3 Exclusion criteria: Therap y mentioned under criterion 8 were further specified or 
removed. Exclusion criterion 18 was removed.
Section 6.1.1.2 CTL019 infusion: Requirements regarding immunosuppressive therapies were 
updated and wording was revised, for consistency.
Figure 6-2Progressive Multifocal Leukoencephalopathy (PML ): diagnosis and treatment: 
Figure was modified to include one box “Infectious disease consultation”.
Section 6.2.4.2.2
Potential toxicities: Wording regarding hepatitis reactivation was updat ed.
Section 6.2.7 Prohibited concomitant therapy : Allowed dose for steroids was updated for 
consistency .
Table 7-1Primary  visit evaluation schedule: Table was updated to move the PET-CT scan from 
screening to prior to start of lymphodepleting therapy ; theallowed interval was added for D4 
and D7 visit; adverse events assessment was updated to be consistent with Section 8.1; HBsAb 
testing was added to viral serology ; CTL 019 pharmacokinetics by flow cytometry  assessm ent 
was added to D1 visit;
Table 7-1Prima ry visit evaluation schedule: Two laboratory  assessments were added. “Flow 
cytometry  before leukapheresis (peripheral blood)” and “flow cytometry  (leukapheresis 
product)”.
Section 7.1.1 Screening phase: HBsAb testing was added to viral serology .
Section 7.1.1 Screening phase: Wording regarding flow cy tometry  was added.
Section 
7.1.1.1 Criteria for repeating screening procedures prior to CTL019 infusion: Criteria 
to repeat screening procedures were clarified.

Novartis Confidential Page 27
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 7.1.2 Pretreatment phase: Wording added r egarding the PET -CT scan to be performed 
within four weeks prior to the scheduled infusion.
Section 7.1.3 Treatment and primary  follow -up phase: Wording was added to clarify  the 
interpretation of the Day  28 imaging assessment .
Section 7.2.1 Efficacy  assessments: Wording was clarified regarding the PET-CT scan to be 
performed within four weeks prior to the scheduled infusion.
Table 7 -3Imaging or disease assessment collection plan: Wording clarified regarding the PET -
CT scan to be performed w ithin four weeks prior to the scheduled infusion.
Section 7.2.2 Safet y and tolerability  assessments: Wording regarding requirements to repeat 
assessments during screening was removed due to duplication.
Table 7-5Local clinical laboratory  parameters collec tion plan: HBsAb assessment was added 
to viral serology .
Table 7-5Local clinical laboratory  parameters collection plan: Flow cytometry  was added as 
additional assessment.
Table 7 -8CTL 019 pharmacokinetics by  flow cy tometry  in peripheral blood collection l og: D1 
assessment was added and PK sample numbers were updated accordingly .
Table 7-14  CTL019 Pharmacokinetics (PK),  
treated patients during CRS : Dose reference ID was added.
Section 
8.2.2.4 Post-treatment protocol: Wording regarding long-term follow -up protocol was 
added for clarification.
Section 10.6.1.2 Data handling of Serum C ytokine Data: Wording was corrected.
Section 13 References: Two referen ces were added.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.

Novartis Confidential Page 28
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Amendment 2 (12-Nov-2015)
Amendment rationale
The protocol was mainly amended to implement clarifications in line with health authority  
feedback and to incorporate recent experience from the Universit y of Pennsy lvania (Penn) study 
CTL 019A2101J/UPCC13413.
The following modifications were implemented in the protocol:
Histological confirmation of relapse b y central pathology  review before enrollment was 
added on health authority request to verify  that patients entering the study  have 
histological relapse
“relapsed/refractory  disease after ≥2 lines of chemotherapy  …” was defi ned as “relapsed 
or refractory  disease after ≥2 lines of chemotherapy , includin g rituximab and 
anthracy cline,” to ensure patients will have received prior standard treatment regimen.
Data generated from clinical samples from stud y CTL 019A2101J/UPCC13413 id
entified 
T cell/histiocyte rich large B cell ly mphoma (THRBCL) as a subpopulation that is 
unlikely  to derive greater benefit from treatment with CTL 019. Therefore, patients with 
THRBCL will be excluded from this trial.
Based on one case of encephalitis in study  UPCC13413/A2101J the DMC of study  
CTL 019 recommended excluding patients with active neurological or inflammatory  or 
auto immune disorders (e.g. Guillain -Barre S yndrome, Amyotrophic Lateral Sclerosis) 
from this trial. This exclusion criterion was adde d accordingl y.
It was clarified that patients with primary  cutaneous large B -cell ly mphoma, primary  
mediastinal B- cell ly mphoma (PMBCL), EBV positive DLBCL of the elderly , Richter’s 
transformation, and Burkitt lymphoma are excluded as they  are considered to be separate 
disease entities.
 
Contraception requirements were also clarified to better define the minimal duration of 
contraception after infusion.
Expected toxicities were updated to provide more detailed recommendations for treatment 
of cytokine release s yndrome
Language regarding liver safet y monitoring was added as per current Novartis standard 
and in order to ensure patients safet y and enhance reliability  in determining the 
hepatotoxic potential of an investigational treatment.
Pharmacokinetics and correlative objectives and endpoints were updated and clarified to 
better define the specific anal ysis  

Novartis Confidential Page 29
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
 
 
In general, the pharmacokinetics sections were split for clarification.
Recommendations on vaccination were added
At time of this amendment seven patients had been enrolled. None of the enrolled patients 
would have been excluded from the trial had the amendment been in place prior to enrollment. 
Thus, the current amendment is not expected to influence the stud y population.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Glossary  of terms: the term “final enrollment” was specified.
Protocol summary  was updated to be consistent with other sections of the document.
Section 1.2.1 Overview of CTL 019: references to the Investigators Brochure were added.
Section 1.2.1.2 Clinical experience: A summary of Clinical Cellular Kinetics (Pharmaco -
kinetics) was added with current data.
Section 2.3 Rationale for dose and regimen selection: Wording was refined for clarification and 
to differentiate between target dose and allowable dose range.
 
Section 4.1 Description of study  design: Study  design was clarified with a more detailed figure.
Section 4.1.1 Apheresis assessment: Apheresis procedure and assessment of apheresis product 
by Novartis manufacturing was clarified.
Section 4.2 Definition of end of the study : Revision of the wording to align within the document.
Section 5 Population: The patient population was clarified based on feedback from Health 
Authorities and data generated from study  CTL019A2101J/UPCC13413; contraception 
requirements were updated.
Section 6.1.1 Dosing regimen: A definition of the target dose and a description of the 
requirements for infusion of doses below the target dose were added.
Section 6.1.1.1 Lymphodepleting chemotherap y: Wording was clar ified.
Section 6.1.1.2 CTL 019 infusion: Requirements for influenza testing and other criteria to be 
met before CTL019 infusion were clarified; requirements for infusion of doses below the target 
dose were added to align within the document.
Section 6.1.3 R escue medication: Rescue medication that should be available at site was further 
specified.

Novartis Confidential Page 30
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 6.2.4.2.1 Expected toxicities: A recommendation for cardiac monitoring during 
management of Cytokine Release Syndrome (CRS) was added, the CRS Management 
Algorithm was updated to provide additional guidance and a recommendation for vaccination 
was added.
Section 6.2.4.2.2 Potential toxicities: Wording was clarified and recommendations on 
hepatitis B reactivation were added .
Section 6.2.7 Prohibited concomitant therapy : time interval for steroids and anti-proliferative 
therapies prior to infusion was clarified.
Section 6.3.2 Follow -up for toxicities: A section for liver safety  monitoring was added.
Section 6.5.1 Study  drug packaging and labeling: Wording was clarified.
Section 6.5.3 Study  drug compliance and accountability : Wording was clarified.
Section 7.1 Study  flow and visit schedule: Columns and assessments in Tables 7-1 and 7-2 were 
clarified.
Table 7-1Primary  visit and evaluation schedule: Wording on Hepatitis B reactivation was 
removed as it was a duplication of Section 
6.2.4.2.2. Lines for Leukapheresis pre-evaluation 
and acceptance,
 sample descriptions for PK
samples were clarified ; HBcAb testing was added to viral serology .
Section 
7.1.1 Screening phase: Assessments to be performed during the screening phase were 
clarified and aligned with other sections of the document and criteria to repeat screening 
procedures prior to CTL019 infusion were aligned with S ection 7 .2.2.
Section 7.1.2 Pre-treatment phase: Wording regarding l ymphodepleting therapy  was clarified.
Section 7.1.3 Treatment and primary  follow -up phase: Requirements to perform a tumor biops y 
were clarified.
Section 7.1.5 Survival follow -up phase: Wording wa s revised for clarification.
Table 7-3 Imaging or disease assessment collection plan: Wording was further specified.
Section 7.2.2.5 Laboratory evaluations: Wording was revised for clarification.
Section 7.2.3 Cellular Kinetics and Pharmacokinetics: Clarifications and updated sample 
numbers were added to sample collection log tables,  
 
Section 8.1.4 Adverse events of special interest: Neurotoxicity  and hepatic events were added 
to the section.
Section 
8.2.2.3 Serious Adverse Event Reporting: Criteria for expedited SAE reporting were 
added.

Novartis Confidential Page 31
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 8.4 Pregnancies: Contraception requirements were updated.
 
Section 10.4.4.1 Subgroup anal ysis: Criteria for subgroup anal yses were clarified.
Section 10.5.2.1 Duration of overall response (DOR): Optional additional data summary  was 
added.
Section 10.5.2.6 Efficacy  in histological and molecular subgroups: subgroup of T-cell 
histiocy tic-rich large B -cell ly mphoma was removed due to exclusion of this subgroup.
Section 10.5.3.4 Immunogenicity : Wording was revised for clarification
Section 10.5.3.6 Safety subgroup analysis: subgroup of T-cell histiocy tic-rich large B-cell 
lymphoma was removed due to exclusion of this subgroup.
Section 10.5.4 Pharmacokinetics: Wording was revised for clarification.
Section 10.6.1 Wording was revised for clarification.
Section 10.6.1.3 Basic Tables, Listings and Figures: Wording was revised for clarification.
 
Section 10.6.4 Efficacy  in sub- populations: EFS was added as endpoint for the anal ysis.
Section 14.1 Guidelines for efficacy  evaluation in DLBCL  and FLstudies: Analy sis of PET 
results was specified.
IRB/I EC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The change s herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 32
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Amendment 1
Amendment rationale
As of February  2015, this study  has not been initiated at any site. The main changes in the 
amendment are as follows:
An interim analy sis was added once the first DLBCL 50 patients have been treated and followed 
up for 6 months. Based on the α-spending function according to Lan-DeMets (O’Brien -
Fleming), if the lower bound of 99.08% exact confidence interval for ORR is greater than 20% 
then statistical significance can be declared. If the predicted probability  of success (i.e., positive 
result at the end of the study) is less than 10% then the study  may  be terminated due to futility .
At the beginning of the trial, a safet y run-in stage will be conducted to enroll at least three 
patients to assess the acute safet y profile and product characteristics of the Novartis 
manufactured 
CTL019 cell p roduct.
 
The inclusion and exclusion criteria have been modified to ensure a homogenous population.
Language in the protocol has been changed to be consisten t with the approved CTL 019 standard 
protocol language and protocol language associated with discontinuation from the clinical trial 
has also been updated .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined font for insertions.
Section 1.2.1 Overview of CTL 019: 2ndparagraph re -written to be consistent with agreed upon 
CTL 019 standard protocol language. Updated reference (Maude et al 2014 ) added
Section 1.2.1.2 Clinical experience: Updated reference (Maude et al 2014 ) added. Table 1-1
Summary  of ongoing human studies, updated with additional information from July 2014 to 
January  2015.
Section 
2.1Study  rationale and purpose: Updated information from the University  of 
Pennsy lvania phase II l ymphoma study  added
Section 2.2 Rationale for the study  design: Bendamustine added as a lymphodepleting 
chemotherap y option for those patients with cyclophospha mide resistance, language added to 
clarify  that patients who either complete or discontinue from the primary  follow -up phase will 
have an End of Treatment and Primary  Follow -Up Visit. L anguage added for which section to 
refer to for more information on expected toxicities. Language added to indicate all patients 
will be asked to consent to the L TFU study . Language added for safet y run -in stage.
Section 2.2.1 Rationale for lymphodepletion: Updated information from ongoing CTL 019 trials 
included in regards to lymphodepleting chemotherap y.
Section 2.3 Rationale for dose regimen and selection: Updated information in regards to 
Cytokine Release Sy ndrome (CRS) and neurologic disturbances added.

Novartis Confidential Page 33
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 3 Objectives and endpoints: Changes have been made to further explain and clarify  the 
intended study  objectives and endpoints in Table 3-1. Evaluate efficacy  and safet y in 
histological and molecular subgroups added as a secondary objective. The secondary objective 
“characterize the in vivo cellular PK profile” has been updated to indicate as summarized by 
clinical response, corresponding endpoint updated for clarification.  
 
 
Specific histological 
subty pes added to secondary  objective analysis.  
 
 
 
 
Section 4.1 Description of study  design: Language added to indicate reason why CT/MRI, PET-
CT have been added to stu dy design. Description of safet y run -in stage added.
 
 
 
Section 4.2 Definition of end of the study : New paragraph added to document that patients who 
discontinue from the primary follow -up phase will continue to be followed in the secondary 
follow -up phase to collect health authority requested data. Language added to indi cate survival 
follow -up can be conducted via a form or b y telephone contact.
Section 4.3 Early study termination: New discontinuation language added to protocol
Section 5.1 Patient population: Clarification to indicate approximately  100 patients enrolled to 
allow for 80 patients to be treated added
Section 5.2 Inclusion criteria: At last relapse removed from inclusion criterion #3 and criterion 
#3 updated to clarify  DLBC L to be histologically  confirmed by local pathology . Allogeneic 
HSCT removed from inclus ion criteria #4. Absolute lymphocy te count (ALC) ≥ 300/mm3added 
to criterion #8. 8a eGFR criterion modified and without transfusion removed from criterion 8e. 
Criterion #9 clarified to indicate must have an apheresis prod uct accepted for manufacturing.
Section 5.3 Exclusion criteria: Histology  other than DLBCL present on biopsy  sample, and 
transformed indolent NHL  or CLL and allogeneic HSCT removed as exclusion criteria. 
Chemotherap y and radiation therapy  exclusion changed from 4 weeks prior to enrollment to 2 
weeks. Language added to clarify  that chemotherapy  other than lymphodepleting chemotherap y 
within 2 weeks of enrollment is an exclusion criterion. Language added to clarify  that HIV 
positive patients are excluded from the stud y.
Section 6.1.1.2 CTL 019 infusion: section modified to be consistent with CTL 019 standard 
protocol language, including criteria to be met prior to infusion, infusion time and what to do 
with unused supplies. Criteria #5 updated to be consistent with DLBCL criteria. Language 

Novartis Confidential Page 34
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
added to indicate a study physician must evaluate the patient prior to infusion. Infusion time 
interval for CTL019 injection removed.
Section 6.1.3 Rescue medication:  
 
 Language added to indicate 
steroids given to treat CRS must be listed on the concomitant medication CRF.
Section 6.1.5 Treatment du ration: infusion time interval of 2 -20 minutes removed
Section 6.2.4.1.1 Criteria for stopping or pausing the study : Section modified to be consistent 
with CTl019 standard protocol language, no new information included and language added 
about stopping or pausing the study  during the safety  run-in stage added.
Section 6.2.4.2.1 Expected toxicities: Updated information from study  UP13413 in regards to 
CRS added. Table 6-2 High dose vasopressor use, dosing information updated
Section 6.4.1 Patient numbering: Clarification provided to indicate center number is four digit 
followed b y a three digit patient number
Section 6.5.3 Study  drug compliance and accountability : Section updated to be consistent with 
CTL 019 standard protocol language
Section 6.5.3.2 Study  drug accountability : Verbiage deleted and added to section 6.5.3 to be 
consistent with CTL 019 standard protocol language
Section 6.5.4 Study  drug disposal and destruction: Section title updated and additional language 
added to refer to product handling manual
Section 7.1 Study  flow and visit schedule: Table 7-1Primary  visit evaluation schedule has been 
updated. Antineoplastic therapies after CTL019 infusion indicated after D2 until M60. Imaging 
updated to indicate at M3 if no PET CT and M6. Language added to CRS assessments to 
indicate to refer to additional tables in protocol. Language added to clarify  peripheral blood 
assessments. CTL019 pharmacokinetics b y flow cytometr y (peripheral blood) added as a study 
assessment.  CTL 019 PK by flow cytometry 
removed from Peripheral blood -
central assessment, additional peripheral blood central 
assessment adde d at day 11.  
 Survival follow -up updated 
to start after day  2.
Section 7.1.1 Screening phase: Clarification provided to indicate centra l pathology  assessment 
and central subtype determination not part of the medical history . Language added to clarif y 
FDG PET should be a dedicated machine. Language added to viral serology  to indicate that if 
the HIV test is positive at screening than a confirmatory  HIV test is to be performed as per 
current local guidelines.
Section 7.1.1.1 Rescreening: ECHO/MUGA to be repeated after 6 weeks, and additional 
clarifications per the CTL019 standard protocol language added.
Section 7.1.1.2 Eligibility  screening and enrollment: Verbiage has been removed in regards to 
confirming clinical eligibility  since this will be done via IRT.

Novartis Confidential Page 35
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 7.1.2 Pre-treatment phase: Section updated to be consistent with CTL 019 standard 
protocol language and also clarifications on timing intervals for lymphodepleting chemotherap y 
updated for DLBCL patients. Language added to indicate that additional frozen samples from 
the apheresis material as well as the CTL019 product will be collected at the manufacturing site 
for correlative st udies.
Section 7.1.3 Treatment and primary  follow -up phase:  
 
Language added to clarify  FDG 
PET should be a dedicated machine at the site. Additional language added for clarification on 
survival follow- up every  3 months.
Section 7.1.3.1 End of treatment and primary  follow -up (EOT) visit (M60 ±14d) including 
premature withdra wal: Language added to indicate that the patient will be followed for survival 
until the end of this study or the patient enrolled in the long term follow -up (LTFU ) study , 
whichever comes first.
Section 7.1.4.1 Criteria for premature patient withdrawal from the study : Language added to 
provide additional information on research results and biological samples.
Section 7.1.5 Survival follow -up phase: Language added to indicate survival status can be 
obtained via phone contact
Section 7.1.7 Discontinuation of study  treatment: Section added to be consistent with new 
discontinuation language.
Section 7.1.8 Withdrawal of consent: Section added to be consistent with new discontinuation 
language.
Section 7.1.9 Follow -up for safet y evaluations: Section added to be consistent with new 
discontinuation language.
Section 7.1.10 Lost to follow -up: Section added to be consistent with new discontinuation 
language.
Section 7.2.1 Efficacy  assessments: Clarification added that efficacy evaluation will be done in 
all lymphomas, not just DLBCL . Language added to describe process to be followed for 
radiological imaging and what will be centrally  reviewed by the IRC. Language added to clarify 
central lab is responsible for pathology  assessment and molecular subty pe determination. 
Randomization changed to enrollment. Language added to indicate acceptable imaging 
modalities for the study .
Section 7.2.2.1 Physical examination: Wrong CRF page originall y indicated, updated with 
correct CRF page
Section 7.2.2.5 Laboratory evaluations: Table 7-5updated to indicate if an initial HIV screening 
test is positive then a confirmatory  HIV test is required to be performed as per current local 
guidelines.  

Novartis Confidential Page 36
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 7.2.3 Pharmacokinetics: Table 7-7updated with additional clarifications. A new table 
inserted for CTL019 pharmacokinetics by flow cytometry  in peripheral blood collection log. 
Sample volume updated in Table 7
-12from 6 mL to 10 mL . Table 7 - 14  CTL 019 
PK treated patients updated.  
 Language removed to indicate that the D -1 aliquot will be collected pre- infusion.
 
 
 
 
 
 
Section 8.1.2 Reporting: The word “documented” deleted to indicate all infections are to be 
recorded in adverse events CRF. Language added to clarify  that regardless of causality  all lab 
abnormalities deemed clinically  significant, will be recorded in the Adverse Event s CRF. 
Language added to indicate within 28 day s after CL019 infusion patients will require multiple 
days of ICU care
Section 8.1.4 Adverse events of special interest: Language added to indicate that adverse events 
of special interest may require further i nvestigation. Clarification in regards to current defined 
AESI s for CTL019 and definitions may be updated as new data arises.
Section 8.2.2 Reporting: Section updated to be consistent with approved CTL 019 standard 
protocol language, reporting procedures are now clarified by what is required at the different 
study  phases, screening/pre -treatment, study -related treatment to Month 12, Month 12 to Month 
60, and post -treatment.
Section 8.4 Pregnancies: Language added to clarify that each pregnancy occurring once patient 
has been infused with CTL 019 must be reported within 24 hours. Language updated to be 
consistent with the approved CTL019 standard protocol language. In case of live birth, 
newborns will now be foll owed for 6 months instead of 3.
Section 8.6 Data Monitoring Committee: language added to section to indicate DMC will 
review data related to interim anal ysis and safet y data at regular intervals.
Section 10.4.1 Variable: change has been made in regards to best overall disease response of 
progressive disease from 12 weeks to 14 weeks after CTL019 infusion as per the Novartis 
modified Cheson criteria.
Section 10.5.2.2 Event free survival (EFS): Adequate assessments no longer available added as 
a censoring reason.
Section 10.5.2.6 Efficacy  in histological and molecular subgroups: Section added for 
clarification.
Section 10.5.3.2 Adverse Events (AEs): Section indicated that AESI s will be updated prior to 
reporting and Table 10 -2 removed

Novartis Confidential Page 37
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Section 10.5.3.6 Safet y subgroup analysis: histological and molecular subg roups added to 
analysis
Section 10.5.4 Pharmacokinetics: Updated to include language about what q-PCR generated 
CTL 019 concentrations will be display ed graphically . “Mass x time x volume -1” removed from 
Table 10 -
2 noncompartmental pharmacokinetic paramete rs.  
 
Section 10.6.1.3 Basic Tables, Listings and Figures: Language about CTL019 protein detection 
reagent removed. Language about anal ysis of leukocy te transcriptome analy sis added.
 
 
Section 10.7 Interim analy sis: New section to protocol amendment, an interim analy sis has been 
added when approximately  50 of the planned 80 patients have received their infusion and 
completed 6 months from study  day 1 infusion or discontinued earlier. Table 10 -3included to 
describe the simulated scenarios for interim anal ysis and final anal ysis.
Section 10.8 Sample size calculation: Language updated to clarify the rationale for sample size 
calculation
Section 13 References: additional references included in the proto col amendment including; 
(Lan and Demets 1983 ), (Maude et al 2014 )
IRB/IEC/REB A pproval
A copy  of this amended protocol will be sent to the Institutional Review Board (IRBs)/ 
Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. The changes herein affect the informed consent. Sites are required to update 
and submit for approval a revised Informed Consent that takes into account the changes 
described in thi s protocol amendment.

Novartis Confidential Page 38
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Protocol summary :
Protocol number CCTL019C2201
Title A Phase II, single arm, multicenter trial to determine the efficacy and safety of 
CTL019 in adult patients with relapsed or refractory DLBCL
Brief title Study of efficacy and safety of CTL019 in adult DLBCL patients
Sponsor and 
Clinical PhaseNovartis
Phase II Multicenter
Investigation type Biological
Study type Interventional
Purpose and rationale DLBCL is the most frequent lymphoma subtype, representing 30-35% of all non-
Hodgkin lymphomas (NHL). Two-thirds of patients are cured by a combination of 
chemotherapy agents ± radiotherapy in addition to rituximab, but one-third of patients 
have disease that is either refractory to initial therapy or relapses after standard 
therapy. Whether patients refractory to a rituximab -containing regimen should be 
retreated with rituximab is currently unknown based on available data. Relapsed and 
refractory patients have a poor prognosis, particularly those who do not respond to 
2ndline chemotherapy. The median survival of patients non-responding to 2ndline 
chemotherapy is 4 months and only 4% are alive after 1 year. For patients relapsing 
with chemotherapy -sensitive disease, high-dose chemotherapy followed by 
autologous hematopo ieticstem cell transplantation (HSCT) provides the best chance 
of cure. However, due to advanced age and comorbidities, only half of all patients 
are eligible for such an intensive approach. Yet, only a modest minority of patients 
undergoing HSCT are cured. In su mmary, treatment options for patients who do not 
respond to 2ndline chemotherapy or who relapse after autologous HSCT are 
generally considered palliative. Novel therapies are urgently need ed for this patient 
population.
The B-cell marker CD19 has emerged as a target for DLBCL treatment in the past 
years. It is widely expressed on normal and malignant B-cells throughout B-cell 
maturation but not on pluripotent stem cells or non B-cell tissues. The vast majority 
of DLBCL expresses CD19. Autologous T cells have been developed that are 
genetically modified ex-vivo via a lentiviral transduction to express a chimeric antigen 
receptor (CAR) consisting of a CD19 antigen recognition domain attached to 
intracellular signaling domains that mediate T -cell activation. Data from patients with 
B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), 
which are both CD19 expressing B cell malignancies, and preliminary data from 
patients with DLBCL show that CTL019 therapy has potent anti -tumor activi ty.
The purpose of this study will be to determine the safety and efficacy of CTL019 in 
adults with relapsed or refractory DLBCL and to monitor all patients exposed to 
CTL019 for 5 years following CTL019 infusion.
Primary Objective(s) 
and Key Secondary 
ObjectiveTo evaluate the efficacy of CTL019 therapy, defined as overall response rate (ORR), 
which includes complete response (CR) and partial response (PR) based on the 
as determined by a central 
independent review committee. ( Cheson et al 2014 )
Secondary Objectives Evaluate safety of CTL019
Evaluate time to response (TTR)
Evaluate durat ion of overall response (DOR)
Evalu ate event free survival (EFS)
Evaluate progression free su rvival (PFS)
Evaluate overall survival (OS)
Evaluate safety and efficacy in histol ogical and molecular subtypes
Characterize the in vivo cellular PK profile (levels, persistence , trafficking) of 
CTL019 transduced cells into target tissues (blood, bone marrow, cerebral spinal 
fluid (CSF) an d other tissues if available)
Describe the incidenc e of immunogenicity to CTL0 19
Describe presence of RCL

Novartis Confidential Page 39
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Study design This is a single arm, open -label, multi -center, phase II study to determine the efficacy 
and safety of CTL019 in patients ≥ 18 years with relapsed or refractory diffuse large 
B-cell lymphoma (DLBCL). The study will have the following sequential phases: 
Screening, Pre-Treat ment, Treatment and Primary follow -up, Secondary follow -up, 
and Survival follow -up. The total duration of the study is 5 years. Efficacy will be 
assessed until progression; safety will be assessed throughout the full duration of the 
study. Patients will be monitored for delayed adverse events for up to 15 years after 
last CTL019 infusion in a separate destination protocol per the health authority 
guidelines. Approximately 100 patients will be enrolled to allow for 80 patients to be 
treated in the main study cohort. Further to this main cohort anadditional cohort 
(Cohort A) will evaluate the impact of manufacturing site on clinical outcome.
Approximately 18patients will be enrolled in the additional cohort to allow for 15
patients to be treated. This c ohort will assess the clinical profile (safety and efficacy, 
PK) of CTL019 manufactured at the Fraunhofer Institut für Zelltherapie (Leipzig, 
Germany). After the amendment 5 of the protocol, approximately 10additional 
Japanese patients will be enrolled , to allow for at least 6additional patients to be 
treated (total 9 treated in Japan).
At the beginning of the trial, a safety run -in stage will be conducted to enroll at least 
three patients to assess the acute safety profile and product characteristics ofthe 
Novartis manufactured CTL019 cell product. The initial patients will be enrolled in this 
trial subsequently with minimum interval between CTL019 infusions of 14 days. Full 
safety profiles and product characteristics of these patents following lymphode pleting
chemotherapy and CTL019 infusion will be reported to the Health Authorities.
Population The target population is comprised of adults ≥ 18 years with relapsed or refractory 
DLBCL not eligible for HSCT. A minimum of 25 patients in each of the two most 
common molecular subtypes of DLBCL: GC and ABC type will be treated in the main 
cohort . 
Inclusion criteria 1.Written informed consent must be obtained prior to any screening procedures
2.Patients must be ≥18 years of age
3.Histologically confirmed DLBCL (by central pathology review before enrollment).
a.Sufficient FFPE tumor samples must be available for histological and 
molecular subtype testing along with a corresponding pathology report. A 
recent tumor sample obtained for the purpose of this study must be submitted 
however if not clinically feasible, an archival tumor biopsy from the most 
recent relapse may be submitted instead. Excisional biopsies should be 
submitted wherever possible; in cases where this is not possible, a core 
needle biopsy is allowable. Fine needle aspiration (FNA) is not allowed.
4.Relapsed or refractory disease after ≥2 lines of chemotherapy, including rituximab 
and anthracycline, and either having failed autologous HSCT, or being ineligible 
for or no t consenting to autologous HSCT
5.Measurable disease at time of enrollment:
a.Nodal lesions greater than 20 mm in the long axis, regardless of the length of 
the short axis
b.Extranodal lesions (outside lymph node or nodal mass, but including liver and 
spleen) ≥ 10 mm i n long AND short axis
For detailed information please refer to Section 14.1 Appendix 1: Guidelines for 
efficacy evaluation in diffuse large B cell lymphoma and follicular lymphoma studies 
6.Life expectancy ≥12 weeks
7.ECOG performance status that is either 0 or 1 at screening
8.Adequate organ function:
a.Renal function defined as:
●A serum creatinine of ≤1.5 x ULN OR
●
eGFR ≥ 60 mL/min/1.73 m 2
b.Liver function defined as:
●ALT ≤ 5 times the ULN for age

Novartis Confidential Page 40
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
●Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert –
Meulengracht syndrome; patients with Gilbert -Meulengracht syndrome 
may be included if their total bilirubin is ≤ 3.0 x  ULN and direct bilirubin ≤ 
1.5 x ULN
c.Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 
dyspnea and pulse oxygenation > 91% on room air
d.Hemodynamically stable and LVEF ≥ 45% confirmed by echocardiogram or 
MUGA
e.Adequate bo ne marrow reserve without transfusions defined as:
●Absolute neutrophil count (ANC) > 1.000/mm 3
●Absolute lymphocyte count (ALC) > 300/mm 3,andabsolute number of 
CD3+ T cells > 150/mm 3
●Platelets ≥ 50.000//mm 3
●Hemoglobin > 8.0 g/dl
9.Must have an apheresis product of non-mobilized cells accepted for 
manufacturing
10.Women of child-bearing potential, defined as all women physiologically capable 
of becoming pregnant, and all male participants must use highly effective 
methods of contraception for atleast 12 months following CTL019 infusion and 
until CAR T cells are no longer present by PCR.
Highly effective contraception methods include:
●Total abstinence (when this is in line with the preferred and usual lifestyle of the 
patient. Periodic abstinen ce (e.g. calendar, ovulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptable methods of contraception
●Female sterilization (surgical bilateral oophorectomy with or without 
hysterectomy) or tubal ligation at least six weeks befor e taking study treatment. 
In case of oophorectomy alone, only when the reproductive status of the woman 
has been confirmed by follow up hormone level assessment.
●Male sterilization (at least 6 months prior to screening). For female patients on 
the study, the vasectomized male partner should be the sole partner for that 
patient .
● BOTH of the following forms of contraception must be utilized:
a.Use of oral, injected or implanted hormonal methods of contraception or other 
forms of hormonal contraception that have comparable efficacy (failure rate 
<1%), for example hormonal vaginal ring or transdermal hormonal 
contraception AND
b.Barrier methods of contraception: condom or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
●Use of intrauterine devices (IUDs) isexcluded due to increased risks of infection 
and bleeding Placed IUDs may remain inplace but additional measures of 
contraception are mandated. Additionally, drugs that induce cytochrome P450 
(CYP) enzymes can increase the clearance of sex hormones that are eluted by 
the devices and reduce contraceptive efficacy; given the poly-pharmacy for these 
patients this presents a real risk of device failure and possible resultant 
inadvertent conception.
●In case of use oforal contraception women should have been stable on the same 
pill for a minimum of 3 months before taking study treatment.
11.Sexually active males must use a condom during intercourse for 12 months the 
tisagenlecleucel infusion and until CAR T-cells are no longer present by qPCR 
on two consecutive tests. qPCR test results will be available upon request. A 
condom is required for allsexually active male participants to prevent them from 
fathering a child AND to prevent delivery of study treatment via seminal fluid to 
their partner after treatment as they should not father a child in this period. A 
condom is required to be used also by vasectomized men (as well as during 
intercourse with a male partner or sterile female partner )as W BCs are a normal 
part of semen and transmission of CTL019 transduced cells may occur.

Novartis Confidential Page 41
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Exclusion criteria 1.Prior treatment with any prior anti-CD19/anti -CD3 therapy, or any other anti-CD19 
therapy
2.Treatment with any prior gene therapy product
3.Active CNS involvement by malignancy
4.Prior allogeneic HSCT
5.Eligible for and consenting to autologous HSCT
6.Chemotherapy other than lymphodepleting chemotherapy within 2 weeks of 
infusion
7.Investigational medicinal product within the last 30 days prior to screening
Note: Investigational therapies must not be used at any time while on study until the 
first progression following CTL019 infusion
8.The following medications are excluded:
●Steroids: Therapeutic doses ofsteroids must be stopped > 72 hours prior to
leukapheresis and > 72 hours prior toCTL019 infusion. However, the following 
physiological replacement doses of steroids are allowed: <12 mg/m2/day 
hydrocortisone or equivalent
●Immunosuppression: Any immunos uppressive medication must be stopped ≥ 2
weeks prior to leukapheresis and ≥ 2 weeks prior to CTL019 infusion. This could 
include check point inhibitors (monoclonal antibodies and small molecule 
modulators).
●Antiproliferative therapies other than lymphodepleting chemotherapy within 2 
weeks of leukapheresis and 2 weeks prior toinfusion
●Short acting drugs used to treat leukemia or lymphoma (e.g. tyrosine kinase 
inhibitors, and hydroxyurea) must bestopped > 72 hour prior to leukapheresis 
and > 72 hours prior to CTL019 infusion
●Other cytotoxic drugs, including low dose daily or weekly maintenance 
chemotherapy, must not be given within 2 weeks prior to leukapheresis and 
within 2 weeks prior to CTL019 infusion .
●Fludarabine may be associated with prolonged lymphopenia. This should be 
taken into consideration when evaluating the optimal timing for leukapheresis.
●Antibody use including anti-CD20 therapy within 4 weeks prior to infusion or 5 
half-lives of the respect iveantibody, whichever is longer. Note: Rituximab is 
excluded within 4 weeks prior to infusion
●CNS disease prophylaxis must be stopped > 1 week prior to CTL019 infusion 
(e.g. intrathecal methotrexate)
9.Prior radiation therapy within 2 weeks of infusion
10.Active replication oforprior infection with hepatitis B or active hepatitis C(HCV 
RNA positive)
11.HIV positive patients
12.Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood 
culture positive ≤ 72 hours prior to in fusion)
13.Unstable angina and/or myocardial infarction within 6 months prior to screening
14.Previous or concurrent malignancy with the following exceptions:
●Adequately treated basal cell or squamous cell carcinoma (adequate wound 
healing is required prior to study entry)
●In situ carcinoma of the cervix or breast, treated curatively and without evidence 
of recurrence for at least 3 years prior to the study
●A primary malignancy which has been completely resected and in complete 
remission for ≥ 5 yea rs
15.Pregnant or nursing (lactating) women
16.Intolerance to the excipients of the CTL019 cell product
17.Cardiac arrhythmia not controlled with medical management
18.Removed
19.Prior treatment with any adoptive T cell therapy

Novartis Confidential Page 42
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
20.Patients with T -cell rich/histiocyte rich large B-cell lymphoma (THRBCL), primary 
cutaneous large B-cell lymphoma, primary mediastinal B-cell lymphoma 
(PMBCL), EBV positive DLBCL of the elderly, Richter’s transformation, and 
Burkitt lymphoma
21.Patients w ith active neurological auto immune or inflammatory disorders (e.g. 
Guillain -Barre Syndrome, Amyotrophic Lateral Sclerosis)
Investigational and 
reference therapyA single target dose of 5 x 108 of viable autologous CTL019 transduced T cells will 
be administered via intravenous infusion.
Efficacy assessments Imaging (CT or MRI, PET-CT or dedicated PET), physical examination, bone 
marrow biopsy, B-Symptoms
Safety assessments Adverse events and laboratory anomalies (type, frequency and severity)
Selec ted adverse events
Immunogenicity assessments (Humoral and cellular)
Detection of replication competent lentivirus
Detection of monoclonal or oligoclonal vector integration 
PKs Pharmacokinetic assessments planned for this trial include:
Characterization of CTL019 PK (e.g. Cmax, Tmax, AUCs, etc .) in blood, bone 
marrow and other relevant tissues if available by quantitative Polymerase Chain 
Reaction (qPCR) and /orflow cytometry.
Data analysis Primary endpoints:
The primary analysis will be carried out after 80 treated patients have completed at 
least 3months of follow -up or have discontinued due to any reason. Selected 
efficacy and safety analysis will be updated annually. A final Clinical Study Report 
(CSR) will be produced once all patients complete or discontinue from the study. 
The primary efficacy endpoint, ORR will be analyzed based on the data observed 
by IRC in the full analysis set (FAS). 
The primary efficacy analysis will be performed by testing the nul l hypothesis of 
ORR being less than or equal to 20% against the alternative hypothesis that the 
ORR is greater than 20% at overall one -sided 2.5% level of significance, powered 
for ORR of 38%. The ORR will be summarized along with the 2-sided 95% exact 
Clopper-Pearson confidence intervals. The study will be considered successful if 
the lower bound of the 2 -sided 95% exact confidence interval for ORR is greater 
than 20%, so that the null hypothesis that the ORR is less than or equal to 20% can 
be rejected.
Sensitivity analyses will be performed on the Enrolled Set, the per -protocol set 
(PPS) and with all patients who satisfy all clinical eligibility criteria (excluding the 
inclusion criteria that pertains to the patient’s accepted apheresis product) using the
same method as described above. Additional sensitivity analysis will be performed 
using the ORR as assessed by local investigators in the FAS population.
One interim analysis is planned when approximately 50 patients with DLBCL are 
treated and followed up for 3 months. If the lower bound of 99.08% exact 
confidence interval for ORR is greater than 20% then statistical significance can be 
declared. If the predicted probability of success (i.e., positive result at the end of the 
study) is less than 10% then t he study may be terminated due to futility.
Secondary endpoints:
Analysis of secondary  endpoints will be descriptive and may include 

Novartis Confidential Page 43
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
summary statistics such as means, standard deviations, 95% confidence intervals, 
if applicable, Kaplan -Meier curves and median time to event will be presented for 
time-to -event variables (DOR, TTR, EFS, PFS and OS), if appropriate. 
Pharmacokinetics parameters will be descriptively summarized and will include 
geometric and arithmetic means, SD, CV% and CV% geome tric-mean, median, 
minimum, and maximum (for Tmax only median, minimum and maximum will be 
presented). PK parameters will be summarized by best overall response.
Sample size: In two retrospective studies in relapsed and refractory DLBCL patients 
receiving 2nd or 3rd line therapies, the observed ORR were 14% and 20% 
(Seshadri et al 2008 , Elstrom et al 2010 ). In a recent prospective clinical trial with 
ibrutinib in patients who had a median of 3 prior lines of therapy, the ORR in the 
ABC subtype (N=29) was 40% and in the GC subtype (n=20) 5% leading to an 
overall OR R of 21.7% ( Wilson et al 2012 ).
Base d on the null hypothesis of ORR ≤ 20% and alternative hypothesis of 
ORR>20%, 80 patients in the primary analysis will provide 94% power to 
demonstrate statistical significance at one sided 0.025 level of significance, if the 
underlying ORR is 38%. In this setting, an ORR of 24/80=30% will be needed to 
claim success.
Assuming approximately 20% enrolled patients will not be infused due to reasons 
such as , worsening of patient’s condition, etc., at least 100 
patients need to be enrolled t o ensure 80 patients are treated.
Key words Relapsed/refractory DLBCL, CTL019

Novartis Confidential Page 44
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
Non-Hodgkin Lymphomas (NHL) comprise a heterogeneous group of malignancies. Estimated 
new cases are 70,800 and deaths are 18,990 in the United States (US) for 2014 ( National Cancer 
Institute 2014). There were 66,371 lymphoid malignancies registered in 2000-2002 by 44 
European cancer registries ( Sant et al 2010 ). NHL are classified according to the current WHO 
classification (WHO 2008 ) into immature lymphoid neoplasms, mature B -cell neoplasms, T-
cell and NK-cell neoplasms, and post-transplant lymphoproliferative disorders (PTLD) . Mature 
B
-cell lymphomas are further classified into indolent lymphomas (e.g. multiple myeloma, CLL) 
and aggressive l ymphomas (e.g. diffuse large B -cell ly mphoma (DLBCL ). DLBCL is the most 
frequent lymphoma subty pe, representing 30-35% of all non-Hodgkin lymphomas (NHL) 
(Ghielmini et al 2013). Estimated incidence in the European Union is 3–4/100 000/year, 
increasing with age from 0.3/100 000/y ear (35–39 years) to 26.6/100 000/year (80– 84 years) 
(Tilly  H 2012). About 10,000 deaths per year are due to DLBCL in the US (National Cancer 
Institute).
Most patients with localized DLBCL can be cured with conventional combination immuno -
chemotherap y or with combined –modality  therapy . For patients with advanced -stage disease, 
the majority  of patients can be cured with doxorubicin- based combination chemotherap y and 
rituximab (e.g. R-CHOP). Prognosis depends on individual risk factors. The International 
Prognostic Index (IPI) for aggressive NHL  (diffuse large cell lymphoma) includes five 
significant risk factors prognostic of OS:
1.Patient age ( ≤60 y ears vs. >60 y ears)
2.Serum lacta te deh ydrogenase (LDH) (normal vs. elevated)
3.ECOG performance status (0 or 1 vs. 2 –4)
4.Stage (stage I or stage II vs. stage III or stage IV)
5.Extranodal site involvement (0 or 1 vs. 2 –4)
Patients with ≥2 risk factors after age -adjustment have a poor prognosi s with a 5 year OS-rate 
of 21 -46%. Age -and stage -adjusted modifications are used for younger patients with localized 
disease (Moller et 
al 2013 ). Very  recentl y a revised IPI, the NCCN -IPI, has been proposed to 
better reflect the individual patient’s risk in the rituximab era. Very  similar to the original IPI, 
five prognostic factors were identified:
1.Patient age (>40 to ≤60 vs. >60 to ≤75 vs. >75 y ears)
2.Normalized serum LDH (>1 to ≤3 vs. >3 x UL N)
3.ECOG 
performance status ( ≥2)
4.Ann Arbor Stage (Stage ≥III)
5.Extranodal site involvement (Disease in bone marrow, CNS, liver/GI tract, or lung)
The NCCN -IPI can discriminate four prognostic groups: low (0-1), low-intermediate (2-3), 
high-intermediate (4- 5), and hi gh (6 -8).
DLBCL is a heterogeneous disease with several molecular subtypes. Subty pes were identified 
by molecular profiling based on biologic similarity  to normal stages of B-cell development, 

Novartis Confidential Page 45
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
dividing DLBCL into germinal center -like (GC), activated B -cell-like (ABC) tumors, and 
primary  mediastinal large B cell ly mphoma (PMBCL) (Lenz et al 2008 ) (Alizadeh et al 2000 ). 
The turnaround time for gene expression profiling (GEP) is not useful for initiation of therapy 
in most DLBCL patients. There are immunohistochemistry  (IHC) algorithms, which 
approximate the GEP. These IHC models predict a 3 -year overall survival (OS) of 85% in GC 
tumors compared to 65% i n ABC tumors ( Hans et al 2004).
Despite overall improvement in outcomes of DLBCL , approximately  one-third of patients will 
develop relapsed/refractory (r/r) disease that remains a major cause of morbidity  and mortalit y. 
Refractory  disease is defined as a <50% decrease in lesion size with induction therap y or the 
appearance of new lesions (Cheson et al 2007 ). Progressive or relapsed disease reflects the 
appearance of new lesions after attainment of complete remission (CR) (Cheson et al 2007). 
Relapsed and refractory  patients have a poor prognosis, particularly  those who do not respond 
to 2nd 
line chemotherapy  (Friedberg 2011 ). Left untreated, life expectancy  is 3 to 4 months, 
similar to what is seen in patients not responding to 2ndline chemotherap y (Elstrom et al 2010 ).
While approximately  60% of patients with r/r DLBCL  remain sensitive to conventional 2nd-line 
salvage immunochemotherap y, <10% have prolonged disease -free survival. ( Gisselbrecht et al 
2010) Patients with r/r DLBC L responding to 2nd-line immunochemotherapy  and undergoing 
subsequent high-dose chemotherap y and stem cell transplantation (HSCT) maintain their 
response over longer time (3-year PFS 39% in patients with HSCT vs
. 14% for patients without 
HSCT) (Gisselbrecht et al 2010) (Sehn 2012). Patients relapsing within 12 months of rituximab -
containing 1st-line therapy have a particularl y poor prognosis even with HSCT ( Gisselbrecht et 
al 2010). Without HSCT, chemotherap y provides only short-term disease control in r/r DLBCL. 
For transplant candidates who fail second line therapy  or who relapse post-transplant, prognosis 
is grave . Molecular analysis 
of biopsies from the CORAL  trial in 2ndline DLBCL  (Gisselbrecht 
et al 2010 ) showed equal distribution of GC vs. non-G C DLBCL ( Thieblemont et al 2011 ).
In summary , treatment options for patients who do not respond to 2ndline salvage therap y or 
who relapse after autologous HSCT are only palliative and overall survival (OS) is 3 -4 months. 
Novel therapies are urgently  needed for this patient population.
Ibrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a key component of B 
cell receptor (BCR) signaling has preferential activity  in the ABC subty pe. The survival of ABC 
but not GC DLBCL cell lines is sustained by  "chronic active" B cell receptor (BCR) signaling. 
Gain -of-function mutations affecting the BCR subunit CD79B occur in 21% of ABC but only 
5% of GC DLBCL tumors. An open -label Phase II study  ([STUDY_ID_REMOVED]) with ibrutinib in 
patients who had a median of 3 prior lines of therapy , reported an ORR in the ABC subty pe 
(N=29) of 40% compared to 5% in the GC subty pe (n=20) leading to an overall ORR of 21.7% 
(Wilson et al 2012). Rituximab, a chimeric monoclonal antibody  against CD20, improves the 
survival of both the GC and non-GC subty pes analy zed by Hans algorithm (Fu et al 2008). 
Based on current experience, CTL 019 is expected to be effective in the different molecular 
DLBCL subt ypes.
1.1.1 Historical experience with retroviral gene therapies
To date, malign
ant cell transformation after vector -mediated insertional mutagenesis has been 
observed in three clinical entities (X-linked Severe Combined Immunodeficiency  [SCID-X1], 
Chronic Granulomatous Disease [CGD], and Wiskott -Aldrich Syndrome [WAS]) which have 

Novartis Confidential Page 46
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
involved the use of first-generation gamma -retroviral vectors harboring long terminal repeats 
(LTRs) with strong enhancer/promoter sequences (Hacein -Bey-Abina et al 2003, Howe et al 
2008, Boztug et al 2010 ,Stein et al 2010, Persons and Baum 2011). In contrast, data from 
lentiviral vector trials have demonstrated more polyclonal patterns of vector insertion (Cartier 
et al 2009, Biffi et al 2011 ), with the exception of the first patient reported from a thalassemia 
trial (Cavazzana -Calvo et al 2010). Importantl y, despite a very high transduction efficiency 
achieved using lentiviral vectors, molecular clonality  studies have not indicated any reasons for 
concern, to date, in published clinical trials ( Schambach et al 2013 ).
Retroviral vectors are useful gene delivery  vehicles because they insert a deoxy ribonucleic acid 
(DNA) copy of their genome into the host cell. However, insertion of vector sequences is 
distributed throughout the cellular genome and insertion has the potential to up-regulate, 
dysregulate, or knockout local gene expression
. Thus, there has alway s been a theoretical risk 
of insertional oncogenesis resulting from disruption of normal function of genes that control 
cell growth. This risk has been realized in a clinical trial utilizing murine -derived retroviral 
vectors to transfer the γ signaling chain to stem cells of infants with SCID-X1 (Hacein -Bey-
Abina et al 2003 ). A total of 4 of 9 children in that trial have developed integration site -induced 
cancers, and one of those children died after relapse. I n a parallel study where the same disease 
load and target cells were used, no 
tumorigenesis was observed at first, suggesting that minor 
differences, such as vector envelope and stem cell growth factors, might be relevant in long 
term safet y of integrating vectors (Gaspar et al 2004 ). However, in December of 2007, one of 
the 10 children treated in that study  also developed insertion- mediated oncogenesis (Howe et al 
2008). Today , the causes of insertional oncogenesis remain poorly  understood, but in the SCID -
X1 studies, a common integration site, LMO -2, is observed in at least 3 of the 5 patients. In 
general, the target cel l, vector, and disease payload are considered major factors contributing to 
the risks of vector -induced tumors. However, there is insufficient data to date to support the 
relative contribution of each of these factors in assuring safet y of retroviral gene transfer.
Lentiviral vectors are a major subset of retroviral vectors, but demonstrate distinct integration 
patterns compared to oncoretroviral vectors which have been the predominant vector to date for 
gene transfer studies. The integration pattern of lentiviral vectors tends to be inside active 
transcription units as opposed to upstream in the locus control region where the insertion would 
have a greater chance of up-regulating gene expression. In addition, lentiviral vectors have no 
enhancer activity  in their long terminal repeat (LTRs) regions and have lower levels
 of poly -A 
read-through, all factors which may improve gene transfer safety  (Zaiss et al 2002 ). Thus, it 
may be that lentiviral vectors are a safer alternative to oncoretroviral vectors for gene transfer. 
Animal models have provided supporting evidence for this (Montini et al 2006). As lentiviral 
vectors are also superior for gene transfer , it is anticipated that these vectors will ultimately  
replace oncoretroviral ve ctors for stable gene transfer.

Novartis Confidential Page 47
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
In direct contrast to oncoretroviral vectors, lentiviral vectors have not been shown to be 
oncogenic in nature except for a single study  in neon atal mice where direct injection for liver 
delivery  was performed (Themis et al 2005). The oncogenesis in this study  may be associated 
with a vector element that can be modified to reduce such a risk ( Schambach et al 2006), and 
also may  be unique to the animal model used in that study. A newer stud y in tumor prone mice 
comparing the tumorigenicity  of retroviral vectors to lentiviral vectors demonstrat ed that 
lentiviral vector gene transfer into hematopoietic stem cells of up to an average of 6 copies per 
cell was not 
tumorigenic in contrast to retroviral vectors at an average copy  number of 3 per 
cell (Montini et al 2006). It is notable that T cell leukemia is not a recognized side effect of 
human immunodeficiency virus (HIV) lentiviral infection.
More recently , retroviral and lentiviral safety  has been demonstrated in modified T cell gene 
therap y trials. A long-term retrospective study  of >500 patient- years of collective patient 
samples tested for at least 11 years after infusion from three clinical trials using gamma -
retroviral modified T cells to express CD4zeta chimeric antigen receptor (CAR) did not show 
evidence of transgene silencing, atypical gamma -retroviral integration patterns, or clonal 
expansion (Scholler et al 2012 ). A favorable safet y profile was also determined for a 
conditionally  replicating HIV -derived lentivirus that delivered HIV envelope antisense to 
patient T cells. In two separate treatment cohort analy ses, no evidence for insertional 
mutagenesis or enrichment of vector copies near proto- oncogenes was observed ( Levine et al 
2006, and Wang et al 2009 ). These data represent follow - up after 21-36 months (Levine et al 
2006) and 28-32 weeks (Wang et al 2009). Another group reported no apparent risk of vector 
related AEs following 263 infusions of autologous, lentiviral transduced T cells with a long 
ribonucleic acid (RNA) antisense to HIV -1 envelope ( McGarrit y et al 2013 ). More recently  ex 
vivo lentiviral transduced hematopoietic stem cells were used to correct an inherited storage 
disease in three children and in an inherited WAS in 3 children with follow up for up to 24 
months and 20-32 months, respectively . Lentiviral integration studies showed sustained gene 
marking with polyclonal engraftment of transduced cells with no evidence of aberrant clonal 
expansion, no evide nce of in vivo selection of clones carry
ing integrations near oncogenes and 
therefore no evidence of vector- induced genotoxicity  (Biffi et al 2013 ,Aiuti et al 2013 ).
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of CTL019
Immunotherap y is a treatment that involves activating or enhancing the immune system to help 
fight diseases including cancer. Adoptive immunothe rapy with allogeneic donor leukocy tes (e.g. 
donor lymphocy te infusion) has potent anti-leukemic effects, however the benefit is confined 
largel y to patients with myeloid leukemia’s, as B -ALL has a durable remission rate of less than 
10% (Kolb et al 1995), and often at the cost of substantial morbidity  due to GVHD (Appelbaum 
2001, Sullivan et al 198 9).
Adoptive T
-cell therapy for cancer involves the infusion of native or geneticall y modified 
mature T cells that have the capacit y to recognize and possibly  eliminate the patient’s malignant 
cells. In particular, chimeric antigen receptor -based approach involves engineering T cells with 
sequences that encode antibody -based antigen recognition moieties linked to signaling domains. 

Novartis Confidential Page 48
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Unlike T cell receptors (TCR), CARs allow the T cells to specifically  target and destroy  tumor 
cells in a Major Histocompatibil ity Complex (MHC) independent manner (Mellman et al 2011 ).
A promising target antigen for B cell malignancies is CD19, a cell-surface protein whose 
expression is restricted to B cells and their precurso rs (Sadelain et 
al 2003 , Brentjens et al 2010 , 
Porter et 
al 2011 ). CD19 is not expressed on hematopoietic stem cells or non-B cell tissues. It 
is a member of the immunoglobulin (Ig) superfamily  and a component of a cell surface signal 
transduction complex that regulates signal transduction through the B cell receptor (Ledbetter 
et 
al 1988 , Stamenkovic and Seed 1988 , Fearon and Carroll 2000 ). Mice lacking CD19 have 
decreased number of B cells in peripheral lymphoid tissues, decreased B cell response to oral 
vaccines and mitogens, and decreased serum Ig levels ( Ledbetter et al 1988 , Stamenkovic and 
Seed 1988 ,Tedder and Isaacs 1989 , Fearon and Carroll 2000 ).
First generation CARs contain the TCR activation signal domain 
consisti ng of TCRζ. Second 
generation CARs contain costimulatory signaling domains as well: either CD28 or 4 -1BB. The 
3rdgeneration CARs contain further advancements such as double costimulatory  modules 
comprised of CD28, 4
-1BB plus TCRζ ( June 2007 , June et al 2009, Kohn et al 2011 ).
CTL 019 (CART -19) is an adoptive cellular immunotherap y that uses the aut ologous peripheral 
blood T cells that have been genetically  modified ex vivo to target CD19 on the surface of B 
cells. As shown in Figure 1-1, the CAR approach uses genetically  programmed lymphocy tes 
transfected with chimeric receptor genes to combine the effector functions of T lymphocy tes 
with the ability  of antibodies to recognize predefined surface antigens with 
high specificity  in 
a non-MHC restricted manner ( Gross et al 1989 , Pinthus et al 2003 ). These receptors have the 
ability  to recognize intact membrane proteins independent of antigen processing. The tumor 
antigen binding function of CAR is usually  accomplished by the inclusion of a single chain 
variable fragment (scFv) antibody , containing the heav y chain variable domain (VH) and light 
chain variable domain (V L) joined b y a peptide linker of about 15 residues in length ( Mullaney  
et al 2001).
Figure 1 -1 CTL019 chimeric antigen receptor design

Novartis Confidential Page 49
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Early results from ongoing clinical trials of CTL019 in r/r CLL and r/r ALL have shown 
promising and durable anti-tumor efficacy  
(Porter et al 2011, Grupp et al 2013, Maude et al 
2014). It is anticipated that CTL 019 may offer a therapeutic alternative for patients with r/r B 
cell malignancies, including DLBCL, who are either SCT ineligib
le or who h ave relapsed after 
SCT, which may offer a greater durabilit y of remission than current salvage therapies. In the 
future CTL 019 may also have the potential to replace SCT as a therapeutic choice, expanding 
patient eligibility  by obviating the need for match ed donors along with potentially  lower rates 
of upfront mortality  and morbidity . For further information refer to the [CTL019 Investigator’s 
Brochure ].
1.2.1.1 Non- clinical experience
Extensive literature supports the use of engineered T cells for tumor immunotherap y in rodent 
tumor models (Calogero et al 2000 , Clay et al 2002 , Hombach et al 2002 , Pule et al 2003, 
Sadelain 2003). Others have used electroporation or retroviral vectors to create CAR T cells 
and have shown in vivo safet y and efficacy  of adoptively  transferred T cells in immunodeficient 
mouse models (Willemsen et 
al 2000, Roessig et al 2002, Brentjens et al 2003 , Cooper et al 
2003, Serrano et al 2006 ). The incorporation of costimulatory  signaling modules such as CD2 8 
and 4-1BB in second generation CARs increases potency  of the engineered T cells in pre-
clinical studies (Finney  et al 1998, Krause et al 1998, Eshhar et al 2001 , Maher et al 2002, 
Finney  et al 2004 , Friedmann -Morvinski et al 2005 , Brentjens et al 2010 ). The pre- clinical data 
supporting CAR T cell persistence, expansion and anti-tumor efficacy  have been published 
(Gross and Eshhar 1992 , Milone et al 2009 ).
1.2.1.2 Clinical experience
At the National Cancer Institute, 10 
patients with NHL (4 DLBCL, 4 PMBCL , 2 low grade 
lymphomas) have received CAR modified CTL s directed against CD19. (Recombinant DNA 
Advisory  Committee (RAC) meeting 2013 ). Response rate was 70% (DLBCL : 1 CR, 2 PR, 1 
SD; PMBCL : 1 CR, 1 PR, 1 SD, 1 NE; Other: 2 PR). Atthe University  of Penns ylvania 
(UPENN), a Phase II trial with CTL 019 in 30 heavily  pretreated, relapsed/refractory  NHL 
patients including 9 with DLBCL has started in January  2014. To date fourteen patients (9 
DLBCL, 5 FL) have 
been treated with CTL019. Most patients had early clinical responses, with 
2 out of 2 patients evaluated with CT showing PET-negative CRs. One patient progressed 
before response assessment. In ALL, across both children and adults, more than 85% of patients 
have achieved a complete response (CR) within 28 days of infusion (Grupp SA 2013, 
unpublished data as of February  19th, 2014). In CLL , the response rate has been lower, and no 
relapses have yet been observed in patients who achieve CR (Porter DL 2013, unpublished data 
as of February 19th, 2014).I n patients with severe CRS, tocilizumab was administered with rapid 
(within hours) resolution of fevers and hemod ynamic instability . Patients achieving a complete 
remission (CR) also experienced B-cell aplasia and hypogammaglobulinemia, which was 
supported with periodic intravenous immune globulin infusions ( Grupp et al 2013 ). For further 
information refer to the [CTL 019 Investigator’s Brochure] .

Novartis Confidential Page 50
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
There are currently  5ongoing human treatmen t studies using CTL 019 therapy  (Table 1-1).
Results from these ongoing clinical trials of CTL019 in r/r CLL and r/r adult and pediatric ALL 
have shown promising and durable anti-tumor efficacy  (Porter et al 2011 , Grupp et al 2013 , 
Maude et al 2014 ). It is anticipated that CTL 019 may offer a therapeutic alternative for patients 
with r/r B cell malignancies who are either SCT ineligible or who have relapsed after SCT, 
which may offer a greater durability  of remission than current salvage therapies. In the future, 
CTL 019 may also have the potential to replace allogeneic SCT as a therapeutic choice, 
expanding patient eligibility  by obviating the need for matched donors along with potentially 
lower rates of upfront mortality  and morbidit y.
As of January  2015, 
26 patients (18 DLBCL, 8 FL) have been enrolled in the Universit y of 
Pennsy lvania (UP) phase II trial (UPCC13413), and 20 patients have been treated with CTL019 
(5x108CTL 19+ cells). Overall response rate (ORR) at three months after CTL 019 infusion in 
18 evaluable patients (12 DLBCL, 6 FL) was 67%, with 6 patients showing PET -negative CRs 
(5 DLBCL, 1 FL ), and 6 patients showing disease progression. Six patients progressed before 
response assessment. Although data is preliminary  in terms of duration of response, all 
responding patients so far remain in remission up to 280 days. (Schuster et al. ASH 2014, 
abstract 3087). Other investigators have also reported their results in CLL, NHL and ALL with 
autologous anti-CD19 CARs (Davila et al 2014, Brentjens et al 2011, Kochenderfer et al 2012).
To date, no vector related AEs have 
been seen with higher CTL019 transgene levels of 
expression or persistence, with the longest periods of observation being 9, 10, and 22 months 
in three pediatric patients with r/r ALL and 12, 22, 42 and 43 months in 4 adult patients with r/r 
CLL as of March 2014.
Post-infusion monitoring for RCL in 
these trials with University  of Penns ylvania manufactured 
CTL 019 (CART -19) therapy  has shown no Vesicular Stomatitis Virus, Gly coprotein (VSV -G) 
by quantitative Polymerase Chain Reaction (q-PCR) (test for RCL ) detectable in any of the 
patient samples at time points up to 2 y ears (7 patients from UPCC03712 trial; 16 patients form 
UPCC04409 trial, 11 patients from CHP959 trial).
Clinical Cellular Kinetics (Pharmacokinetics)
r/r ALL
Based on preliminary  data, following infusion of CTL 019, a rapid expansion occurs with a 
median Tm ax occurring around 9 -10 da ys as measured by qPCR (copies of CTL019 transgene) 
and flow cy tometry  (% of CD3+/CTL 019+ and % CD3/CD8+ CTL 019) in patients with a best 
response of CR or CRi. The mean half-life in the CR/CRi patients (n=35) were reported to be 
approximately  32 days measured by PCR. The mean overall exposure (AUC28d) was 
approximately  12.4 and 15.5- fold lower in NR patients (n=3) compared with CR/CRi (n=46) 
for % of CD3+/CTL019+ and % CD3/CD8+ CTL019, respectively , signify ing the roles of both 
expansion and persistence for eliciting clinical response. AUC84d and Cmax also tended to be 
higher for CR/CRi patients compared to NR as measured by both qPCR and flow cytometry. 
Bone marrow concentrations of CTL019 (quantified as CD3+/CTL019+%) were measur able at 
1 month post-CTL 019 infusion in 40 of 46 CR/CRi pediatric ALL patients, and within those 
patients by 3
 months measurable in 24 of 46 patients sampled showing trafficking of CTL 019 
to the bone marrow space as measured by flow cytometry . Bone marrow data was limited in 

Novartis Confidential Page 51
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
NR patients (n=2) with very  low levels b y 1 month. Trafficking of CTL019 cells has also been 
demonstrated into the cerebral spinal fluid (CSF) in this patie
nt population ( Grupp 2013).
CLL
Rapid expansion occurs with a median Tmax occurring around 13 day s post infusion in CLL 
patients with a best response of CR or CRi as measured b y qPCR (copies of CTL 019 
transgene) and flow cy tometry  (% of CD3+/CTL 019+ and % CD3/CD8+ CTL 019). Limited
data from preliminary  analy sis suggests that Tmax may  be slightl y dela yed (ranges from 17.0 
-28.0 day s) in CLL patients achieving a PR/ PRi/NR/PD in Study  A2201 relative to CR/CRi 
patients. Based on limited data there appears to be a trend for a longer CT L019 half -life in 
CR/CRi CLL patients compared with PRi and PRi/NR/PD patients, this trend is consistent
with results observed in other indications (e.g. ALL).
 
 
 
 
Clinical Safety
Adult r/r ALL
As of Januar y 2015, 18 adult r/r ALL patients have been treated on a phase I trial (UPCC04409 
protocol, [STUDY_ID_REMOVED]) or phase II trial (UPCC21413 protocol, [STUDY_ID_REMOVED]) under the 
Penn I ND. The age range is 21 to 66 years. CRS was seen in 16 of 18 patients. Twelve patients 
(66.7%) had grade 3 or 4 CRS and nine (75%) of these patients required anti -cytokine therap y 
with tocilizumab.
The phase II adult r/r ALL UPCC21413 trial utilized a single infusion of a higher dose of 
CTL 019 cells. Among the first six patients treated, three deaths were attributable to Grade 5 
refractory  CRS in the setting of signi ficant concomitant infections. The subsequent six patients 
on this trial were then treated with a reduced cell dose of CTL 019. Two early  deaths out of these 
six subsequent patients were seen with the lower dose of CTL019 cells, however, CRS in these 
two ca ses was deemed not to be refractory to intervention.
Adult r/r B -NHL
At the University  of Pennsy lvania (UP), a Phase II trial with CTL019 in heavily  pretreated, 
relapsed/refractory  NHL patients has started in January  2014 (UPCC13413). This trial includes 
adult patients with relapsed or refractory  NHL including diffuse large B-cell lymphoma 
(DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). As of January  2015, 
26 patients (18 DLBCL, 8 FL) have been enrolled, and 20 patients have been treated with 
CTL 019 (5x108CTL19+ cells). All patients developed fever following T cell infusion, 
attributed to cytokine release syndrome (CRS). CRS was detected in 15 patients: 13 patients 
with grade 2 CRS, 1 patient with grade 3, and 1 patient with grade 4 CRS. One patient received 
steroids and tocilizumab for grade 4 CRS. CRS occurred within the first week of T cell infusion 
in all patients. Neurologic toxicity  was observed in 11 pts (1 grade 3 encephalopath y that 

Novartis Confidential Page 52
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
resolved with corticosteroids; 1 grade 3 dysarth ria and grade 3 ataxia). There was no treatment -
related mortalit y (Schuster et al. ASH 2014, abstract 3087).
Other institutions have also reported fatal SAEs in adult patients associated with the use of
CD19 CARs. In one of these fatal SAEs, death occurred 44 hours post-CD19 CAR T cell 
infusion. The investigators concluded that concomitant sepsis was the most likely  cause of death 
and attributed the etiology  of the death as possibly  related to CAR T cellinfusion (Brentjens 
2010). Two other fatal SAEs in adult patients have been reported by other institutions outside 
the Universit y of Penns ylvania. Each of these deaths occurred within the first two weeks of 
CAR infusion.
Table 1
-1 Summary  of ongoing human studies as of January  2015
Study Patients 
infusedPopulation Infusion Schedule Median CTL019 
transduced cells
UPCC04409, Phase 
I20
(14 CLL 
and 6 ALL)r/r CD19+ adult 
leukemia/lymphomaDay 0; 10%
Day 1; 30%
Day 2; 60%1.4 x 108
CHP959, Phase I 43
(42 ALL)r/r CD19+ pediatric 
leukemia/lymphomaDay 0; 10%
Day 14; 30%
Day 28; 60%
Later amended to 
Day 0, 1 and optional 
Day 14 (or later)3.5 x 106/kg body weight 
UPCC03712, Phase 
II28 r/r CLL Day 0; 100% Low dose cohort (14):
2.1 x 107
High dose cohort (14):
2.6 x 108
UPCC21413, Phase 
II12 r/r ALL Day 0; 100% 5 x107
UPCC13413, Phase 
II26 enrolled
(18 DLBCL 
and 8 FL)NHL:
Follicular (FL), 
Mantle Cell (MCL) & 
Diffuse Large B-Cell 
(DLBCL)Day 0; 100% 5 x108
14BT022, Phase II 15 r/r ALL Day 0; 100 % 5.0 x 106/kg body 
weight
For further information regarding clinical experience with CTL019, refer to the [CTL019 Investigator’s Brochure]
2 Rationale
2.1 Stud y rationale and purpose
Current therapies for DLBC L consist of combination chemotherapies with CD20- targeting 
immunotherapies. While over 50% of patients reach long-lasting complete remissions, 
approximately  one-third of patients are refractory  to therap y or will relapse after initial response. 
These patients have a poor prognosis, especially if they  do not respond to or are not e ligible for 
salvage regimen including HSCT.
The B-cell marker CD19 has emerged as a target for DLBCL treatment in the past years. It is 
widely expressed on normal and malignant B-cells throughout B-cell maturation but not on 
pluripotent stem cells or non–B- cell tissues. The vast majority  of DLBCL expresses CD19 

Novartis Confidential Page 53
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
(Kimura et al 2007 ). We have developed chimeric antigen receptor (CAR) T cells to target 
CD19+ cells (CTL019). This approach involves autologous patient
-derived T cells that are 
geneticall y modified ex-vivo via lentiviral transduction to express a CD19 antigen recognition 
domain attached to intracellular signaling domains that mediate T-cell activation. Data from 
patients with B -cell acute lymphocy tic leukemia (ALL), chronic l ymphocytic leukemia (CLL), 
and other CD19 expressing B cell lymphomas show that CTL 019 therapy  has potent anti-tumor 
activity .
As of January  2015, 26 patients (18 DLBCL, 8 FL) have been enrolled in the Universit y of 
Pennsy lvania (UP) phase II trial (UPCC13413), and 20 patients have been treated with CTL019 
(5x108CTL019+ cells). Overall response rate (ORR) at three months after CTL019 infusion in 
18 evaluable patients (12 DLBCL, 6 FL) was 67%, with 6 patients showing PET -negativ
e CRs 
(5 DLBCL, 1 FL ), and 6 patients showing disease progression. Six patients progressed before 
response assessment. Although data is preliminary  in terms of duration of response, all 
responding patients so far remain in remission up to 280 days. (Schuster et al. ASH 2014 , 
abstract 3087).
If CTL019 has preferential activity  in a subtype of DLBCL  is currentl y unknown. Since the 
mechanism of action of CTL019 is independent of BCR signaling, it is anticipated that patients 
with GC and ABC subtype and patients failing ibrutinib will equall y respond to CTL019. In 
addition, a cross -resistance with CD20
-targeted therapies such as rituximab is not expected.
Figure 2 -1 Mechanisms of actions of rituximab, ibrutinib and CTL019 in B 
lymphocy tes:
The monoclonal antibody rituximab targets CD20 on the cell surface, activates complement mediated
cytotoxicity, opsonic phagocy tosis also known as antibody -dependent cell -mediated cytotoxicity 
(ADCC) and direct lysis by NK cells. Ibrutinib targets the intracellular Bruton’s ty rosine kinase and 
interferes with cell signaling, inhibits the activating signal for PI3K and for NFkB, an inhi bitor of 
apoptosis. CTL019, CAR modified T -cells targeting CD19, lead to c ytokine release, T -cell proliferation 

Novartis Confidential Page 54
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
and activation of macrophages, neutrophils and other ly mphocy tes. Preclinical models are being 
investigated to determine the effects of ibrutini b on CTL019.
In summary , novel therapies for relapsed or refractory  DLBCL are urgently  needed. Targeting 
CD19 by CAR expressing T-cell therapy  has been shown to be effective eliminating very 
advanced B-cell malignancies and has the potential to induce complete remissions in patients 
otherwise beyond treatment. This trial will therefore assess the clinical activity  of CTL 019 in 
patients with relapsed/refractory  DLBCL mea sured as overall response rate.
2.2 Rationale for the study  design
This is a 5 y ear single ar m, multi -center, phase II study  to determine the efficacy  and safety  of 
CTL 019 in adult patients with relapsed or refractory  DLBC L. A single arm therapy  study design 
is supported by  the absence of effective therapies in this setting, and high unmet medical need. 
This study  will enroll approximately  100 patients to allow 80 patients treated in the main cohort . 
Approximately  18 patients will be enrolled in cohort A to allow for 15 patients to be treated. 
After the amendment 5 of the protocol, approximately  10 additional Japanese patients will be 
enrolled, to allow for at least 6 additional patients to be treated (total 9 treated in Japan) . After 
assessment of eligibility , patients qualify ing for the study  will be enrolled and start 
lymphodepleting chemotherap y, i.e. fludarabine and cyclophosphamide, or bendamustine for 
patients with cyclophosphamide resistance, as indicated per protocol, followed by a sin gle dose 
of CTL 019 transduced cells.
Previous clinica l data with CTL 019 therapy  has been generated using cell product manufactured 
at the Cell and Vaccine Production Facility  (CVPF) at the Universit y of Pennsy lvania. This trial 
will utilize product manufactured at a Novartis manufacturing facility. Alimited safety run -in 
stage will be conducted at the beginning of this trial. These patients will be included in the total 
targeted patient population.
The efficacy of CTL019 will be evaluated through the primary endpoint of ORR as determined 
by an Independent Review Committee (IRC) assessment, including CR and PR, until 
progression or relapse for up to 5 years. The choice of ORR as the primary  endpoint is based 
on evidence that ORR is a standard outcome measurement in DLBCL 
(Cheson et 
al 2007). Objective response is the most predictive factor of outcome after 
autologous HSCT (i.e. after salvage therap y)
 (Johnston et al 2008 ). For patients not responding 
to the first salvage regimen, the outcome is extremely  poor, with a median OS of approximately  
4 months ( Elstrom et al 2010 , Friedberg 2011).
Safety  will be monitored throughout the trial. Per Health Authorit y guidelines (FDA, EMA) for 
gene therapy  products or advanced therapy  medicinal products that utilize integrating vectors 
(e.g. lentiviral vectors), all patients treated with CTL 019 must be monitored for specific 
toxicities for up to a total of fifteen years, irrespective of their response to 
CTL 019. All patients 
will be monitored in this trial for five years, followed by semiannual and annual safet y 
assessments in a separate long-term safet y follow -up protocol (CCTL019A2205B) for 
additional ten years. 
The purpose of this is to assess the risk of acute and delay ed AEs suspected 
to be related to CTL019 therap y, and to monitor for replication competent lentivirus (RCL ).
During the “treatment and primary follow -up phase” all adverse events will be collected for the 
first 12 months only . After 12 months, if a patient is still in the primary  follow -up phase, only 

Novartis Confidential Page 55
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
protocol defined adverse events and adverse events of special interest will be collected. Patien ts 
completing or discontinuing from this primary  follow -up phase will have an “End of Treatment 
and Primary  Follow -Up Visit”. Patients who discontinue the “treatment and primary follow -up 
phase” before month 60 will continue to be followed in the secondary follow -up phase in order 
to collect data on delay ed adverse events, in line with HA recommendation for gene therapy 
products. Patients not entering or finishing the secondary  follow -up will be followed in a 
separate long-term safety follow- up protocol (LT FU, CCTL 019A2205B). It is anticipated that 
patients may leave the primary  follow -up and move to secondary  follow -up for the following 
reasons ( Figure 2 -2):
1.Progression of disease/relapse
2.Pursuing HSCT while in remission
3.Withdrawal from the primary  follow up
Figure 2 -2 Expected flo w of patients in CTL019C2201
Based on current clinical experience with CTL019 therapy  acute toxicities are expected in the 
first 28 days after single infusion of CTL 019 cells. Expected acute toxicities include elimination 
of normal CD19 positive B cells, cytokine release syndrome (CRS)/macrophage activation 
syndrome (MAS) associated with the onset of antitumor responses mediated by  large numbers 
of activated T cells, tumor lysis syndrome (TLS), and toxicities associated with the 
lymphodepleting chemotherap y conditioning regimen used with adoptive T
-cell therapy . For 
more details and guidance on manage ment of these toxicities refer toSection 6.2.4.2.1 . These 
acute toxicities, with the exception of B cell depletion or aplasia, are all typically  reversible and 
resolved within several week
s to months of CTL019 infusion.
Potential long-term toxicities of CTL 019 therap y may include continued B cell aplasia with 
increased risk of infections if CTL019 cells persist. Other potential toxicities may include 
insertional site oncogenesis, expression of replication competent lentivirus (RCL ) detection, 
and potential effects of maternal CTL019 cells on pregnancy  outcome. RCL , autonomous 
proliferation of infused CTL 019 T cells, and insertional site oncogenesis during the CTL019 
therap y trials have not been observed to date.
Collection of such long term effects of CTL019 cell therap y will help to further define the risk -
benefit profile of CTL019 in patients with B cell malignancies. These observations will also 

Novartis Confidential Page 56
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
serve to provide further guidance to patients, health care providers and investigators of such 
risks and their detection and management.
Patients that complete or discontinue from this study  will be requested to consent to the L TFU 
study , CCTL 019A2205B, to meet health authorit y guidelines.
2.2.1 Rationale for ly mphodepletion
Adoptive immunotherapy  strategies may be able to capitalize on homeostatic T cell 
proliferation (Dummer et al 2002), a recent finding that naive T cells begin to proliferate and 
differentiate into memory -like T cells when total numbers of naive T cells are reduced below a 
certain threshold (Goldrath and Bevan 1999, Surh and Sprent 2000 ). Host lymphodepletion may 
enhance the effectiveness of adoptively  transferred T cells (Dummer et 
al 2002). Homeostatic 
T 
cell proliferation can lead to activation of certain immune cell subsets (King et al 2004), 
providing a clue to improved anti-tumor responses. T cells can undergo up to seven rounds of 
cell division after being deprived of contact with antigen presenting cells (Kaech and Ahmed 
2001, van Stipdonk et al 2001). Lymphodepletion eliminates regulatory T -cells and other 
competing elements of the immune system that act as “cytokine sinks”, enhancing the 
availability  of cytokines such as IL-
7 and IL-15 ( Klebanoff et al 2005). This hypothesis has 
been tested clinicall y in patients with metastatic 
melanoma refractory  to conventional 
treatments ( Dudley  et al 2002 ). The patients received a l ymphodepleting conditioning regimen 
consisting of cyclophosphamide (60 mg/kg x 2 days) and fludarabine (25 mg/m2x 5 days) prior 
to adoptive transfer of T cells. More than 40 patients with myeloma have been treated with 
CARs and lymphopenia after lymphodepleting chemotherap y, and observed improved 
engraftment (Laport et al 2003, Rapoport et al 2005 ). In this protocol, it is proposed to infuse 
CTL 019 T cells into patients that are rendered lymphopenic as a result of cytotoxic 
chemotherap y. Recent data indicates that the increased antitumor efficacy of adoptive transfer 
following host conditioning is more than simply  “making room” because the quantitative 
recovery  of adoptivel y transferred T cells in mice reveals that in vivo proliferation following 
adoptive transfer is identical in mice with or with out previous irradiation ( Palmer et al 2004
).
As of January  2015 in the ongoing CTL019 lymphoma study  UPCC13413, all 20 patients 
infused with CTL 019 cells received a lymphodepleting chemotherap y prior to adoptive transfer 
of T cells. Five patients received a l ymphodepleting regimen consisting of benda mustine, nine 
patients received cyclophosphamide, one patient received fludarabine and cyclophosphamide, 
two patients received EPOCH; one patient received lenalidomide + CHOP, and two patients 
received cyclophosphamide in combination with radiation therapy (Schuster et al. ASH 2014, 
abstract 3087). Similarly, in ongoing CTL019 pediatric and adult ALL studies, most patients 
infused with CTL019 received a lymphodepleting conditioning regimen prior to adopt ive 
transfer of T cells.
For further information regarding clinical experience with lymphodepletion prior to 
CTL 019 
infusion, refer to the [CTL019 Investigator’s Brochure].
2.3 Rationale for dose and regimen selection
The dose selected for this trial is a single infusion of 5 x 108CTL019 cells based on available 
data collected in patients with CLL, ALL and non -Hodgkin’s l ymphoma (NHL) indicating it is 
well tolerated. A clear relationship between response and dose of infused transduced CTL019 

Novartis Confidential Page 57
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
cells has not been established in data collected to date in patients with CLL, ALL, and non-
Hodgkin’s l ymphoma but will be explored further in this trial. This is likely  the consequence of 
the ability  of CTL019 transduced cells to proliferate and expand extensively  (e.g. 1000 
to >10,000 fold) in vivo. Thus, the administered dose may underestimate the number of CTL 019 
cells in vivo following engraftment and expansion and will 
vary from patient to patient, and 
across diseases. Additional considerations in this dose selection will have to take into account 
the manufacturing feasibility  of producing adequate numbers of CTL019 transduce d cells and 
important differences in toxic ity profile across indications.
Animal studies supported a threshold dose of CTL 019 cells and therefore the initial clinical 
dose selection was within the range of 1 x 107to 1 x109CTL019 transduced cells 
(Milone et al 2009 ). Please see IB for further information on preclinical studies.
For safet y reasons, initial dosing in the pilot study  CTL019B2102J/UPCC04409 was divided 
among three split infusions: 10%, 30% and 60% of the total cell dose (up to 5x109). In this 
study , autologous CART -19 transduced cells were administered to 20 patients with 
relapsed/refractory  CD19+ B-cell malignancies (14 CLL and 6 ALL). While the target cell dose 
was5x109, the acceptable r ange was 1.5 x107to 5 x109 CART -19 cells. Of the 11 patients that 
had a CR, 7 patients received a single infusion (approximately  5x108cells) due to the onset of 
fevers, yet CRs were observed with either 1 to 3 infusions. Thus, patients responded both aft er 
a single infusion and after multiple infusions of CART -19 cells.
Based on results from study  CTL019B2102J/UPCC04409, the target dose levels of 1-5x107and 
1-5x108 CART - 19 transduced cells were selected for a subsequent dose optimization study  in 
CLL (study CTLA019A2201/UPCC03712). Patients with heavily  pretreated CLL frequently 
have a significantl y lower percentage of CD3+ cells in leukapheresis products than patients 
with other types of hematologic malignancy . Lentiviral transduction and expansion there fore 
could be limited in the setting of reduced CD3+ cells. As observed in the phase I study , 
manufacturing success rates declined to approximately  50% when targeting 109or more CART -
19 cells. Targeting 108or fewer cells has not been an issue from a manu facturing standpoint. A 
single infusion of CART- 19 cells in the dose optimization study  (CTL019A2201/UPCC03712) 
was clinicall y well tolerated and responses have been seen with both dosing schemas. The most 
recent data update from this dose optimization study in CLL have not shown a discernible 
difference with regards to incidence or severity  of CRS or any other toxicity  between the low 
and the high dose schedules tested (i.e. 1-5x107 vs 1-5x108). Of the 26 patients dosed to date, 
14 have experienced CRS (6 in the high dose and 8 in the low dose arm, respectivel y). CRS 
cases 
have occurred several days post CTL 019 infusion and have been generall y mild to 
moderate and manageable. No treatment related deaths have been noted in either arm. Notably, 
in patients wi th CLL achieving CR or a lasting PR, the number of infused CTL 019 transduced 
cells has ranged from 1.4 x 107to 1.1 x 109cells. This two -log-fold difference did not support 
a statistically  significant dose response relationship in spite of a numerically  higher response 
rate amongst patients dosed in the high dose arm. Thus far, 8 out of 23 assessable patients have 
responded (4 CR and 4 PR), including 5 (50%) responders in the high dose arm and 3 (23%) 
responders in the low dose arm (p=0.37).
In the ongoing trial UPCC13413 in adult patients with relapsed or refractory  NHL (including 
diffuse large B-cell lymphoma (DLBCL) , follicular lymphoma (FL), and mantle cell lymphoma 
(MCL )), treated patients have received a single dose of 5 x 108CTL 019 transduced cells 

Novartis Confidential Page 58
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
(translating into a median dose of 5.8 x 106/ kg (range: 3.7 – 8.9 x 106) CTL 019 transduced 
cells) .
Unique adverse events following T cell infusion included cytokine release syndrome (CRS) and 
neurologic disturbances. CRS occurred within the first week of T cell infusion, and there were 
no episodes of delay ed CRS. Neurologic toxicity  was observed in 11 pts: Three patients 
developed transient delirium (1 grade 2, 2 grade 3) and one patient developed a possibly  related, 
grade 5 encephalopathy . Like in CLL, preliminary  data suggest no dose-response or dose-
toxicity  relationship became obvious (18 evaluated patients January  2015).
Data from the adult ALL trials previously  supported a safe and efficacious dose range of 1.4 x 
107to 1.1 x 109CTL019 transduced cells. However, 3 
patients with adult r/r ALL in study 
UPCC21413 died within 16 days post-CTL019 infusion possibly  related to CTL 019 infusion 
(in the presence of concomitant infectious complications in all three instances). After health 
authority  consultation , the dose for treatment of patients with adult ALL in study  UPCC21413 
was reduced to 1 to 5 x 107transduced CAR T cells. No deaths have occurred in ongoing 
pediatric ALL trials. In pediatric ALL patients, clinical responses were seen after the infusion 
of CTL 019 transduced cell doses ranging from 1.1 to 18.1 x 106transduced CTL 019 cells/kg 
body  weight with an age range of 5 to 22 and a weight range of 18.3 to 122.0 kg. Toxicity  as 
assessed by severit y of CRS appears to correlate with pre-infusion tumor burden in pediatric 
ALL but 
not with transduced CTL019 cell numbers within the range of cell doses studied. 
Therefore, the targeted CTL 019 cell dose for pediatric ALL patients is 2 to 5 x 106CTL019 
transduced cells per kg body  weight with a maximum dose of 2.5 x 108CTL 019 transduced 
cells (non-weight adjusted). Based on the current safet y profile, no dose modifications were 
instituted in other indications than ALL.
It is important to note that the severity  and incidence of CRS induced by similar CTL 019 dos ing 
schemas differs between adult ALL and CLL or NHL and therefore, dose selection for the latter 
indications should be based on toxicity  and efficacy  data observed in trials for patients with 
CLL or NHL. It is important to note that no deaths have been reported to date amongst more 
than 50 patients with CLL or NHL treated in clinical trials at the University  of Pennsy lvania. 
This is likely  because the use of doses ranging from 1 to 5x108cells in CLL or NHL (the dose 
range used to treat approximately  two t hirds of patients) has been associated with less frequent 
and more attenuated forms of CRS compared with those induced by the same dose range in 
adult ALL. Furthermore, in the dose optimization study  in CLL, the highest dose range tested 
(1 to 5x108) rende rs numericall y higher response rates compared with the lower dose range (1 
to 5x107).
In summary , based on clinical experience from past and ongoing trials in r/r CLL and NHL at 
the University  of Pennsy lvania, where the upper range of the target dosing tested in study  
CTL 019A2201/UPCC03712 (i.e. 1-5x108) was effective and safe, a target dose of 5 x 108
CTL 019 viable transduced cells has been chosen for further development in CLL and NHL. 
The allowable dose range is 1 -5x108viable transduced cells.
2.4 Rationale for choice of combination drugs
Not applicable.

Novartis Confidential Page 59
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
2.5 Rationale for choice of comparators drugs
Not applicable.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1 below.

Novartis Confidential Page 60
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary : Refer to Section 10.4
Evaluate the efficacy of CTL019 therapy in the main cohort Overall response rate (ORR), which includes complete response (CR) and 
partial response (PR) as determined by IRC assessment in the full analysis 
set (FAS) of the main cohort
In addition sensitivity analyses will be performed using the local investigator 
response assessments
Key secondary : Refer to Section 10.5.1
Not applicable Not applicable
Other secondary : Refer to Section 10.5.2
Evaluate safety of CTL019 Type, frequency and severity of adverse events and laboratory abnormalities
Evaluate time to response Time to response, i.e. time between date of CTL019 infusion until first 
documented response (CR or PR) 
Evaluate duration of overall response (DOR) Duration of response, i.e. the time from achievement of CR or PR, whichever 
occurs first, to relapse or death due to DLBCL
Evaluate event free survival (EFS) EFS, i.e. the time from date of CTL019 infusion to the date of first 
documented disease progression or relapse, new treatment f or lymphoma or 
death due to any cause
Evaluate progression free survival (PFS) PFS, i.e. the time from date of CTL019 infusion to the date of first 
documented disease progression or death due to any cause
Evaluate overall survival (OS) OS, i.e., the ti me from date of CTL019 infusion to the date of death due to 
any cause
Evaluate efficacy and safety in histological and molecular 
subgroups (GC, ABC, other)ORR, PFS, OS, EFS, DOR and AEs in histological and molecular subtypes
Characterize the in vivo cellular PK profile (levels, 
expansion, persistence) of CTL019 transduced cells into 
target tissues (blood, bone marrow, cerebral spinal fluid 
and other tissues if available), summarized by clinical 
response-PK parameters: Cmax, Tmax, AUCs, T1/2, Clast, Tlast and/or other relevant 
PK parameters in peripheral blood, bone marrow , as appropriate
Characterize immunogenicity (pre-existing (pre -dose) and 
post-infusion) in patient treated with CTL019-Summary of immun ogenicity(cellular and humoral)

Novartis Confidential Page 61
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Objective Endpoint Anal ysis
Describe presence of RCL - RCL by VSV-g q -PCR
Evaluate efficacy and safety in cohort A ORR, PFS, OS, EFS, DOR and AEs in cohort A 
Evaluate the Overall response rate for all patients treated ORR in all patients treated

Novartis Confidential Page 62
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 63
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
4 Study  design
4.1 Description of study  design
This is a single arm, multi- center, phase II study  to determine the efficacy  and safet y of CTL019 
in adult patients with relapsed or refractory  DLBC L. The study  will have the following 
sequential phases for all patients: Screening (Section 7.1.1), Pre-treatment, Treatment and 
Primary  follow -up, Secondary  follow -up, and Survival follow -
up.
Efficacy  for all patients will be evaluated using CT/MRI  based on theLugano Classification 
(updated Recommendations for Initial Evaluation, Staging, and Response Assessment of 
Hodgkin and Non-Hodgkin Lymphoma; Cheson et 
al 2014; Barrington et al 2014)  
 If local health authorities require the use of specific imaging modalities 
(e.g., MRI ) and/or a different imaging schedule for disease 
response assessment purposes a 
decision will be made on a case by case basis upon discussion between Novartis and the 
Investigator. Efficacy  will be assessed at Day 28 and months 3, 6, 9, 12, 18, 24 months and then 
every  12 months for 5 years until documented disease relapse or disease progression. PET-CT 
will be performed at baseline and at Month 3. Due to the mechanism of action of CTL019, the 
Day 28 assessment should be interpreted in context of other clinical parameters that suggest 
true progression rather than pseudo -progression due to inflammatory  changes and tumor 
swelling ( De Velasco et al 2015).
. Although clinical guidelines (ESMO and NCCN) do not recommend routine imaging in 
patients in CR for longer than 2 years, in the context of this clinical trial an extended efficacy 
follow up by  CT/MRI is justified.
At the beginning of the trial, a safet y run-in stage will be conducted to enroll at least three 
patients to assess the acute safet y profile and product characteristics of the Novartis 
manufactured CTL019 cell product. The initial patients will be enrolled in this trial 
subsequently  with minimum interval between CTL019 infusions of 14 days. Full safet y profiles 
and product characteristics of these patients following lymphodepleti ngchemoth erapy and 
CTL 019 infusion will be reported to the Health Authorities. The acute and subacute toxicit y 
profile for CTL019 cell product manufactured at the University  of Pennsy lvania has been 
established in patients with r/r B-NHL with only low grade CRS observed in patients with 
DLBCL.
The data to be reported will include demographics, lymphodepleting chemotherapy , total and 
CTL 019 transduced viable T cell doses, AE/ Serious Adverse Events (SAEs), standard 
laboratory  data (hematology  and chemistry ) and CTL 019 cellular PK.
For the purpose of safety onboarding of new sites, after the above safety  run-in stage has been 
completed, a staggered approach will also be utilized at each new respective site (with no prior 
experience administering CTL 019) and will occur as follows:
1stpatient infusion
, wait 14 day s
2ndpatient infusion, wait 14 days
Following completion of this staggered enrollment of the first two patients, the new site 
may then proceed with infusion of patients without staggering the patients.

Novartis Confidential Page 64
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Safety  will be assessed throughout the stud y.
One additional cohort has been added to the original main study  cohort (80 patients treated with 
CTL 019 manufactured at the Novartis manufacturing facility  in Morris Plains, USA) .
The additional cohort A will enroll approximately  18 
patients to allow at least 15 patients 
infused with CTL019 manufactured at the Fraunhofer Institut für Zelltherapie .After the 
amendment 5 of the protocol, approximately  10 additional Japanese patients will be enrolled, 
to allow for at least 6 additional patients to be treated (total 9 treated in Japan) .
Figure 4-1 CTL019C2201 study  design
4.1.1 Leuka pheresis asse ssment
Non mobilized leukapheresis products collected from the patient prior to study  entry (historical) 
may be usable for CTL019 manufacturing if collected at an appropriatel y certified apheresis 
center and the product is accepted for manufacturing. If a historical leukapheresis product is not 
available, an apheresis procedure will be scheduled for cell procurement prior to final 
enrollment.  
 
 
Sample sentinel vials collected from the leukapheres is will be sent to Novartis manufacturing 
prior or together with the leukapheresis product.
For guidelin e s on optimal patient timing ofapheresis collection, please refer tothe
Leukaphere sisKey Requirements within the[Leukapheresis ,Cryopreservation &Scheduling
Manual ].

Novartis Confidential Page 65
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Following informed consent, information onthe patient’s leukapheresis product will be 
transferred to Novartis manufacturing. Novartis manufacturing will then evaluate the patient’s 
apheresis product for acceptance. Final enrollment is defined as the point at which the patient 
meets all clinical inclusion/exclusion criteria, and the patient’s leukapheresis product is 
accepted for manufacturing .
Please refer to the Leukaphere sis Key Requirements within the [Leukapheresis, 
Cryopreservation &Scheduling Manual ]on the recommended procurement, as well as handling 
and shipment procedures of the apheresis samples to the designated manufacturing facility .
4.2 Definition of end of the study
The end of study  is defined as the last patients last visit (LPLV), which is the last patient’s 
Month 60 evaluation, or the time of premature withdrawal. Patients who discontinue the 
“Treatment and Primary  Follow -Up Phase” before month 60 will continue to be followed in the 
secondary  follow -up phase in order to collect health authority  requested data (e.g. delay ed 
adverse events) up to 5 years after CTL019 infusion. It is anticipated that patients may leave 
the primary  follow -up and move to secondary  follow -up due to reasons including: progression 
of disease, treatme nt failure, relapse after remission, pursuing SCT while in remission, or 
withdrawal from the primary  follow -up.
In addition, semiannual and annual evaluations will be performed for up to 15 years from the 
date of infusion on all patients under a separate long term follow -up (LTFU) protocol as 
recommended by health authority  guidance for patients treated with gene therapies. All patients 
who either complete or prematurel y discontinue from the study  will be enrolled in this 
destination protocol at the time ofstudy  completion/discontinuation (a separate informed 
consent form will be provided for this protocol; Section 7.1.7).
Patients may continue to be followed under the current protocol for survival , pregnancy 
outcomes and secondary  malignancy , which can be conducted via a form or telephone contact 
until Last Patient Last Visit (LPLV) as defined above or until they choose to enroll into the long 
term follow -up protocol (CCTL 019A2205B) , whichever occu rs first.
4.3 Early study  termination
The study  can be terminated at any time for any reason by the sponsor, Novartis, or if any of 
the stopping criteria described in Section 6.2.4.1.1 are met. Should this be necessary , the patient 
should be seen as soon as possible and the same assessments should be performed as described 
in Section 7 for a discontinued or withdrawn patient. The investigator may be infor med of 
additional procedures to be followed in order to ensure adequate patient consideration is given 
to the protection of the patient’s interests. For patients who have received CTL 019 infusion, a 
long term post-study  follow -up for delay ed AEs including monitoring for lentiviral safet y will 
still continue under a separate destination protocol for 15 years post infusion per health authorit y 
guidelines. The investigator will be responsible for informing Institutional Review Boards 
(IRBs) and/or Independent Ethics Committees (IECs) of the earl y termination of the trial.

Novartis Confidential Page 66
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
5 Population
5.1 Patient population
The study  will enroll adult patients ≥ 18 years with relapsed or refractory  DLBCL , having failed 
2 or more lines of therapy  and not eligible for HSCT. A minimum o f 25 patients in each of the 
two most common subtypes of DLBCL: GC and ABC type will be treated in the main study 
cohort . Patients with T cell rich/histiocy te rich large B cell lymphoma (THRBCL), primary 
cutaneous D LBC L, primary  mediastinal B cell l ymphoma (PMBCL), EBV positive DLBCL of 
the elderl y, Richter’s transformation, and Burkitt lymphoma are not allowed.
Patients enrolled in this study  are not permitted to participate in additional parallel 
investigational drug or device studies. The investigator ordesignee must ensure that only 
patients who meet all the following inclusion and none of the exclusion criteria are offered 
treatment in the study .
5.2 Inclusion criteria
Patients eligible for inclusion in this study  have to meet all of the following criteria :
1.Written informed consent must be obtained prior to any  screening procedures
2.Patients must be 
≥18 y ears of age
3.Histologicall y confirmed DLBCL at last relapse (by central pathology review before 
enrol lment).
a.Sufficient FFPE tumor samples must be available for histological and molecular 
subty pe testing along with a corresponding pathology  report. A recent tumor sample 
obtained for the purpose of the study  must be submitted however if not clinically  
feasible , an archival tumor biopsy from the most recent rela psemay be submitted 
instead. Excisional biopsies should be submitted wherever possible; in cases where 
this is not possible, a core needle biops y is allowable. Fine needle aspiration (FNA) is 
not allowed.
4.Relapsed or refractory  disease after ≥2 lines of c hemotherapy , including rituximab and 
anthracy cline, and either having failed autologous HSCT, or being ineligible for or no t 
consenting to autologous HSCT
5.Measurable disease at time of enrollment:
a.Nodal lesions greater than 20 mm in the long axis, regardle ss of the length of the short 
axis
b.Extranodal lesions (outside ly mph node or nodal mass, but including liver and spleen) 
≥ 10 mm in long AND short axis
For detailed information please refer to Section 14.1 Guidelines for efficacy 
evaluation in in diffuse large B cell l ymphoma and follicular ly mphoma studies 
6.Life expectancy  ≥12 weeks
7.ECOG performance status that is either 0 or 1 at screening

Novartis Confidential Page 67
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
8. Adequate organ function:
a.Renal function defined as:
A serum creatinine of ≤1.5 x ULN OR
eGFR ≥ 60 mL /min/1.73 m2
b. Liver function defined as:
ALT ≤ 5 times the ULN for age
Bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert –Meulengracht 
syndrome; patients with Gilbert -Meulengracht s yndrome may  be included if their 
total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x UL
N
c.Must have a minimum level of pulmonary  reserve defined as ≤ Grade 1 d yspnea and 
pulse ox ygenation > 91% on room air
d.Hemody namicall y stable and LVEF ≥ 45% confirmed by  echocardiogram or MUGA
e.Adequate bone marrow reserve without transfusions defined as:
Absolute neutrophil count (ANC) > 1.000/mm3
Absolute ly mphocy te count (AL C) >300/ mm3, and
absolute number of C D3+ T cells 
>150/mm3
Platelets ≥ 50.000/mm3
Hemoglobin > 8.0 g/dl
9.Must have an apheresis product of non -mobilized cells accepted for manufacturing.
10.Women of child- bearing potential defined as all women physiologicall y capable of 
becoming pregnant, and all male participants must use highl y effective methods of 
contraception for at least 12 months following CTL019 infusion and until CAR T cells are 
no longer present by  qPCR on two consecutive tests.
Highl y effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
patient . Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post- ovulation 
methods) and withdrawal are not acceptable methods
ofcontraception
Female sterilization (surgical bilateral oophorectomy  with or without hysterectom y)
or tubal ligation at least six weeks before taking study  treatment. In case of 
oophorectom y alone, only  when the reproductive status of the woman has been 
confirmed b y follow up hormone level assessment.
Male sterilization (at least 6 months prior to screening). For female patient son the 
study  the vasectomized male partner should be the sole par tner for that patient.
BOTH of the following forms of contraception must be utilized:
Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
exampl e hormonal vaginal ring or transdermal hormonal contraception
Barrier methods of contraception: condom or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
Use of intrauterine devices (IUDs) is excluded due to increased risks of infection and bleeding. 
Placed IUDs may  remain in place but additional measures of contraception are mandated.

Novartis Confidential Page 68
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Additionally , drugs that induce cytochrome P450 (CYP) enzymes can increase the clearance of 
sex hormones that are el uted by  the devices and reduce contraceptive efficacy ; given the pol y-
pharmacy  for these patients this presents a real risk of device failure and possible inadvertent 
resultant conception.
In case of use oforal contraception women should have been stable on the same pill for a 
minimum of 3 months before taking stud y treatment.
11.Sexually active males must accept to use a condom during intercourse for 12 months after 
treatment as they  should not father a child in this period. A condom is required to be used 
also by  vasectomized men (as well as during intercourse with a male partner or sterile 
female partner ) as WBCs are a normal part of sem enand transmission of CTL019 
transduced cells may  occur .
5.3 Exclusion crit eria
Patients eligible for this study  must not meet anyof the following criteria:
1. Prior treatment with an y prior anti-CD19 /anti-CD3 therap y, or any  other anti -CD19 
therap y
2. T reatment with an y prior gene therap yproduct
3.Active CNS involvement by  malignancy
4.Prior allogeneic HSCT
5. Eligible for and consenting to autologous HSCT
6.Chemotherapy other than lymphodepleting chemotherap y within 2 weeks of infusion
7.Investigational medicinal product within the last 30 day s prior to screening
Note: Investigational therapies must not be used at any  time while on study  until the first 
progression following CTL 019 infusion.
8.The following medications are excluded:
a.Steroids: Therapeutic doses of steroids must be stopped > 72 hours prior to 
leukapheresis and > 72 hours prior to CTL 019 infusion. However, the following 
physiological replacement doses of steroids are allowed: <12 mg/m2/day 
hydrocortisone or equivalent
b.Immunosuppression: Any other immu nosuppressive medication must be stopped ≥ 
2weeks prior to leukapheresis and ≥ 2 weeks prior to CTL 019 infusion. This could 
include check point inhibitors (monoclonal antibodies and small molecule 
modulators).
c.Antiproliferative therapies other than ly mphodepleting chemotherap y within 2 
weeks of leukapheresis and 2 weeks prior to infusion
Short acting drugs used to treat leukemia or ly mphoma (e.g. t yrosine kinase 
inhibitors, and hy droxyurea) must be stopped > 72 hour prior to leukapheresis 
and > 72 hours prior to CTL 019 infusion
Other cy totoxic drugs, including low dose daily  or we ekly maintenance 
chemotherap y, must not be given within 2 weeks prior to leukapheresis and 
within 2 weeks prior to CTL 019 infusion.

Novartis Confidential Page 69
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Fludarabine may  be associated with prolonged l ymphopenia. This should be 
taken into consideration when evaluating the optima l timing for leukapheresis 
collection.
d.Antibody use including anti -CD20 therap y within 4 weeks prior to infusion or 5 half -
lives of the respect iveantibody , whichever is longer. Note: Rituximab is excluded 
within 4 weeks prior to infusion.
e.CNS disease prophylaxis must be stopped > 1 week prior to CTL 019 infusion (e.g. 
intrathecal m ethotrexate)
9.Prior radiation therap y within 2 weeks of infusion
10.Active replication of orprior infection with
hepatitis B or active hepatitis C (HCV RNA 
positive)
11.HIV positive patients
12. Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture 
positive ≤ 72 hours prior to infusion)
13.Unstable angina and/or my ocardial infarction within 6 months prior to screening
14.Previous or concurrent malignancy  with the following exceptions:
a.Adequatel y treated basal cell or squamous cell carcinoma (adequate wound healing is 
required prior to study  entry )
b.In situ carcinoma of the cervix or breast, treated curatively  and without evidence of 
recurrence for at least 3 years prior to the study
c.A primary  malignancy  which has been completel y resected and in complete remission 
for ≥ 5 y ears
15.Pregnant or nursing (lactating) women .NOTE: 
female study  participants of reproductive 
potential must have a negative serum or urine pregnancy  test performed within 24 hours 
before lymphodepletion
16.Intolerance to the excipients of the CTL 019 cell product
17.Cardiac arrh ythmia not controlled with medical management
18. R emoved
19.Prior treatment with an y adoptive T cell therap y
20.Patients with T -cell rich/histiocy te rich large B -cell ly mphoma (THRBCL), primary  
cutaneous large B -cell lymphoma, primary  mediastinal B -cell l ymphoma (PMBCL ), EBV 
positive DLBCL  of the elderly , Richter’s transformation, and Burkitt ly mphoma
21.Patients with active neurological auto immune or inflammatory  disorders (e.g. Guillain -
BarréSyndrome, Am yotrophic Lateral Sclerosis)
6 Treatment
6.1 Stud y treatment
CTL 019 is an autologous cellular immunotherapy  product that is comprised of CD3+ T cells 
that have undergone ex vivo T cell activation, gene modification, expansion and formulation in 
infusible cry omedia. The transgene to be expressed via lentiviral vector transduction is a CAR 
targeted against the CD19 antigen. The CAR contains a murine scFv that targets CD19 lin ked 

Novartis Confidential Page 70
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
to a transmembrane region derived from the CD8 receptor, which is linked to an intracellular 
bipartite signaling chain of TCR -ζ (or CD3- ζ) and 4 -1BB intracellular signaling domains. The 
extracellular scFv with specificit y for CD19 is derived from a mouse monoclonal antibody . T 
cells which are enriched from a patient leukapheresis unit are expanded ex vivo using 
commerciall y available magnetic beads that are coated with anti-CD3 and anti-CD28 
monoclonal antibodies. The cells are transduced with the CD19 CAR lentiviral vector which 
ensures that only peripheral white blood cells enriched for lymphocy tes are exposed to the 
vector. The residual non-integrated vector is washed away  during the process. CTL019 cells 
will be expanded ex vivo for up to 10 days. Atthe end of the culture, the CTL019 cells are 
depleted of magnetic beads, washed, concentrated, and cryopreserved. Results from a release 
testing procedure are required prior to release of the product for infusion.
6.1.1 Dosing regimen
The target dose of CTL019 transduced cells for adult patients will consist of a single infusion 
of 5 x 108viable CTL019 transduced cells, which will be administered via intravenous infusion. 
The acceptable dose range is considered as 1 -5x108viable CTL 019 transduced cells.
6.1.1.1 Lymph odepleting chemotherapy
It is anticipated that many  patients will have been receiving chemotherapy  for relapsed or 
resistant disease. Prior to CTL 019 cell infusion, an additional lymphodepleting chemotherap y 
cycle is planned. The use of any additional chem otherap y prior to the recommended 
lymphodepleting chemotherap y will be at the discretion of the investigator and dependent on 
the patient’s disease burden. If patients have a White Blood Cell (WBC) count ≤1,000 cells/µL 
within one week prior to CTL 019 infusion, ly mphodepleting chemotherapy is NOT required.
When given, lymphodepleting chemotherap y should be started 14to 5days before CTL 019 
infusion (D1) to allow for at least 48 hours from last dose of lymphodepleting chemotherap yto 
CTL 019 infusion
.The chemotherapy  start date will vary based on the selected chemotherapy . 
The purpose of this chemotherap y is to induce lymphopenia in order to facilitate engraftment 
and homeostatic expansion of CTL 019 cells. For lymphodepleting chemotherap y, 
cyclophosph amide -based regimens are the agents of choice as there is the most experience with 
the use of these agents in facilitating adoptive immunotherapy. The proposed lymphodepleting 
regimen is:
Fludarabine (25 mg/m2intravenousl y [i.v.] daily  for 3 doses) and cy clophosphamide (250 
mg/m2i.v. daily  for 3 doses starting with the first dose of fludarabine)
If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the patient 
demonstrated resistance to a previous cyclophosphamide -containing regime n, then the 
following regimen should be used:
Bendamustine 90 mg/m2i.v. daily  for 2 day s
Note: Female patients of childbearing potential must have a negative pregnancy  test (urine or 
serum) within 24 hours prior to the start of lymphodepleting therapy . Ifthe patient does not 
require l ymphodepleting therap y, sheshould still have a negative pregnancy test at the required 
visit that takes place 14 to 5 day s before CTL019 infusion (see Table 7 -1).

Novartis Confidential Page 71
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
6.1.1.2 CTL019 infusion
The CTL019 cell product will be prepared and released by the manufacturing facilit y to the 
study  site approximately  4-5weeks after manufacturing has commenced, provided all required 
safet y and quality  release criteria have been met. Upon receipt of the cryopreserved CTL019 
cell product, an inventory must be performed and a drug receipt log filled out and signed b y the 
person accepting the shipment. The cryopreserved CTL 019 cell product should be kept in the 
vapor phase of liquid nitrogen until CTL019 infusion. For details on the cryopreserved 
components, and the specific storage and handling requirements of the CTL 019 cellproduct, 
see the [I nvestigational Product Handling Manual ].
Prior to CTL019 infusion the following criteria must be met:
1.All patients must undergo a rapid influenza diagnostic test within 10 day s prior to the 
planned CT L019 infusion. If the patient is positive for influenza, oseltamivir phosphate or 
zanamivir should administered for 10 day s as preventative treatment (see Tamiflu® or 
Relenza®package insert for dosing). The patient must complete their 10 day  preventative 
treatment course prior to receiving CTL019. The test does not need to be repeated prior to 
CTL 019 infusion however, if flu -like or respiratory  signs and s ymptoms are present, 
CTL 019 infusion should be delay ed until the patient is asy mptomatic.
For patients residing in theUnited States, Canada, Europe and Japan, influenza testing is 
required during the months of October through May  (inclusive). For patients residing in 
the southern hemisphere such as Australia, influenza testing is required during the months 
of April through November (inc lusive). For patients with significant international travel, 
both calendar intervals above may  need to be considered.
2. Patient should not experience a significa ntworsening inclinical status comparedto initial
eligibility c riteriathatwould, i n theopinion of the treating phy sician,increasetheriskof 
adverse events associated with experime ntalcellinfusion. CTL 019 infusion should be 
delay ed in such cases.
3.Rapidly  progressing patients, or patients experiencing laboratory abnormalities after 
enrollment, that in the opinion of the treating investigator or PI may  impact patient safet y 
or the patients’ ability  to receive the CTL019 infusion, may  have their infusion delay ed 
until both the treating investigator and PI determine it is clinically  appropriate to proceed 
with the CTL 019 infusion.
4.Patients experiencing toxicities from their preceding ly mphodepleting chemotherapy  will 
have their infusion schedule delay ed until these toxicities have resolved. The specific 
toxicities warranting delay  of CTL 019 cell infusion include:
a.Pulmonary : Requirement for supplemental oxy gen to keep saturation greater than 
91% or presence of progressive radiograph ic abnormalities on chest x- ray
b.Cardiac: Cardiac arrhy thmia not controlled with medical management
c.Hypotension requiring vasopressor support
d.Uncontrolled active infection, as evidenced b y positive blood cultures for bacteria, 
fungus, or PCR positivity  for viral DNA in blood within 72 hours of CTL 019 cell 
infusion, or cl inical or radiographic evidence

Novartis Confidential Page 72
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
5.Following ly mphodepleting chemotherapy  patients must not have progressive disease in 
order to receive CTL019 infusion, as this will potentially  put them at an unacceptable risk 
for severe CRS. Patients should not receive CTL019 infusion if they  exhibit sig nificant 
progression of disease following ly mphodepleting chemotherapy  as evidenced by :
a.Significant increase in nodal disease
b.Significant increases in extranodal areas
c.Occurrence of new ly mphoma manifestations
d. Clinical evidence of CNS disease
6.If patients a re taking any of the following medications, their infusion must be delay ed 
until the medications have been stopped according to the below:
a.Steroids: Therapeutic doses of steroids must be stopped >72 hours prior to CTL 019 
infusion. However, the following ph ysiological replacement doses of steroids are 
allowed: < 12 mg/m2/day hy drocortisone or equivalent
b. Antiproliferative therapies other than the protocol specified lymphodepleti ngtherapy  
must have been stopped ≥ 2weeks prior to CTL019 infusion
c.Short acting drugs used to treat leukemia or ly mphoma (e.g. t yrosine kinase 
inhibitors, and hy droxyurea) must be stopped > 72 hour prior to leukapheresis and > 
72 hours prior to CTL 019 infusion . Other cy totoxic drugs, including low dose daily  or 
weekl y maintenance chem otherap y, must not be given within 2 weeks prior to 
leukapheresis and within 2 weeks prior to CTL019 infusion.
d.Immunomodulatory  drugs m ust be stopped ≥ 2 weeks prior to infusion . This could 
include check point inhibitors (monoclonal antibodies and small molecule 
modulators).
e.Antibodies including anti -CD20 therap y must be stopped ≥ 4 weeks prior to infusion 
or 5 half -lives of the respective antibody prior to infusion, whichever is longer. Note: 
Rituximab is excluded within 4 weeks prior to infusion.
f.CNS pr ophy laxis treatment must be stopped > 1 week prior to CTL019 infusion (e.g. 
intrathecal methotrexate).
Patients experiencing toxicities from their preceding chemotherap y will have their CTL019 
infusion delay ed until the above toxicities have been resolved. If any of the above criteria are 
not met and a period of delay  is 4 or more weeks from completing lymphodepleting 
chemotherap y and the WBC>1000/µL , the patient will need to be re-treated with 
lymphodepleting chemotherap y, and these criteria will need to be re-established prior to 
CTL 019 infusion.
Additional safety procedures prior to administration :
The risk of tumor lysis syndrome 
(TLS) is dependent on disease burden. Patients will be closel y 
monitored both before and after lymphodepleting chemotherap y and CTL 019 infusions 
including blood tests for potassium and uric acid. Patients with elevated uric acid or high tumor 
burden will receive prophy lactic allopurinol, or a non-allopurinol alternative (e.g. febuxostat). 
Infection proph ylaxis should follow local guidelines dictated only by the preceding 
lymphodepleting chemotherap y. Infection proph ylaxis per sefor CTL019 is not recommended.

Novartis Confidential Page 73
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
The site must confirm that two doses of tocilizumab are on site prior to CTL019 infusion
and one dose of siltuximab (if available in country) must be accessible within 24 hours of 
infusion for administration in order to manage suspected toxicities. (see Section 6.2.4.2.1
for details).
Premedication :
Side effects from T c ell infusions can include fever, chills and/or nausea. All patients should be 
pre-medicated with acetaminophen or paracetamol and diphenh ydramine or another H1 
antihistamine. These medications can be repeated every  6 hours as needed. Non -steroidal anti -
inflammatory  medication may  be prescribed if the patient continues to have fever not relieved 
with acetaminophen or paracetamol. Steroids should NOT be used for premedication. It is 
recommended that patients NOT receive systemic corticosteroids other than physiologic 
replacement of hydrocortisone at any time, except in the case of life threatening emergency , 
since this may  have an adverse effect on CTL 019 cell expansion and function.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Novartis Confidential Page 74
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Following CTL019 infusion: Should emergency treatment be required in the event of life-
threatening h ypersensitivity  or other acute infusion -related reaction, supportive therap y such as 
oxygen, bronchodilators, epinephrine, antihistamines, and corticosteroids should be given 
according to local institutional guidelines. Patients should be evaluated and carefull y monitored 
until complete resolution of signs and s ymptoms.
Supportive care: Local guidelines will be followed for the supportive care of 
immunosuppressed and chemotherap y treated patients including infection management. All 
blood products administered should be irradiated. Immunosuppressive medications, including 
steroids, should not be administered unless life threatening circumstances arise.
6.1.2 Ancillary  treatments
As side effects from T cell infusions can include fever, chills and/or nausea, all patients should 
be pre-medicated with acetaminophen or paracetamol and diphenh ydramine or an H1 
antihistamine, as described above in Section 6.1.1.2 . If fever develops please follow your 
institutional guidelines for patients with fever/neutropenia an
d strongly  consider admission for 
close observation.
6.1.3 Rescue medication
Rescue medications are medications given for severe CRS due to CTL 019 therapy 
(Figure 6-1) . CTL 019 administration may require tocilizumab (recommended dose 8 mg/kg 
i.v.),steroids, andsiltuximab (11 mg/kg IV over 1 hour) for the treatment of suspected CRS 
toxicities as described below in Section 6.2.4.2.1.
The site must confirm that two doses of tocilizumab are on site and available for 
administration prior to CTL019 infusion and one dose of siltuximab (if available in 
country) must be accessible within 24 hours of infusion .(see Section 6.2.4.2.1 for details).
All rescue medications (except for tocilizumab or siltuximab ), including steroids given to treat 
CRS, must be listed on the concomitant medication CRF. Tocilizumab or siltuximab therapy 
administration should be reported on the “Dose Administration Record -Tocilizumab ” or “Dose
Administration record -Siltuximab ” eCRF, respectively. Steroids given to treat CRS must be 
listed on the concomitant medication CRF.
6.1.4 Guidelines for continuation of treatment
Not applicable
6.1.5 Treatment duration
A single dose of CTL019 transduced cells will be given.
6.2 Dose escalation guidelines
Not applicable
6.2.1 Starting dose rationale
Not applicable

Novartis Confidential Page 75
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
6.2.2 Provisional dose levels
Not applicable
6.2.3 Guidelines for dose escalation and determination of MTD/RP2D/RDE
Not applicable
6.2.3.1 Implementation of Dose Escalation Decisions
Not applicable
6.2.3.2 Intra -Patie nt dose escalation
Not applicable
6.2.4 Definitions of dose limiting toxicities (DLTs) in a phase II study
6.2.4.1 Toxicity  management, stopping rules and study termination
Itisexpected that AEs w ill occur frequently in thispopulation based on theunde rlying ad vanced
malig
nancy and thatthese ca n be S AEs. Therefore,thereisnospecificoccurrenc e of SAEs
that define a st opping rule, but thereview of S AEs will form the b asisforpotentia l early
stopping of thestudy. Only unexpected S A Esthatarerelatedtothe CTL 019 transduced cells
would de fine astopping rule . The re view ofthese adverseevents, and any dec isionto
prematu relystop patient enrollment, will be determined by theData Monitoring Committee 
(DMC) a
nd re viewed by theIRB.
Premature termination of thec linicaltrialmay occur beca useofa regulatory a uthori ty decis ion, 
c
hange inopini on of theIRB, theDMC , or d etermin ation thatthere are p roblems inthecell 
produc t g eneration or s afety at thediscretion of the studyinvest igators. Addit ional ly,
recruitment may be stopp ed at the sponsor’s discretion and may  include reasons such as 
low recruit ment,protocol viol ati ons, orinadequa te da tarecordin g.
6.2.4.1.1 Criteria for stopping or pausing the study
During the safety run
-in stage the study  will be paused, and health authorities notified, if at 
least one of the following events occur:
Life-threatening (grade 4) toxicity  attributable to protocol therap y that is unmanageable, 
unexpected and unrelated to chemotherap y and attributable to CTL 019 therapy . High 
fevers, h ypotension, hy poxia, disseminated intravascular coagulation, encephalopathy  
(e.g. lethargy , confusion, aphasia, seizures), intensive care unit (ICU) admission, dialy sis 
and mechanical ventilation are expected. The expected side effects can also result in grade 
4 liver toxicity , nephrotoxicity  and other organ involvement
Death suspected to be related to CTL 019 therapy
After the safety  run-in stage the study  may be paused pending notification of the health 
authorities and the DMC for investigation and possible protocol amendment if any patient 
experiences an y of the following events within three weeks of the CTL019 cell infusion:

Novartis Confidential Page 76
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Life- threatening (grade 4)toxicity att ribut able to pr otocol the rapythat is unmanag eable, 
unexpected and unre l ated to chemotherapy and att ributa bleto CTL 019 the rapy.
High feve rs, hypotension, hy poxia, disseminated intravascular coagulation, 
encephalopathy  (e.g. lethargy, confusion, aphasia, seizures), intensive care unit 
(ICU) admis sion, dial ysis and mechanica l ven tilati on are expected. Th e expected 
adverse effec ts can also r esultin grade 4 liver tox icity, ne phroto xicit y a nd other organ 
invol
veme nt.
Death suspected to be related to CTL 019 therapy
A
ny patient deve lops un c ontrol led T cellproliferation bey ond 8 weeks from CTL 019 
cell product infusion that d o
es not re spond to man agement
Any patient deve lops detectable replication competent lentivirus (RCL ) during the stud y
The Investigator, Sponsor, DMC, or
any indepe ndent re view boardorregulato ry body
decides for an y re a sonthatpatient s afety may be c omprom ised by conti nuing thestudy
TheSponsor decides to discont i nuethedevelopment oftheintervention tobe use d inthis
study
6.2.4.2 General toxicity  management considerations
Patients treated with CTL019 should not donate blood, organs, tissues, sperm, oocy tes and cells.
6.2.4.2.1 Expected toxicities
Acute Infusion reaction
Acetaminophen/paracetamol and diphenhy dramine/H1 antihistamine may be repeated every  6 
hours as needed. A course of non- steroidal anti -inflamma tory medication may  be prescribed if 
the patient continues to have fever not relieved by acetaminophen/paracetamol. It is 
recommended that patients not receive corticosteroids at any time, except those alread y on 
physiologic replacement therapy , or in the case of a life threatening emergency , since this may 
have an adverse effect on CTL 019 cells.
Cytokine Release Syndrome (CRS) / Macro phage A ctivation Syndrome (MA S)
Data from CTL019 treated patients experiencing CRS show marked elevations in IL-6andIFN-
g. The symptoms generally  occur 1-14 days after cell infusion and may include high fevers, 
rigors, myalgia/arthralgias, nausea/vomiting/anorexia, fatigue, headache, encephalopath y, 
hypotension, dyspnea, tachy pnea and hypoxia. Renal failure/renal injury , hyperbilirubinemia 
and increased ALT or AST can also occur. Supportive care and anti-cytokine therap yhave been 
used for effective management of CRS. Prompt responses to tocilizumab have been seen in 
most patients; Several patients with a suboptimal resp onse to the first dose of tocilizumab have 
received a second or third dose of tocilizumab with CRS resolution. In patients with incomplete 
resolution of CRS after several doses of tocilizumab, CRS resolution has been observed 
following siltuximab administr ation.  
 
 
Fatal outcomes 

Novartis Confidential Page 77
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
associated with CRS have been observed in adult ALL patients in the context of current 
significant clinical infections. Findings from study  UP13413 could imply  a higher risk to 
develop CRS in patients with bone marrow involvement (Schuster, unpublished data). 
Accordingl y, patients with lymphoma involving the bone marrow should be monitored even 
more closel y for signs of CRS.
A detailed treatment algorithm has been established with clear criteria for CRS management 
and guidance on when to administer tocilizumab and siltuximab as presented below in
Figure 6-1 and must be followed by investigators. Tumor necrosis factor (TNF alpha) 
anta
gonists have been used with CTL 019 associated CRS with little evidence for efficacy . 
Given the apparent lack of activity  combined with their immunosuppressive effects, TNF 
antagonists are not recommended . This approach was designed to avoid life-threatenin g 
toxicities, while attempting to allow the CTL019 transduced cells to establish a proliferative 
phase which appears to correlate with tumor response. Patients will be required to remain 
proximal to the treating site for the first 21 day s.
The management of CRS is based solely  upon clinical parameters as described in Figure 6-1
below.  
 Cases of transient left ventricular dysfunction, as 
assessed by echocardiogram 
(ECHO), have been reported in some patients with severe (Grade 4) CRS. Therefore 
consideration should be given to monitoring cardiac function, by ECHO, during sever e CRS, 
especiall y in cases with prolonge d severe hemody namic instability , delayed response to high 
dose vasopressors, and/or severe fluid overload.
Clinically  significant coagulopathy  is often seen with moderate to severe CRS (Grade 3 and 4) 
and may continue as CRS is beginning to clinically  resolve. Coagulation parameters (PT, aPTT, 
and fibrinogen) should be more frequentl y monitored in this setting. CTL 019 associated 
coagulopath y with or without clinical bleeding and hypofibrinogenemia is strongl y 
recommended to be managed with cryoprecipita te of fibrinogen concentrate in addition to 
routine blood product support.CTL 019 related CRS can be associated with neurologic events. 
Two types of neurologic events with respect to timing of onset have been observed. Onset of 
neurologic events can be conc urrent with high fevers during the development and maximal 
grade of CRS. Delay ed onset of neurologic events can also occur as CRS is resolving or after 
CRS has completely  resolved. Consideration should be given to monitoring for neurologic 
events during an d after resolution of CRS.
A modification of the Common Terminology Criteria for Adverse Events (CTCAE) CRS 
grading scale has also been established to better reflect CTL 019-therapy -associated CRS as 
presented in Table 6 -1.
Specific CRFs have been developed for the capture of CRS elements, severity, management 
and response to intervention.

Novartis Confidential Page 78
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Figure 6-1 CRS Management A lgorith m
Pretreatment
Acetaminophen/paracetamol and diphenhydramine /H1 anti- histamine
Prophylaxis for complications of TLS as appropriate
CTL019 infusion
Prodromal sy ndrome: low grade fevers, fatigue, anorexia (hours to days)
Observation, rule out infection (surveillance cultures)
Antibiotics per local guidelines (febrile neutropenia)
Symptomatic support
Symptom progression: High fevers, hypoxia, mild hypotension
1st Line Management:
Oxygen, fluids, low dose vasopressor support, antipyretics
Monitor/manage complications of TLS
Further sy mptom progression:
● Hemodynamic instability despite intravenous fluids and moderate to “high dose” vasopressor1support 
OR
● Worsening respiratory distress, including pulmonary infiltrates increasing oxygen requirement 
including high -flow Oxygen (O2) and/or need for mechanical ventilation OR
● Rapid clinical deterioration
2nd Line Management:
Tocilizumab: IV infusion over 1 hour
● Patient weight < 30 kg: 12 mg/kg i.v.
● Patient weight ≥30 kg: 8 mg/kg i.v. (max dose 800 mg)
Hemodynamic and respiratory support
Lack of clinical improvement while awaiting tocilizumab response
3rdLine Management:
Consider other diagnosis causing clinical deterioration (i.e. sepsis, adrenal insufficiency)
If no improvement within 1stdose of tocilizumab within 12 to 18 hours, consider steroids (plan rapid taper
after hemodynamic normalization ):
2 mg/kg methylprednisolone as an initial dose, then 2 mg/kg per day. As steroids are tapered quickly, 
monitor for adrenal insufficiency and need for hydrocortisone replacement
If no response to steroids within 24 hours , consider 2nddose of Tocilizumab (dose das above)
Hemodynamic and respiratory support
Lack of clinical improvement while awaiting response to 3rdline management
4thLine Management:
Consider other diagnosis causing clinical deterioration (i.e. sepsis , adrenal insufficiency )
If no response to steroids and 2 nddose of tocilizumab within 24 hours or further clinical deterioration , 
consider siltuximab 11 mg/kg IV over 1 hour (if available in country).
Hemodynamic and respiratory support
Lack of clinical improvement while awaiting response to 4thline management
5thLine Management:
Consider other diagnosis causing clinical deterioration (i.e. sepsis , adrenal insufficiency )
In ongoing CRS despite prior therapy, consider anti -T cell therapies such as cyclophosphamide, anti-
thymocyte globulin, or alemtuzumab
Hemodynamic and respiratory support
1See specific definition of “high dose” vasopressors in Table 6 -2below

Novartis Confidential Page 79
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 6-1 CTL019 therapy associated grading for cy tokine release sy ndrome: 
The Penn Grading Scale for Cy tokine Release Sy ndrome (PGS -CRS)
●Marked elevations in IL -6, interferon gamma and less intensely TNF
●Symptoms occur 1 to 14 days after cell infusion
●Symptom s may include: high fever, rigors, myalgia, arthralgia, nausea, vomiting, anorexia, fatigue, 
headache, hypotension, encephalopathy, dyspnea, tachypnea and hypoxia
1 2 3 4
Mild reaction: Treated 
with supportive care such 
as antipyretics and 
antiemetics.Moderate reaction: 
Requiring intravenous 
therapies or parenteral 
nutrition; some signs of 
organ dysfunction (i.e. 
grade 2 creatinine or 
grade 3 liver function 
tests [LFTs]) related to 
CRS and not attributable 
to any other condition. 
Hospitalization for 
management of CRS 
related symptoms 
including feve rs with 
associated neutropenia.More severe reaction: 
Hospitalization required 
for management of 
symptoms related to 
organ dysfunction 
including grade 4 LFTs or 
grade 3 creatinine related 
to CRS and not 
attributable to any other 
conditions; this excludes 
management of fever or 
myalgias. Includes 
hypotension treated with 
intravenous fluids or low 
dose vasopressors, 
coagulopathy requiring 
fresh frozen plasma 
(FFP) or cryoprecipitate
or fibrinogen concentrat e, 
and hypoxia requiring 
supplemental oxygen 
(nasal cannula oxygen, 
high flow oxygen, 
Continuous Positive 
Airway Pressure [CPAP] 
or Bilateral Positive 
Airway Pressure 
[BiPAP]). Patients 
admitted for management 
of suspected infection 
due to fevers and/or 
neutropenia may have 
grade 2 CRS.Life-threatening 
complications such as 
hypotension requiring 
high dose vasopressors 
(see Table 6 -2) or 
hypoxia requiring 
mechanical ventilation.

Novartis Confidential Page 80
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 6-2 High dose vasopressor use
Definition of “High -Dose” Vasopressors
Vasopressor Dose for ≥ 3 hours
Norepinephrine monotherapy ≥ 0.2 mcg/kg/min
Dopamine monotherapy ≥ 10 mcg/kg/min
Phenylephrine monotherapy ≥ 200mcg/min
Epinephrine monotherapy ≥ 0.1 mcg/kg/min
If on vasopressin High-dose if vaso + Norepinephrine Equivalent (NE) of ≥0.1 
mcg/kg/min (using Vasopressin and Septic Shock Trial (VASST) 
formula)
If on combination vasopres sors (not 
vasopressin)Norepinephrine equivalent of ≥ 20 mcg/min (using VASST formula)
Vasopressin and Septic Shock Trial (VASST) Equivalent Equation:
Norepinephrine equivalent dose = [norepinephrine (mcg/min)] + [dopamine (mcg/kg/min) ÷ 2] + [epinephrine
(mcg/min)] + [phenylephrine (mcg/min) ÷10]
Criteria from Russell et al (2008)
Tumor ly sis sy ndrome
Close monitoring for TLS before and after chemotherapy  and CTL019 infusions, including 
blood tests (potassium, uric acid, etc.) will be done as follows:
Screening phase :
Prophy lactic allopurinol, or a non-allopurinol alternative (e.g. febuxostat), and 
increased oral/ IV hydration prior to lymphodepleting chemotherap y and CTL019 
infusion should be given in patients with elevated uric acid or high tumor burden
Early and prompt implementation of supportive care in case of sy mptoms of acute TLS 
(i.v. hydration and rasburicase as clinically  indicated, when uric acid continues to rise 
despite allopurinol/febux ostat and fluids)
Post-infusion monitoring phase :
Frequent monitoring of the following laboratory  tests (2 to 3 times/week for 3 weeks 
from start of lymphodepleting chemotherap y, then weekly ): potassium, phosphorus, 
calcium, creatinine, and uric acid
Encou rage oral h ydration
Laboratory  and clinical TLS is defined as follows:
Laboratory  TLS is defined as two or more of the following values within three days before or 
in the day s following CTL019 infusion.
Uric acid 
≥ 8 mg/dL or 25% increase from baseline
Potassium ≥ 6 mEq/L  or 25% increase from baseline
Phosphorus ≥ 4.5 mg/dL  or 25% increase from baseline
Calcium ≤ 7 mg/dL  or 25% decrease from baseline
If zero or one of the laboratory  values above are abnormal, continue to manage with allopurinol 
or a non-allopurinol alternative (e.g. febuxostat) and oral hydration. Consider IV fluids and 
rasburicase if uric acid levels remain elevated, and consider in hospital monitoring .

Novartis Confidential Page 81
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
If Laboratory  TLS exists, manage with i.v. fluids, laboratory blood tests every 6 to 8 hours and 
inpatient care. Cardiac monitoring should be considered, and rasburicase should be considered 
if uric acid levels remain elevated .
Clinical TLS is defined as the presence of laboratory  TLS plus ≥ 1 of these criteria in the 
absence of other causes.
Serum creatinine ≥ 1.5 times the upper limit of normal range
Symptomatic hy pocalcemia
Cardiac arrh ythmia
If Clinical TLS exists, manage with IV fluids, laboratory blood tests every 6 to 8 hours, cardiac 
monitoring, rasburicase/allopurinol/febuxostat an d inpatient care (consider ICU)
Criteria modified from Cairo and Bishop (2004) .
Neurological adverse reactions
Neurological events , including events indicative of encephalopath y and delirium of non-
infectious origin, have been observed in patients following various types of T cell directed 
therap y including CTL019 and other CAR -T cell therapies of other institutions. The 
pathophy siology  for neurologica l events, in particular in case of late events, is not fully  
understood but thought to be related to generalized T-cell mediated inflammation rather than 
direct toxicity  of CAR -T-cells on the brain (Tey 2014) . Some of the neurological events 
observed may  be related to CRS, but whether this results from s ystemic cy tokines crossing the 
blood brain barrier and engaging cytokine receptors in the brain or from direct cytokine 
production in the CNS is not clear (Maus et 
al 2014). There are no obvious predictors of 
neurologic toxicity . Confounders, such as preceding or newl y induced anti-cancer treatment 
regimens, might be involved.
Early neu rological events are the second most -common adverse reaction associated with CAR -
T therapies. In attempt to standardize the assessment of these events, the CARTOX working 
group has suggested the name CART -cell-
related- encephalopath y syndrome (CRES) (Neelapu 
et al 2018 ). This sy ndrome is described as a toxic encephalopath y with a wide range of variable 
symptoms such as aphasia, confusion, delirium, tremors, occasionall y seizures and rarely  life-
threatening cerebral edema. The manifestation of CRES is biphasic, with the first phase 
occurring concurrently  with cytokine release syndrome (CRS) symptoms typically  within the 
first 5 days after CAR -
T-cell therapy , and the second phase after CRS subsides. Delayed 
neurological events with seizures or episodes of confusion 3-4 weeks following CAR - T-cell 
therap y have been reported to occur in approximately  10% of patients.
In clinical trials, the majority of neurological events following CTL 019infusion were observed 
within 8 weeks , however, neurological events with later onset > 8 weeks and not in the context 
of CRS have also been reported. Most neurological events observed within 8 weeks were 
transient or self-limiting in nature .Frequently , encephalopathy , confusional state and delirium 
were observed. Other manifestations include a multifarious set of signs and symptoms including 
seizures, aphasia, speech disorder, and tremor. Some of the events are severe and may have a 
life-threatening outcome. 

Novartis Confidential Page 82
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Notably , the onset of neurological events after CTL019 infusion can be concurrent with CRS, 
following resolution of CRS or in the absence of CRS. The incidence appeared to be greater 
with higher CRS severity  and prior history  of CNS leukemia and history of other prior CNS 
diseases. Encephalopathy  typically occurred after peak CRS symptoms and tended to be self-
limiting with some exceptions. Delay ed onset of neurological events may  also occur as CRS is 
resolving or aft er CRS has completely resolved.
The causality  assessment of neurological events in patients treated with CTL 019 can be 
confounded, as CNS toxicity  can be associated with chemotherap y used for lymphodepletion 
and the presence of co -morbid conditions such as CRS, fever and infec tions.
Prolonged deple tion of normal B cells and hypogammaglobulinemia
Based on previous clinical experience, it is likely that CTL019 therapy  will result in B ce ll
depletio n and hyp ogam maglobulinemia. Experience with CTL 019 therap y shows that patients 
with persistent B cell aplasia demonstrate hypogammaglobulinemia which has been managed 
with immunoglobulin therap y. Intheevent of hypogam maglobulinemia, patients should be
considered for immunoglobulin therapy  perlocal cli nicalpractice guidelines.
Infections and i nfectious complications
Depletion of B cells with resulting h ypogammaglobulinemia is expected as a result of CTL019 
on target effects. CTL019 related hypogammaglobulinemia is typically managed with 
immunoglobulin replacement therapy  dependent upon age specific, disease specific and local 
institutional guidelines. Immunoglobulin replacement during the stud y period will be recorded. 
In general B cell aplasia and hypogammaglobuline mia, of various causes, can be associated 
with increased rates of infection. Such infections are typicall y sinopulmonary  but other sites 
and ty pes of infections have also been reported.
Institutional guidelines for vaccination (e.g. pneumococcus) should be followed before starting 
CTL 019 therapy . No live vaccines should be used in CTL 019 recipients or prospective 
recipients as the lack of effective B cells after infusion makes the likelih ood of a systemic 
infection considerable and the value negligible.
Other potential complications of B cell aplasia include progressive multifocal 
leukoencephalopath y (PML) and reactivation of hepatitis B virus.
For the first 12 months of the study , all data on infections will be collected for patients in the 
primary  follow -up. After 12 months for CTL 019 treated patients or if patients move to the 
secondary  follow -up, data on infections will only be collected when they are opportunistic or 
serious and requir ing intervention as defined:
1.Requires anti -infective treatment
2.Leads to significant disability  or hospitalization
3.Needs surgical or other intervention
Viral Reactivation
Patients with active hepatitis B or active hepatitis C have been excluded from clinica l studies 
with CTL 019, because of the potential risk of viral reactivation and the risk of fulminant 
hepatitis, hepatic failure and 
fatal outcome. HIV positive patients have been also excluded, 
because of the possible effect on HIV viral suppression. 

Novartis Confidential Page 83
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
In addition, there is currently  no experience with manufacturing CTL019 for patients testing 
positive for HBV, HCV and HIV. Patients are to be screened for an y active HBV, HCV or H IV 
infection prior to leukapheresis.
Subjects with active hepatitis B orhepati tis C or subjects with HIV confirmed by serology wi ll 
not be enrolled in the study .
Hematological disorders including cytopenias
The etiology  of cy topenias is multifactorial, likely  reflecting a combination of effects from the
underly ing disease, cytotoxicity  from prior anticancer treatment, bridging chemotherap y during
the CTL 019 manufacture waiting time and conditioning lymphodepleting chemotherap y just
prior to CTL 019 infusion in addition to the CAR -T cell therap y per se, which is frequentl y
associated with B-cell aplasia as on-target effect. Prolonged hematological cytopenias and
hematological disorders are considered a sequelae .
6.2.4.2.2 Potential toxicities
Cerebral Edema
Five fatal cases of cerebral edema occurred in the ROCKET study  in adult ALL treated with 
JCAR015 and were characterized by a rapid evolution soon after JCAR15 infusion appeared to 
be resistant to anti -cytokine treatment, and ensued brain death within 1 -2 day s after diagnosis. 
 
 
No fatal cerebral edemas have 
been reported following CTL019 infusion in the clinical 
development program or the post-marketing setting to date that would resemble the clinical 
course reported for JCAR015. JCAR015 presents a different construct of an anti-CD19 CAR -
T
-cell product compared to CTL 019.
Replication -competent lentivirus (RCL) testing
Replication
-competent lentivirus (RCL )may be generated during CTL019 manufacturing using 
a lentiviral vector to encode anti-CD19 CAR or subsequentl y after introduction of vector 
transduced viable T cells into the patient. However, RCL  resulting from manufacturing is highl y 
unlikely  since elements are incorporated in the design of the vector system that minimize vector 
recombination and generation of RCL . Furthermore, the vector used to transduce the product 
undergoes sensitive assay s for detection of RCL . Thus patients will only receive cell products 
that meet RCL  release criteria considered sufficient to confirm the absence of RCL  in CTL 019
and the negligible probability  of de novo generation of any  RCL .None of the subjects tested in 
the development program showed evidence of RCL. However, generation of an RCL  following 
CTL 019infusion remains a theoretical possibility . The development of R CL could pose a risk 
to patient sand therefore, monitoring for RCL  will be conducted during the course of the trial 
(see Product Handling Manual for a description of the assay s).Blood samples for RCL testing 
will be collected as per Table 7-1. If blood samples test are negative through Month 12, all 
samples taken after Month 12 will be store d for potential future testing. Additional, unscheduled 
samples for RCL  testing, for persistence testing of CAR tr ansgene sequences, and/or for B and 
T-cell enumeration canbe collected anytime on a case-by-case basis. If a positive RCL  assay 

Novartis Confidential Page 84
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
result is obtained from a patient blood specimen, (as detected by Vesicular Stomatitis 
Virus/Gly coprotein (VSV -G) qPCR, for example) the Investigator will be informed and the 
patient rescheduled for a retest of the DNA test. , 
As per guidance for gene therapy  medicinal products, patients exposed to CTL 019 will be 
monitored for 15 years following last treatment for vectors persist ence and RCL  within the 
long-term follow -up study . In case of suspected secondary  malignancies, as per the guidance 
“Testing of Retroviral Vector -Based Human Gene Therap y Products for Replication Competent 
Retrovirus During Product Manufacture and Patient Follow -up” (FDA 2020), biopsy  sample of 
neoplastic tissues or relevant autopsy  tissues will be collected for RCL  testing.
Secondary malignancies (including vector insertion site oligo/monoclonality )
Secondary  malignancies in cancer patients, i.e., newly  occurring malignancies other than the 
primary  malignancy  (e.g., T
-cell and non-T- cell hematological malignancies, solid tumors), can 
be increased as a result of both previous chemotherap y and radiation therapy  exposure and 
partly  due to increased rates within families (Friedman et al 2010 ).The rate of new malignancy 
detection following CTL019 therapy  will need to take into account these additional 
c
onfounding risk factors.
Transduction of a patient’s T cells with the lentiviral vector could lead to insertional 
mutagenesis resulting in an uncontrolled T -cell proliferation and an oncogenic effect that could 
result in a T -cell and non -T-cell malignancie s. 
Ruella et al. (2018) reported a B-cell ALL patient treated in an early clinical study  at the 
University  of Penns ylvania (UPenn) / Children’s Hospital of Philadelphia with CTL019 as 
manufactured by UPenn. The patient showed an initial response to treatm ent and relapsed 9 
months after infusion with CD19- negative leukemia cell that aberrantly expressed the anti -
CD19 CAR. The CAR gene was unintentionally  introduced into a single leukemic B cell during 
CAR -T cell manufacture at Penn and its product bound in cis to the CD19 epitope on the surface 
of leukemic cells, masking it from recognition by  and conferring resistance to the CAR -T. 
 
 
 
 
CTL 019 uses third generation self-inactivating lentiviral vector to safeguard against the 
potential oncogenic effects. Insertional mutagenesis was evaluated in two lentivirus insertion 
site analy sis (LISA) studies where 12 batches of manufactured patient product ready for 
infusion and two batches of product manufactured from health y donor cells were anal yzed. The 
results indicate that there was no preferential integration near genes of concern, no preferential 
sites of integration (hot spots), and no preferential outgrowth of cells harboring integration sites 
of concern.
CTL 019is based on autologous, fully differentiated T cells and therefore the carcinogenicit y 
risk is considered to be low in comparison to genetic modification or repair such as HSC gene 
therap y. In a recent review of CAR -T cell therapies, Bonifant et al (2016) as well as Mohanlal 
et al (2016) discussed that to date no cases of malignant transformation have been reported for 

Novartis Confidential Page 85
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
genetic modification of T cells and that there currentl y is no evidence for vector -induced 
immortalization, clonal expansion, or enrichment for integration sites near genes implicated in 
growth control or transformation. This is supported by the results of the lentivirus insertion site 
analysis (LISA) studies performed during the developme nt of CTL 019.
Theoretically , CAR -positive viable T cells could proliferate without control of normal 
homeostatic mechanisms. In pre -clinical studies (Milone et al 2009 )and clinical experience to 
date (Porter et al 2011, Grupp et al 2013, Maude et al 2014 ),CAR -positive viable T cells have 
only proliferated in response to physiologic signals or upon exposure to CD19 antigen. In the 
context of CTL019 t herapy , it is expected that the T cells will proliferate in response to signals 
from the CD19 expressing malignant tumor and normal B cells. This could be either harmful 
depending on the extent of proliferation or beneficial, since clonal dominance of adop tively 
transferred T cells has been associated with tumor reduction in adoptive transfer trials (Dudley 
2002, Dudley  2005 ).
All secondary  malignancy  should be managed/treated according to current medica l practice and 
local standard of care. 
For the follow -up of secondary  maligna ncy, please refer to Section 8.10.
CTL019
6.2.5 Criteria for
discont inuing a patient’s p articipa tionin the study
If apatient deve lops a condit ion thatprecludes CTL 019infusion afte r enrollment but b efore 
infusion, thepatient will be pre matu relydiscont inued. This will be done at the jud gment of
the PI, and c ould include forexample,theoccurrence of an int ercurrent il lness requiring the 
institution of sy stem ic im munosuppr ession.
6.2.6 Concomitant Therapy
Clinically significant prescription and nonprescription medication, excluding vitamins, and 
herbal and nutritional supplements, and procedure -related (inpatient or outpatient) medications
taken by the patient during the 30 days prior to screening will be recorded. At every  visit 
following the screening visit up to the month 60visit, concomitant medications will be recorded 
in the medical record and on the appropriate CRF.
Durin g selected trial phases concomitant medication collection will be modified as outlined in
Appendix 3:CTL019 Modified Data Reporting -Treatment and Primary Follow Up Phase,
Appendix 4
: CTL019 modified data reporting –Secondary  Follow Up Phase, CRF Completion 
Guidelines (CCGs), and Table 6-3below. Modified collection of concomitant medications 
during these periods are designed to capture CTL019 -related toxicity , severity , interventions 
and response/resolution following intervention. Any additions, deletions, or changes of these 
medications will be documented.

Novartis Confidential Page 86
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 6-3 Concomitant medication reporting by  study  period
Study  period Inpatient/ICU Outpatient
Pre-treatment period (ICF to LD chemo/pre -infusion) Modified Modified
Treatment period (LD chemo/pre -infusion through M12) Modified All concomitant medications
Post-treatment period (after M12 through M60) Modified Modified
The following guidelines must be adhered to during the stud y:
Granulocy te macrophage -colony  stimulating factor (GM -CSF) should be avoided due to the 
potential to worsen CRS symptoms. Short acting granulocyte colon y stimulating factor (G -
CSF) should not be given within 72 hours of CTL 019 infusion and long acting G-CSF 
should not be given within 10 day s of CTL019 infusion. The effects of gran ulocy te colony 
stimulating factor (G -CSF) on the other hand, are unknown.
Steroids or other immunosuppressant drugs should NOT be used as pre-medication for 
CTL 019 therap y (refer to Section 6.1.1.2) or following CTL 019 infusion, except as required 
for physiological glucocorticoid replacement therap y, or under life threatening 
circumstances. Use of steroids with blood product administration should be eliminated just 
prior to and following CTL 019 if possib le or at least minimized.
Patients with moderate to severe signs and symptoms attributable to CRS should be 
managed with supportive care and administration of tocilizumab as defined in Figure 6
-1
and Section 6.2.4.2.
6.2.7 Prohibited concomitant therapy
The foll owing medications are excluded:
a.Steroids: Therapeutic doses of steroids must be stopped > 72 hours prior to leukapheresis 
and > 72 hours prior to CTL019 infusion. However, the following physiological 
replacement doses of steroids are allowed: <12 mg/m2/day hydrocortisone or equivalent
b.Immunosuppressive therapies: Any dru g used for immunosuppression must be stopped ≥ 
2weeks prior to leukapheresis and ≥ 2weeks prior to CTL 019 infusion
. This could include 
check point inhibitors (monoclonal antibodies and small molecule modulators ).
c.Antiproliferative therapies other than lymphodepleting chemotherap y within 2 weeks of 
leukapheresis and 2 weeks prior to infusion.
Short acting drugs used to treat leukemia or lymphoma (e.g. tyrosine kinase inhibitors, 
and hydroxyurea) must be stopped > 72 hour prior to leukapheresis and > 72 hours prior 
to CTL 019 infusion
Other c ytotoxic drugs, including low dose dail y or weekly maintenance chemotherap y, 
must not be given within 2 weeks prior to leukapheresis and within 2 weeks prior to 
CTL 019 infusion.
Fludarabine may  be associated with prolonged lymphopenia. This should be taken into 
consideration when evaluating the optimal timing for apheresis collection.
Antibody  use including anti-CD20 therap y within 4 weeks prior to infusion or 5 half-lives of 
the respective antibody, whichever is longer. Note: Rituximab is excluded within 4 weeks prior 
to infusion.

Novartis Confidential Page 87
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
d.CNS disease prophylaxis must be stopped > 1 week prior to CTL 019 infusion (e.g. 
intrathecal methotrexate)
e.Investigational therapies must not be used at any time while on study  until the first 
progression following CTL 019 infusion
.
6.3 Dose modifications
6.3.1 Dose modification and dose delay
Not applicable
6.3.2 Follow -up for toxicities
6.3.2.1 Liver safety monitoring
To ensure patient safet y and enhance reliability  in determining the hepatotoxic potential of an 
investigational treatment, a standardized process for identification, monitoring and evalu ation 
of liver events has to be followed.Liver events are divided into two categories:
Liver events of special interest (AESI) which consist of elevated transaminases and/or 
bilirubin (elevated liver function tests (LFTs))
Medically  significant liver event s which are considered as serious adverse events (SAEs) 
and which consist of marked elevations of LFTs and / or pre -specified adverse events.
Please refer to Appendix 5 Section 14.5.1 for complete definitions of liver events.
Any liver event which meets the criteria for “medically significant ” event as outlined in 
Appendix 5 Section 14.5.1should follow the standard procedures for SAE reporting as 
described in Section 8.2.
Every  liver event as defined in Appendix 5 Section 14.5.1 should be followed up by the 
investigator or designated personal at the trial site as summarized below. Detailed information 
is outlined in Appendix 5 Section 14.5.2. .
Repeating the LFT to confirm elevation as appropriate
Hospitalization of the patient if appropriate
A causality  assessment of the liver event via exclusion of alternative causes (e.g., disease, 
co-medications)
An investigation of the liver event which needs to be followed until resolution.
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -up information, and 
the procedures performed should be recorded on appropriate CRF pages .
For additional details please r
efer to Section 6.2.4
6.3.2.2 Follow up on potential drug -induced liver injury ( DILI) cases
Subjects with transaminase increase combined with total bilirubin increase may be indicative 
of potential DILI and should be considered as clinically important events.

Novartis Confidential Page 88
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
The threshold for potential DILI may depend on the subject’s baseline AST/AL T and total 
bilirubin value; subjects meeting any  of the following criteria will require further follow -up as 
outlined below:
For subjects with normal ALT and AST and total bilirubin value at baseline: AST or ALT 
> 3.0 x UL N combined with total bilirubin > 2.0 x ULN
For subjects with elevated AST or ALT or total bilirubin value at baseline: [AST or ALT > 
3x baseline ]OR [AST or ALT > 8.0 x ULN], whichever occurs first, combined with [ total 
bilirubin > 2.0x baseline AND > 2.0 x ULN]
As DILI is essentiall y a diagnosis of exclusion, other causes of abnormal liver tests should be
considered and their role clarified before DILI is assumed as the cause of liver injury .
A detailed history , including relevant information such as review of ethanol consumption,
concomitant medications, herbal remedies, supplement consumption, history of any preexisting
liver conditions or risk factors, should be collected.
Laboratory  tests should include ALT, AST, total bilirubin, direct and indirect bilirubin, GGT,
prothrombin tim e (PT)/INR, alkaline phosphatase, albumin, and creatine kinase. If
available, testing of Glutamate Deh ydrogenase (GLDH) is additionally  recommended.
Evaluate status of liver metastasis (new or exacerbation) or vascular occlusion –e.g. using CT,
MRI , or duplex sonography .
Perform relevant examinations (Ultrasound or MRI , Endoscopic retrograde 
cholangiopancreatography  (ERCP ))as appropriate, to rule out an extrahepatic cause of
cholestasis. Cholestasis is defined as an AL P elevation > 2.0 x UL N with R value < 2 in
participants without bone metastasis, or elevation of the liver- specific ALP isoenzy me in
participants with bone metastasis.
Note: The R value is calculated by  dividing the ALT by  the AL P, using multiples of the ULN
for both values. It denotes wheth er the relative pattern of ALT and/or ALP elevation is due to
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and <5) liver injury . In clinical 
situations where it is suspected that ALP elevations are from an extrahepatic source, the GGT 
can b e used if available. GGT may be less specific than AL P as a marker of cholestatic injury , 
since GGT can also be elevated by enzyme induction or by ethanol consumption. It is more 
sensitive than AL P for detecting bile duct injury .
Table 6-4 provides guidanc e on specific clinical and diagnostic assessments which can be
performed to rule out possible alternative causes of observed LFT abnormalities.

Novartis Confidential Page 89
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 6-4
Disease Assessment 
Hepatitis A, B, C, E IgM anti -HAV; HBsAg, IgM & IgG anti -HBc, HBV DNA; anti -HCV, HCV 
RNA, IgM & IgG anti -HEV, HEV RNA
CMV, HSV, EBV infection IgM & IgG anti -CMV, IgM & IgG anti-HSV; IgM & IgG anti -EBV
Autoimmune hepatitis Antinuclear Antibodies (ANA) &Anti-
Smooth Muscle Antibody (ASMA) titers, total IgM, IgG, IgE,IgA
Alcoholic hepatitis Ethanol history, GGT, MCV, CD -transferrin
Nonalcoholic steatohepatitis Ultrasound or MRI
Hypoxic/ischemic hepatopathy Medical history: acute or chronic 
congestive heart failure, hypotension, hypoxia, hepatic venous occlusion. 
Ultrasound or MRI.
Biliary tract disease Ultrasound or MRI, ERCP as appropriate.
Wilson disease (if <40 yrs old) Caeruloplasmin
Hemochromatosis Ferritin, transferrin
Alpha -1 
antitrypsin deficiency Alpha -1-antitrypsin
Other causes should also be considered based upon participants’ medical history 
(hyperthy roidism / thyrotoxic hepatitis –T3, 
T4, TSH; cardiovascular disease / ischemic 
hepatitis – ECG, prior hypotensive episodes; Ty pe 1 diabetes / gl ycogenic hepatitis).
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified, should be considered as “medicall y 
significant,” and thus, meet the definition of a serious adverse event (SAE) and should be 
reported as SAE using the term “potential treatment
-induced liver injury.” All events should be 
followed up with the outcome clearl y documented.
6.3.2.3 Renal safety  monitori ng
The following two categories of abnormal renal laboratory values have to be considered during 
the course of the study :
1. Serum creatinine increase ≥ 25% compared to baseline during normal h ydration status
2.Urine protein
-creatinine ratio (PCR) ≥1g/g or ≥100 mg/mmol, OR new onset dipstick 
proteinuria ≥ 3+ OR new onset dipstick hematuria ≥ 3+ (after excluding menstruation, 
urinary  tract infection, extreme exercise, or trauma)
Renal event findings must be confirmed after ≥24 hours but ≤ 5 daysafter first assessment 
(select as applicable :for Phase 2 and Phase 3).
Every  renal laboratory  trigger or renal event should be followed up by the investigator or 
designated personnel at the trial site as summarized inSection 14.6.1 (Specific Renal Alert 
Criteria and Actions) in Appendix 6 .
6.4 Patient numbering, treatment assignment or randomization
6.4.1 Patient numbering
Upon informed consent completion, the patient will initiate screening. Each patient is identified 
in the study  database by a Subject Number (Subject No.), that is assigned sequentially at each 
site by IRT when the patient is first enrolled for screening and is retained as the primary 

Novartis Confidential Page 90
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
identifier for the patient throughout his/her entire participation in the trial. The Subject No. 
consists of the four digit Center Number (Center No.) (as assigned by Novartis to the 
investigative site) with a sequential three digit patient number suffixed to it, so that each subject 
is numbered uniquel y across the entire database.
The investigator or designated staff will contact the IRT and provide the requested identify ing 
information for the patient to register them into theIRT. Once assigned, the Subject No. must 
not be reused for an y other subject and the Subject No. for that individual must not be changed, 
even if the patient is re -screened. If the patient fails to start treatment for an y reason, the reason 
will be entere d into the appropriate CRF page.
IRT must be notified within 2 day s that the patient was not treated.
6.4.2 Treatment assignment
This is a single -arm open -label study . Patients will be enrolled and assigned to treatment upon 
confirmation of all clinical eligibil ity criteria by the investigator, and acceptance of the 
leukapheres isproduct for manufacturing.
6.4.3 Treatment blinding
This is an open -label study .
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Novartis Confidential Page 91
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 92
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7 -1lists all of the assessments through the end of the Treatment and Primary  Follow -up 
phase ( Section 7.1.1, Section 7.1.2 and Section 7.1.3 ). For patients who discontinue early from 
the Treatment and Primary  Follow -Up Phase prior to Month 60, the patient will enter an 
observ ational Secondary Follow -Up Phase to collect health authority  requested data (e.g. 
delay ed adverse events, etc.). The first visit in the Secondary  Follow -Up Phase is determined 
according to the time when the patient discontinued from the Treatment and Prim ary Follow -
Up Phase since CTL 019 infusion. For example, if the patient discontinued from the Treatment 
and Primary  Follow -Up phase at Month 10, the first visit in the Secondary Follow -Up Phase 
will be Month 12. Table 7-2lists all of the assessments through the end of the Secondary 
Follow -up phase ( Section 7.1.4 ).
In each table, required assessments are indicated with an “X” at the visits when they are 
performed. The letter (D) in Table 7-1and Table 7-2under the category  column indicates the 
assessments that will have data entered into the clinical datab
ase and (S) is for assessments that 
will have data remain as source documentation. All data obtained from these assessments must 
be supported in the pat ient’s source documentation.
No CRF will be used in the patient’s source documentation.

Novartis Confidential Page 93
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 7-1 Primary  visit evaluation schedule
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Obtain Informed 
ConsentD 7.1.1 X
IWRS/IRT 
RegistrationS X X X X
Patient history
Demography D 7.1.1 X
Inclusion/exclusion 
criteriaD 5.2
5.3X
Medical history D 7.1.1 X
Prior antineoplastic 
therapyD 7.1.1 X
Prior/concomitant 
medicationsD 6.2.6 X X X X X X X X X X X X X X X
Concomitant 
medications 
(selected)D 6.2.6 X X X X

Novartis Confidential Page 94
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Antineoplastic 
therapies after 
CTL019 infusionD 7.1.5 X X X X X X X X X X X X X X
Central confirmation 
of diagnosis and 
subtype 
determination (FFPE 
tumor biopsy)D 7.2.1 X
Physical assessments
Physical examination S 7.2.2.1 X X X X X X X X X X X X X X
Performance status D 7.2.2.4 X X X X X X X X X X X X X X
Height D 7.2.2.3 X
Weight D 7.2.2.3 X X X X X X X X X X
Vital signs D 7.2.2.2 X X X X X X X X X X X X X X X X X

Novartis Confidential Page 95
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Pulse oximetry D 7.2.2.2 X X X X X X X
MUGA/ECHO D 7.2.2.6 X
Electrocardiogram 
(ECG)D 7.2.2.6 X X
Intervention
Leukapheresis D 4.1.1 X
Leukapheresis pre -
evaluation and 
acceptanceS 4.1.1 X
Lymphodepleting 
chemotherapyD 6.1.1.1 X
CTL019 infusion 
prerequisite 
assessmentS 6.1.1.2 X
CTL019 transduced 
cell infusionD 6.1.1.2 X

Novartis Confidential Page 96
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Efficacy  assessments
B-symptoms D 7.2.1 X X X X M3 
&M6 
onlyX X X X X
Imaging (CT/MRI) D 7.2.1 X X (if no 
PET-
CT)X X
M3 
(if no 
PET 
CT) & 
M6 
onlyX X X X
Imaging (PET -CT) D 7.2.1 X 
(within 
4
weeks
prior to 
infusion
)X
M3 
only

Novartis Confidential Page 97
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Local response 
assessmentD 7.2.1 X X X 
M3 & 
M6 
onlyX X X X
Bone marrow biopsy 
and/or aspirate D 7.2.1 X X only if 
CR and if 
prior BM 
involvemen
tX M3 
onlyAt time of radiological CR
CSF cytology D 7.2.1 X As clinically indicated
CNS Imaging 
(CT/MRI)S 7.2.1 As clinically indicated

Novartis Confidential Page 98
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Safety  assessments
Adverse events D 8.1
8.2X X X X X X X X X X X X X X X
Protocol defined 
Adverse events and 
AEs of special 
interest, including 
new malignanciesD 8.1
8.2X X X X
Pregnancies D 7.2.2 X X X X X X
Laboratory  
assessments
Hematology D 7.2.2.5 X X X X X X X X X X X X X X X X X
Chemistry D 7.2.2.5 X X X X X X X X X X X X X X X X X
Central flow 
cytometry before 
leukapheresis 
(peripheral blood)D 7.1.1 X

Novartis Confidential Page 99
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Central flow 
cytometry (fresh 
leukapheresis 
product) D 7.1.1 X
Pregnancies D 7.2.2.5 XXX X X
Serum or Urine 
pregnancy testS 7.2.2.5 X X X 
(Ser
um)
Viral serology (CMV, 
EBV, HIV, HbsAg, 
HBsAb, HBcAb, HCV 
RNA)D 7.2.2.5 X
Coagulation (PT, 
aPTT, INR, 
fibrinogen, D -dimer)D 7.2.2.5 X X X X X
Serum 
immunoglobulin 
levels (IgG, IgA, IgM)D 7.2.2.5 X X X X X 
M3 
&M6 
onlyX X 

Novartis Confidential Page 100
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Urinalysis D 7.2.2.5 X
Rapid Influenza
(A and B) TestingD 6.1.1.2
7.1.2
7.2.2.5Within 10 days 
of infusion

Novartis Confidential Page 101
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
CTL019 PK,  and safety  assessments
Serum 
(immunogenicity, 
cytokines, etc.)D 7.2.3
7.2.4X X X X X X X X X X X 
M3 
&M6 
onlyX
M12 
onlyX 
M24 
onlyX 
M3
6 
onl
yX

Novartis Confidential Page 102
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
CTL019 
 
 
 
 
 
 D 7.2.3 see ( Table 7 -14, Table 7 -15)
CTL019 
pharmacokinetics by 
qPCR (peripheral 
blood)D 7.2.3 X X X X X X X X X X X 
M2 
M3 
M6 
onlyX X X X X
CTL019 
pharmacokinetics by 
flow cytometry 
(peripheral blood)D X X X X X X X X X X
M2
M3
M6
OnlyX
X 
M18 
onlyX

Novartis Confidential Page 103
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Tumor biopsy D 7.2.3
7.2.4X X M3 
onlyAs clinically indicated
CTL019 
pharmacokinetics -
CSF (CTL019 PK, 
)D 7.2.3 X As clinically indicated
CTL019 
pharmacokinetics -
Bone marrow 
(CTL019 PK by 
qPCR)D 7.2.3 X X only if 
CRX M3 
onlyAs clinically indicated
CTL019 
pharmacokinetics -
Bone marrow (flow 
cytometry)D 7.2.3 X X only if 
CRX 
M3 
onlyAs clinically indicated

Novartis Confidential Page 104
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
RCL by VSV-g q -
PCRD 7.2.2.5 X X 
M3 
&M6 
onlyX 
M12 
onlyX 
M24
onlyX X
Leukapheresis 
sample for correlative 
studiesD 7.1.2 X
CTL019 cell product 
sample for correlative 
studiesD 7.1.2 X

Novartis Confidential Page 105
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m

Novartis Confidential Page 106
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Survival Follow -up after 
study completionVisit Name
Enrollment/Pre -
chemotherapy 
Lymphodepleting 
Chemotherapy
Pre-infusion
InfusionPost -infusion
End of Treatment and 
Primary Follow -up
Study  day
W-8 to W-4
W-3 to D-8
W-2 to 
D-5
D -1
D1
D2
D4 ±1d
D 7 ±1d
D 11 ±1d
D 14 ±1d
D 17 ±1d
D 21 ±3d
D 28 ±7d
M2 M3 M4 M5 
M6 ±14d
M9M12 ±14d
M18 M24 ±14d
M30 M42 M54 
±14d
M36 M48 ±14d
M60 ±14d
q 3m
Survival follow -up D 7.1.5 For all patients who receive a CTL019 infusion, follow-up for survival every 3 months until end 
of study or enrolling into the long term follow -up, whichever comes first. If a patient misses a 
quarterly scheduled visit where survival status is required, or if the time -point does not align 
with a scheduled visit, survival status can be obtained via phone contactX
End of phase 
dispositionD n/a X X X

Novartis Confidential Page 107
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 7-2 Secondary  follo w-up visit evaluation schedule (for patients who end their primary follo w up before M60)
Phase
Category
Protocol SectionSecondary  Follow -up
Survival Follow -up
after study completionVisit Name Post -infusion
End of Secondary 
Follow -up
Study  dayM2 
±14dM3 
±14dM6 
±30dM9 
±30dM12 
±30dM18 
±60dM24 
±60dM30 
±60dM36 
±60dM42 
±60dM48 
±60dM54 
±60dM60 
±60dq 
3m
Concomitant medications (selected) D 6.2.6 X X X X X X X X X X X X X
Antineoplastic therapies after CTL019 
infusion D 7.1.5 X X X X X X X X X X X X X
IWRS/IRT Registration S X
Physical examination S 7.2.2.1 X X X X X X X X
Performance status D 7.2.2.4 X X X X X X X X
Weight D 7.2.2.3 X X X X X X X X
Vital signs D 7.2.2.2 X X X X X X X X
Efficacy  assessments
Current status of primary malignancy
(only until patient progresses)D 7.2.1 X X X X X X X X X X X X X
Safety  assessments
Protocol defined Adverse events and 
AEs of special interest, including new 
malignanciesD 8.1
8.2X X X X X X X X X X X X X
Pregnancies D 7.2.2 X X X X X X X X X X X X X
Serum or Urine Pregnancy Test S 7.2.2.5 X X X X X X 
(Serum)
Hematology (CBC & differential) D 7.2.2.5 X X X X X X X X X X X X X

Novartis Confidential Page 108
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Phase
Category
Protocol SectionSecondary  Follow -up
Survival Follow -up
after study completionVisit Name Post -infusion
End of Secondary 
Follow -up
Study  dayM2 
±14dM3 
±14dM6 
±30dM9 
±30dM12 
±30dM18 
±60dM24 
±60dM30 
±60dM36 
±60dM42 
±60dM48 
±60dM54 
±60dM60 
±60dq 
3m
Serum (immunogenicity, cytokines, etc.) D 7.2.3
7.2.4X X X
CTL019 transgene persistence D 7.2.2.5 X X X X X X X X X X X X X
Peripheral blood (B and T cell levels in 
blood by flow cytometry)D 7.2.2.5 X X X X X X X
RCL by VSV-g q -PCR D 7.2.2.5 X X X X X X X X
Survival follow -up D 7.1.5 For all patients who receive a CTL019 infusion, follow-up for survival every 3 months until end of study 
or enrolling into the long term follow -up, whichever comes first. If a patient misses a quarterly 
scheduled visit where survival status is required, or if the time -point does not align with a scheduled 
visit, survival status can be obtained via phone contactX
End of phase disposition D n/a X

Novartis Confidential Page 109
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
7.1.1 Screening phase
After informed consent/assent is obtained, blood tests and assessments to determine eligibilit y 
as outlined below are performed.
Patients who have signed an informed consent/assent will be registered in the IRT system and 
undergo a routine l ymphoma staging workup including:
a.Demograph y
b.Medical histo ry and prior/concomitant medications and antineoplastic therapies
c.Tumor biopsy . A FFPE tumor sample obtained for the purpose of this study  must be 
submitted, however if not clinically  feasible, an archival tumor biopsy  at most recent 
relapse may be submitted instead. Excisional biopsies should be submitted wherever 
possible; in cases where this is not possible, a core needle biops y is allowable. Fine needle 
aspiration (FNA) is not allowed. 
If possible, a n additional fresh frozen biopsy  sample 
should be obtained for exploratory  anal ysis.
d.Central pathology  assessment of tumor biopsy
subty pe determination
e.Physical Examination (PE) including height, weight, vital signs, extramedullary  disea se 
assessment and CNS symptom assessment
f.Performance status (ECOG)
g.Pulse oximetry
h.MUGA or ECHO
i.ECG
j.B-symptom assessment
k.Imaging (CT/MRI ). Local assessment will be used to determine eligibility
l.Bone marrow biops y and/or aspirate
m.CSF cy tology
n.CNS Brain Imagi ng (MRI/CT) (if clinicall y indicated)
o.Hematology
p.Chemistry  Panel
q.Serum pregnancy  test (if female of childbearing potential)
r.Viral serology  (CMV, EBV, HIV, HbsAg, HBsAb, HBcAb, HCV RNA ). If HIV screening 
test is positive then a confirmatory  HIV test is required to be performed as per current 
local guidelines (see Appendix 2 for interpretation of Hepatitis B results)
s.Coagulation panel
t.Serum immunoglobulin levels (IgG, IgA, IgM)
u.Flow cy tometry
v.Urinaly sis
x.Adverse events

Novartis Confidential Page 110
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
The below assessments do not need to be repeated if performed in the context of the 
leukapheresis protocol [CCTL 019B2206] or if performed as part of clinical routine within 4 
weeks of the signature of the C CTL 019C2201 ICF:
a.Central f low cy tometry
b.Serum immunoglobulin levels (IgG, IgA, IgM)
c.Viral serology  (CMV, EBV, HIV, HbsAg, HBsAb, HBcAb, HCV RNA). If HIV screening 
test is positive then a confirmatory  HIV test is required to be perf ormed as per current 
local guidelines (see Appendix 2 for interpretation of Hepatitis B results)
7.1.1.1 Criteria for repeating screening procedures prior t o CTL019 infusion
In the event that the time between screening assessment and the enrollment exceeds 8 weeks 
the following must be repeated: ECHO/MUGA, ECG, performance status assessment ,
Complete Blood Count with differential and Platelet Count, Chemistry Panel, Coagulation 
Panel, Urinal ysis, Serum Pregnancy  test.
In the event that the time between screening assessment and enrollment exceeds 12 weeks, the 
below screening procedures must be repeated in addition to the above :
a.Physical Examination (PE) includ ing height, weight, vital signs, extramedullary disease 
assessment and CNS symptom assessment
b.Pulse oximetry
c.Imaging (PET -CT or FDG -PET+CT/MRI)
d.Bone marrow biops y and/or aspirate only ifsuspected or known bone marrow 
involvement
e.CSF cy tology only if suspicion of CNS involvement
f.CNS Brain Imaging (MRI/CT) (if clinicall y indicated)
7.1.1.2 Eligibility  screening and enrollment
For detailed enrollment procedures, including use of Interactive Response Technology  (IRT), 
pleas e refer to the IRT User Manual.
Only following informed consent to study  CCTL C2201 information on the patient’s apheresis 
product will be transferred to Novartis manufacturing. Novartis manufacturing will then 
evaluate the patient’s apheresis product for acceptance. For sites performing the leukapheresis 
as part of this protocol leukapheresis can only be performed after patient consent has been 
obtained .
Enrollment is defined as the point at which a patient meets all clinical inclusion/exclusion 
criteria and the patient’s apheresis product isaccepted for manufacturing. The patient is then 
enrolled using the same Subject No. assigned at screening b y the site investigator or designated 
staff. Once assigned, the Subject No. must not be reused for any other patient and the Subject 
No. for that in dividual must not be changed. If a screened patient is not enrolled for an y reason, 
the specific reason will be entered into the clinical database.

Novartis Confidential Page 111
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
IRT will continuously  monitor the enrollment of different molecular DLBCL subty pes to ensure 
that a minimum of 25 patients are treated in each of the GC and ABC subtypes.
IRT Registration : To document screening and enrollment into the study , the IRT will be 
contacted initially  after informed consent/assent is obtained and again after eligibility  is 
confirmed. Furthermore infusion of CTL 019 must be confirmed in the IRT system within 24 
hours of infusion.
7.1.1.3 Information to be collected on patients not enrolled
The reason for not being enrolled will be entered in the clinical database. The demographic 
information, informed consent, Inclusion/Exclusion pages and any adverse events leading to 
subject discontinuation must also be completed for patients not enrolled. No other data will be 
entered into the clinical database for patients who are not enrolled.
7.1.2 Pre-treatmen t phase
For details of assessments, refer to Table 7-1.
Enrollment/Pre -chemotherapy evaluation visit (W -3 to D -8)
Prior to start of lymphodepleting therapy  (the day before or on the day of the scheduled
lymphodepleting chemotherap y regimen is to begin )the patient will undergo blood collection 
for safet y ssessments  
, humoral & cellular immunogenicity  and RCL  by VSV -G qPCR. In addition, 
adverse events and prior/concomitant medications will be reviewed. Viably  frozen samples 
from the apheresis material as well as the CTL 019 product will be collected at the 
manufacturing site for correlative studies.
Lymphodepleting chemotherapy v isit (-D 14 to D-5) It is anticipated that many  patients will 
have been receiving chemotherap y for relapse or resistant disease. Prior to CTL 019 cell infusion 
and after apheresis, one cycle of lymphodepleting therap y is planned, if patients are not alread y
lymphopenic. The use of additional chemotherapy  prior to the recommended preinfusion 
lymphodepleting therapy will be at the discretion of the investigator and dependent 
on the 
patient’s disease burden. If patients have a White Blood Cell (WBC) count ≤1,000 cells/µL 
within one week prior to CTL 019 infusion, lymphodepleting chemotherapy  is NOT required , 
however a visit should still occur during this time window, and required assessments should be 
completed.
At this visit patients will undergo blood test for hematology  and chemistry , a pregnancy  test(all 
female patients of childbearing potential) , rapid influenza testing and in addition, the patients 
weight, adverse events and prior/concomitant medications will be reviewed. For patients who 
do receive lymphod epleting therapy , this visit should occur within 24 hours of starting 
lymphodepleting chemotherap y.
Lym phodepleting therapy should be started 14 to 5 day s before CTL019 infusion (D1) to allow 
for at least 48 hours from last dose of lympodepleting therapy  to CTL019 infusion. The purpose 
of the ly mphodepleting therapy  is to induce l ymphopenia in order to facilitate engraftment and 
homeostatic expansion of CTL 019 cells. Fludarabine (25 mg/m2i.v. daily  for 3 doses) and 
cyclophosphamide (250 mg/m2i.v. daily  for 3 doses starting with the first dose of fludarabine) 

Novartis Confidential Page 112
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
is the regimen of choice, as there is the most experience with the use of this regimen in 
facilitating adoptive immunotherapy . Refer to Section 
2.2.1 for additional information 
regarding l ymphodepleting chemotherap y.
Note : All patients must undergo a rapid influenza diagnostic test within 10 days prior to the 
planned CLT019 infusion. If the patient is positive for influenza, oseltamivir phosphate or 
zanamivir should administered for 10 days as preventative treatment (see Tamiflu® or Relenza®
package insert for dosing). The patient must complete their 10 day preventative treatment course 
prior to receiving CTL019. The test does not need to be repeated prior to 
CTL019 infusion 
however if influenza signs and symptoms are present, CTL 019 infusion should be delay ed until 
the patient is asy mptomatic.
For patients residing in the United States, Canada, Europe and Japan, influenza testing is 
required during the months of October through May (inclusive). For patients residing in the 
southern hemisphere such as Australia, influenza testing is required during the months of April 
through November (inclusive). For patients with significant international travel, both calendar 
intervals above may  need to be considered.
A PET-CT(or CT/MRI and dedicated FDG PET when PET-CT not available) must be 
performed within four weeks prior to scheduled infusion of the CTL019 product, and should be 
scheduled as close to CTL 019 infusion as possible. This imaging assessment will form the 
baseline for all subsequent efficacy evaluations. B-symptoms will also be evaluated at that time.
Pre-infusion visit (D -1)
On the day prior to the scheduled CTL019 infusion, patients will undergo a physical exam 
(including vital signs), a performance status assessment, blood collection for safet y
assessments and humoral & cellular immunogenicit y. In addition, adverse events 
and prior/concomitant medications will be reviewed.
If at this point the patient does not enter the stud y, this must be indicated in the I RT s ystem.
7.1.3 Treatment and primary  follow -up phase
For details of assessments, refer to Table 7-1.
Infusion visit (D1)
Infusions wi ll begin 2 to14 day s after completion of ly mphodepleting chemotherapy .
The day  of (but prior to) the CTL 019 infusion, patients will undergo a phy sical examination 
including weight, a performance status assessment, pulse oximetry , ECG, and blood tests 
including chemistry , a CBC with differential, and coagulation panel. Final CTL 019 infusion 
pre-requisites (including an ECG and a rapid influenza test) will be checked prior to infusion 
(per Section 6.1.1.2).
CTL 019 transduced T cells will be given as a single dose with a target 
of 5x 108CTL019 
transduced cells. Vital signs will be monitored before and following CTL019 infusion (per 
Section 6.1.1.2). An additional blood sample will be collected post -infusion for CTL019 PK 
assessment. In addition, adverse events and prior/concomitant medications w
ill be reviewed.
Details on the administration of the CTL 019 infusion are found in Section 6.1.1.2.

Novartis Confidential Page 113
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
For all patients who receive a CTL019 infusion, additional follow -up will be made to 
determine survival every  3 months. I f a patient misses a quarterl y scheduled visit where 
survival stat us is required, or if the quarterl y time -point where survival status is required does 
not align with a scheduled visit, survival status can be obtained via phone contact, and the 
survival eCRF must be entered.
Post-infusion visits: D2, D4±1d, D7±1d, D11±1d , D14±1d, D17±1d , D21±3d
At the intervals following infusion listed above, patients will undergo one or more of the 
following: blood tests including chemistry , hematology , coagulation, serum immunoglobulin, 
humoral & cellular immunogenicity ,  flow cytometry  (b cells, 
 and CD19 
assessment), a physical exam (with vital signs), performance status 
assessment and pulse oximetry . In addition, adverse events and prior/concomitant medications 
will be reviewed.
Weekly  sample colle ctions for serum cytokines, CTL 019 PK,  
 are mandated during the first 28 days following CTL019 infusion. However, 
as the time-course and rapidity  of CRS development varies among patients, additional 
unschedul ed samples for these markers may also be collected as needed, if it is clinicall y 
feasible.  
 
 
 
 
Please note that results of cytokine analy ses are NOT to be used for clinical management 
decisions of CRS. A detailed treatment algorithm has been established with clear criteria for 
CRS management (see Figure 6 -
1).
For details of assessments at each visit, refer to Table 7 -
1.
Post-infusion visit (D28 ±7d)
Patients will undergo blood collection for hematology , chemistry , coagulation, serum 
immunoglobulins, cytokines, flow cytometry  (B cells,  and CD19 a
ssessment) 
humoral and cellular immunogenicit y, and CTL019 PK,  
Patients will also have their B-symptoms assessed, Imaging (CT/MRI ) assessments 
performed, a physical examination (including vital signs, weight) and a performance status 
assessment. If at this visit the patient has a radiological CR based upon imaging ass essments, a 
bone marrow biops y needs to be performed in patients that had prior bone marrow involvement
to confirm the CR. Due to the mechanism of action of CTL 019, the Day  28 assessment should 
be interpreted in context of other clinical parameters that suggest true progression rather than 
pseudo- progression due to inflammatory  changes and tumor swelling (De Velasco et al 2015 ).
Adverse events and prior/concomitant medications will be reviewed.
For details of assessments, refer to Table 7
-1.

Novartis Confidential Page 114
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Post-infusion visits M2±14d, M3±14d, M4±14d, M5±14d, M6±14d
At the intervals following infusion listed above, patients will undergo one or more of the 
following: blood collection for hematology , chemistry , serum immunoglobulins, flow 
cytometry  (B cells,  and CD19 assessment), cytokines, humoral & cellular 
immunogenicit y and CTL019 PK,  and RCL by 
VSV -G qPCR. In addition, at the intervals following infusion listed above patients will undergo 
one or more of the following: a physical exam (including vital signs and weight), a performance 
status assessment, B
-symptom assessment, Imaging (CT/MRI) assessment, PET-CT (or 
dedicated FDG PET when PET-CT not available) (Month 3 onl y) a bone marrow biopsy  and/or 
aspirate (Month 3 onl y), . 
 
 
 
Adverse events and prior/concomitant medications will be reviewed. Any  pregnancies 
will be reported.
For details of assessments required at each specific visit, refer to Table 7 -1.
Post-infusion visit M9 ±14d
Patients will undergo one or more of the following: blood collection for hematology , chemistry, 
serum immunoglobulins and CTL 019 PK. In addition, patients will undergo a physical exam 
(including vital signs and weight), performance status assessment, B
-symptom assessment, 
Imaging (CT/MRI) assessment. Adverse events and prior/concomitant medications will be 
reviewed. An y pregnancies will be reported.
For details of assessments, refer to Table 7-1.
Post-infusion visit M12 ±14d
Patients will undergo the following: blood collection for hematology , chemistry , serum 
immunoglobulins, flow cytometry  (B cells,  and CD19 assessment), cytokines, 
humoral & cellular immunogenicit y and CTL019 PK, 
 RCL byVSV -G qPCR. In addition, patients will undergo a physical exam (including 
vital signs and weight), a performance status assessment, B
-symptom assessment, Imaging 
(CT/MRI ) assessment, . 
Advers e events and prior/concomitant medications will be reviewed. Any pregnancies will be 
reported.
Patients with CD19 CART transgene levels equal to or greater than 1% of WBC
If ≥ 1% of the W BC in peripheral blood are positive for CD19 CAR vector sequences b y qPCR 
at > 12 months from CD19 CART infusion, then the patient will be asked to return for a 
confirmatory  blood test prior to the next 6 month visit. I f ≥1% of the WBC is positive upon the 
receipt of the confirmatory  qPCR result, then the genomic vector integration sites will be 
determined. Identified vector integration sites will be evaluated using bioinformatic approaches 
to determine the frequency  of integration events in regions with known relationships to human 
cancers (i.e. near oncogenes). If integrat ion site analysis reveals mono -or oligo -clonality 
pattern and/or integration at or near an oncogenic locus, a monitoring plan, including follow -
up molecular analyses, will be developed in collaboration between the Investigator, Sponsor 

Novartis Confidential Page 115
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
and Health Authorit ies that is specific for the health care risks that are anticipated given the 
nature of the integration site and vector target cell ty pe.
For details of assessments, refer to Table 7-1.
Post-infusion visit M18 ±14d and M24 ±14d
At the intervals following infusion listed above, patients will undergo one or more of the 
following: blood collection for hematology , chemistry , flow cytometry  (B cells,  
and CD19 assessment), cytokines, humoral & cellular immunogenicity and CTL 019 PK, 
, and RCL  by VSV -GqPCR (Month 24 only ). In 
addition, at the intervals following infusion listed above patients will undergo one or more of 
the following: a physical exam (including vital signs and weight), a performance status 
assessment, B-symptom assessment, Imaging (CT/MRI ) assessment  
. Protocol defined adverse events, adverse 
events of special interest (includin g new malignancies) and selected concomitant medications 
will be reviewed. An y pregnancies will be reported.
For details of assessments required at each specific visit, refer to Table 7 -1.
Post-infusion visits M30 ±14d, M42 ±14d, M54 ±14d
At the intervals following infusion listed above, patients will undergo one or more of the 
following: blood collection for hematology , chemistry , flow cytometry . In addition, at the 
intervals following infusion listed a bove patients will undergo one or more of the following: a 
physical exam (including vital signs and weight), a performance status assessment and B
-
symptom assessment. Protocol defined adverse events, adverse events of special interest 
(including new malign ancies) and selected concomitant medications will be reviewed. Serum 
or urine pregnancy test will be done for WOCBP until contraception is no longer required . Any 
pregnancies will be reported.
For all patients who receive a CTL 019 infusion, follow -up for survival every  3 m onths until 
end of study  or enrolling into the long term follow -up, [CCTL 019A2205B] , whichever comes 
first, is required. If a patient misses a quarterl y scheduled visit where survival status is required, 
or if the quarterly  time-point wher e survival status is required does not align with a scheduled 
visit, survival status can be obtained via phone contact.
For details of assessments required at each specific visit, refer to Table 7 -1.
Post-infusion visits M36 ±14d and M48 ±14d
At the intervals following infusion listed above, patients will undergo one or more of the 
following: blood collection for hematology , chemistry , flow cytometry  (B cells,  
and CD19 assessment), cytokines, humoral & cellular immunogenicity and CTL 019 PK, 
, and RCL  by VSV -G qPCR. In addition, at the 
intervals following infusion listed above patients will undergo one or more of the following: a 
physical exam (including vital signs and weight), a performance status assessment, B-symptom 
assessment, Imaging (CT/MRI ) assessment  
. Protocol defined adverse events, adverse events of special interest (including 
new malignanci es) and selected concomitant medications will be reviewed. Serum or urine 

Novartis Confidential Page 116
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
pregnancy  test will be done for WOCBP until contraception is no longer required . Any 
pregnancies will be reported.
For details of assessments required at each specific visit, refer t o Table 7 - 1.
7.1.3.1 End of treatment and primary  follow -up (EOT) visit (M60 ±14d) 
including premature withdrawal
The End of Treatment and Primary  Follow -Up (EOT) visit for each patient will be 60 months 
(5 years) from the date of their infusion if they complete all 
scheduled visits. If a  patient 
discontinues earl y from the primary  follow -up, a visit should be scheduled as soon as possible, 
at which time all of the assessments listed for the Month 60 visit wi ll be performed. An End of 
Treatment and Primary  Follow -Up Disposition Case Report/ Record Form (CRF) page should 
be completed, giving the date and reason for stopping the treatment and primary  follow -up 
phase.
During the End of Treatment and Primary  Follo w-Up visit, patients will undergo the following: 
blood collection for hematology , chemistry , serum immunoglobulins, CTL019 PK, 
 flow cytometry  (B cells, ), cytokines and RCL  by VSV -G
qPCR . In addition, patients will undergo a physical exam (including vital signs and weight), 
performance status assessment, B
-symptom assessment, Imaging (CT/MRI) assessment,  
. Protocol defined adverse events, adverse events of 
special interest (includi ng new malignancies) and selected concomitant medications will be 
reviewed. A Serum pregnancy  test will be done for WOCBP until contraception is no longer 
required . Any pregnancies will be reported.
Following completion of the Treatment and Primary  Follow -Up, patients will be followed for 
survival until the end of the study  as defined in Section 4.2(Section 
7.1.5) or patients will be 
enrolled in the long term follow -
up (LTFU) study , whichever occurs first. Patients who 
discontinue or withdraw from the Treatment and Primary  Follow -Up early for any reason will 
be asked to continue the study  in the Secondary  Follow -up Phase through Month 60.
7.1.3.2 Criteria for premature patient withdrawal from treatment and primary  
follow -up phase
Patients must be followed according to the visit schedule for the Treatment and Primary  Follow -
Up to ensure adequate data are collected for the proper assessment of study  primary  and 
secondary  objectives. Patients may voluntaril y withdraw from the Treatment and Primary 
Follow -Up Phase or be dropped from it at the discretion of the investigator at any time. It is 
anticipated that patients may leave the primary  follow -up and move to Seco ndary  Follow-Up 
due to reasons including:
Disease progression/Relapse af ter remission,
Pursuing HSCT while in remission, or
Patient voluntary  withdrawal from the primary  follow -up.
Patients may  voluntarily  withdraw from the study  or be dropped from it at the discretion of the 
investigator at any time. Patients lost to follow up should be recorded as such on the CRF. For 
patients who are lost to follow -up, the investigator should show “due diligence” by 

Novartis Confidential Page 117
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
documenting in the source documents steps taken to cont act the patient, e.g., dates of telephone 
calls, registered letters, etc.
7.1.4 Secondary  follow -up phase
Patients who discontinue the Treatment and Primary  Follow -Up Phase before month 60 will 
continue to be followed in the secondary  follow -up phase in order tocollect health authorit y 
requested data (e.g. protocol defined adverse events) up to 5 y ears after CTL019 infusion.
The first visit in the Secondary  Follow -Up Phase is determined according to the time since 
CTL 019 infusion when the patient discontinued from the Treatment and Primary  Follow -Up 
Phase. For example, if the patient discontinues from the Treatment and Primary  Follow -Up 
phase at Month 10, the first visit in the Secondary  Follow -Up Phase will be Month 12.
For details of assessments, refer to Table 7-2. During the secondary  follow -up phase, patients 
will undergo one or more of the following at each visit according to Table 7-2: Blood collectio n 
for hematology , serum immunoglobulins, humoral immunogenicit y, cytokines, CTL 019 PK, 
flow cytometry  (B cells, ) and RCL  by VSV -
GqPCR . In addition, patients will 
undergo a physical exam (including weight), vital signs, and a performance status assessment. 
Protocol defined adverse events, adverse events of special interest (including new malignancies) 
and selected prior/concomitant medications will be reviewed. Serum or urine pregnancy  test 
will be done between M30 and M54, and a serum pregnancy test at M60 for WOCBP until 
contraception is no longer required .Any pregnancies will be reported. Efficacy  will be assessed 
until patient progresses. For these patients, relapse status of primary  malignancy  will be 
assessed at each visit.
In the event a patient cannot attend any visit during the secondary  follow -up, the investigator 
should attempt to contact the patient by phone to determine, at a minimum, primary  malignancy 
status and survival status.
For details of assessments, refer to Table 7-2.
Additional follow -up will be made to determine survival status for patients every  3 months. If 
a patient misses a quarterly  scheduled visit where survival status is required, or if the quarterl y 
time-point where survival status is required does not align with a scheduled visit, survival status 
can be obtained via phone contact, and the survival eCRF must be entered.
7.1.4.1 Criteria for premature patient withdrawal from the study
Patients may  voluntarily  withdraw fro m the study  or be dropped from it at the discretion of the 
investigator at any time. Patients lost to follow up should be recorded as such on the CRF. For 
patients who are lost to follow -up, the investigator should show “due diligence” by 
documenting in th e source documents steps taken to contact the patient, e.g., dates of telephone 
calls, registered letters, etc.
Patients may  be withdrawn from the study  if an y of the following occur:
a.The patient is lost to follow -up
b.Patient noncompliance with study  therap y and/or clinic appointments
c.Voluntary  withdrawal; a patient may  remove himself/herself from the study at any  time 
without prejudice.

Novartis Confidential Page 118
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
d.Termination of the stud y by the sponsor or the health authorities
Novartis will continue to retain and use all research results that have already been collected for 
the study  evaluation. All biological samples that have alread y been collected may be retained 
and anal yzed at a later date (or as required b y local regulations).
7.1.5 Survival follow -up phase
For all patients who complete the primary  follow -up or prematurely  discontinue from the 
primary  or secondary  follow -up phase, every  attempt should be made to follow the patients to 
determine survival every 3 months post-CTL019 infusion until the end of study  as defined in 
Section 4.2, or until the patient is enrolled in the long term follow -up (LTFU), whichever occurs 
first. Survival status can be obtained via phone contact with the patient.
7.1.6 Long -term follow -up
As a single administration study , 
patients are followed on study  for 5 years post-infusion for 
safet y and efficacy  evaluations. A long term post-study  follow -up for lentiviral vector safet y 
will continue under a separate destination protocol. Patients will continue tobe followed until 
15 years post -CTL019 infusion per health authority  guidelines.
Under the long term follow -up protocol, semiannual and annual evaluations will be performed 
on all patients who have received a CTL019 cell product infusion as recommended by the FDA 
and EMA in accordance with the relevant guidelines. All patients who either complete the study  
or prematurel y discontinue post-CTL 019 infusion will be automatically enrolled in this 
destination protocol at the time of study  completion/discontinuation (separate informed 
consent/assent forms will be provided for this protocol). One to two times a year patients will 
visit the clinical site for a physical exam and medical history  (including concomitant 
medications and adverse events) with careful atten tion to features possibly related to lentiviral 
associated events such as new malignancies, new incidence or exacerbation of a pre-existing 
neurologic disorder, new incidence or exacerbation of a prior rheumatologic or other 
autoimmune disorder, or new incidence of other hematologic disorders. In addition, labs will 
be drawn to evaluate routine safet y endpoints, CTL019 vector persistence and RCL.
7.1.7 Discontinuation of study treatment
Not applicable as patient will only  receive 1 dose of CTL 019 at Day  1
7.1.8 Withdra wal of consent
Patients may  voluntary  withdraw consent to participate in the study  for any  reason at an y time. 
Withdrawal of consent occurs onl y wh en a patient does not want to participate in the stud y any 
longer, and does not want any further visits or assessments, and does not want anyfurther study 
related contact.
Novartis will continue to retain and use all research results that have already been collected for 
the study  evaluation. All biological samples that have alread y been collected may be retained
and anal yzed at a later date (or as required b y local regulations).
If a patient withdraws consent, the investigator must make every  effort (e.g. telephone, e -mail, 
letter) to determine the primary  reason for this decision and record this information.

Novartis Confidential Page 119
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
7.1.9 Follow up for safety  evaluations
Please refer to Section 7.1.4 and Section 7.1.6.
7.1.10 Lost to follow -up
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw consent, the investigator should show “due diligence” by contacting 
the patient, family  or family  physician as agreed in the informed 
consent and by documenting 
in the source document s steps taken to contact the patient, e.g. dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until due diligence 
has been completed. Patients lost to follow -up should be recorded as such on the appropri ate 
disposition CRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Efficacy  assessments will be performed as indicated in Table 7-1, and as clinically  indicated 
until relapse or progression. Efficacy  evaluation will be based on recommendations by the 
International Malignant Lym phomas Imaging Working Group (Cheson et al 2014; Barrington 
et 
al 2014) and detailed as an appendix to the protocol (Guideline for Efficacy  Evaluation in 
DLBCL and FL 
studies, version 2 ).
An Independent Review Committee (IRC) appointed by Novartis will review data related to 
disease response assessment according to the Guideline for E
fficacy  Evaluation in DLBCL and 
FL studies, version 2. Radiological imaging will be transmitted by the sites to the imaging 
Contract Research Organization (CRO) designated by Novartis to undergo quality  checks and 
central review by the IRC. Clinical data such as, physical exam, bone marrow results, B
-
symptoms, pathology /histology  and cytology  results; as well as, information regarding prior 
interventions, pre-existing radiographic findings that may mimic metastatic disease at 
baseline/screening and on-study interventions will be transmitted to the imaging CRO for 
review by a medical oncologist/hematologist. Further details regarding the IRC assessment will 
be provided in the IRC charter. The central review of the scans will be carried out in a blinded 
fashion. The decision regarding patient management will remain with the local investigator . 
Enrollment eligibility  will be determined by the local staging assessment of the required images 
obtained during screening. Imaging studies used to determine eligibility  must be submitted to
the IRC.
Disease characterization at baseline and evaluation of efficacy  during study  rely on the 
following:
Central pathology  assessment
Molecular subt ype determination by  central laboratory
Imaging
Bone marrow biops y or aspirate

Novartis Confidential Page 120
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
CSF cy tology
B-symptoms
Physical exam
Imaging data will be centrally  collected and checked for qualit y by an imaging Contract 
Research Organization (CRO) designated b y Novartis. The results of the central evaluations 
will be used for primary  anal ysis purposes. The local investigator’s assessment will be used 
for treatment decision making. An y imaging assessments alread y completed during the 
regular work- up of the patient within 8 weeks prior to start of screening , including before 
signing the main study  ICF, c an be considered as the screening images for this study . Any 
imaging assessments obtained after infusion cannot be considered baseline images.
Any potentially  measurable lesion that has been previously  treated with radiotherap y should be 
considered as a non-measurable (non-index) lesion. However, if a lesion previously  treated with 
radiotherap y has clearly  progressed since the radiotherapy , it can be considered as a measurable 
lesion.
Additional imaging assessments may be performed at any time during the study at the 
investigator’s discretion to support the efficacy  evaluations for a subject, as necessary. Clinical 
suspicion of disease progression at any time requires a physical examination and imaging 
assessments to be performed promptly  rather than waiting for the next scheduled imaging 
assessment.
A PET-CT(or CT/MRI and FDG PET when PET
-CT not available) must be performed within 
four weeks prior to scheduled infusion of the CTL 019product, and should be scheduled as 
closely  as possible to CTL019 infusion and at Month 3. The CT component of the PET-CT may 
be used in lieu of a standalone CT/MRI , only if the CT component is of similar diagnostic 
quality  as a contrast enhanced CT performed without PET. If contrast enhanced PET -CT is not 
available, a standard FDG-PET must be performed and a standalone diagnostic CT/MRI  should 
be performed in addition to the FDG -PET scan. If independent CT and PET scanners are used, 
and the subject is receiving both scans on the same day, the PET must be performed prior to the 
CTwith IV contrast as to not compromise PET results. The PET -CT acquisition methodology 
(e.g., administration of intravenous contrast) should remain consistent between baseline and
Month 3 for an y given patient.
Additional imaging assessments may be perform ed at any time during the study  at the 
investigator’s discretion to support the efficacy  evaluations for a subject, as necessary. Clinical 
suspicion of disease progression at any time requires a physical examination and imaging 
assessments to be performed promptly  rather than waiting for the next scheduled imaging 
assessment. It is recommended to verify  disease progression by  PET -CT.

Novartis Confidential Page 121
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 7-3 Imaging or disease assessment collection plan
Procedure Screening/Pre -infusion Post -infusion Assessment
PET-CT with contrast enhanced 
CTMandated within 4 weeks prior to 
scheduled infusion of CTL019 
product Mandated at Month 3
Dedicated FDG PET Mandated if no PET -CT available
within 4 weeks prior to scheduled 
infusion of CTL019 product Mandated at Month 3 if no PET CT 
available
CT/MRI (Chest, Abdomen, Pelvis, 
Neck)Mandated to determine study 
eligibility
Mandated within 4 weeks prior to 
scheduled infusion of CTL019 
product if no PET -CT available or if 
the CT component of the PET -CT 
scan is not of diagnostic qualityMandated at Day 28, Months 6, 9, 
12, 18, 24, 36, 48 and 60 and as 
clinically indicated
Mandated at Month 3 if no PET -CT 
available
Due to the mechanism of action o f 
CTL019, the Day 28 assessment 
should be interpreted in context of 
other clinical parameters that 
suggest true progression rather 
than pseudoprogression due to 
inflammatory changes and tumor 
swelling.
CNS Imaging (CT/MRI) As clinically indicated As clinically indicated
Bone marrow aspirate and biopsy 
DLBCL cellsMandated Mandated at time of radiological 
CR in patients with baseline bone 
marrow disease and as clinically 
indicated
Mandated at Month 3 in all patients
Tumor biopsy (FFPE) for central 
pathology assessment and DLBCL 
subtype determinationMandated n/a
CSF Cytology Mandated As clinically indicated
The status of primary  malignancy  based on clinical routine assessments will be recorded for 
patients with ongoing response during follow up. The CD19 status at time of relapse should be 
recorded.
7.2.2 Safety  and to lerability assessments
For patients in the primary  follow -up, safety  will be monitored by assessing immunogenicity 
against CTL 019, lab abnormalities, physical examination, ECG, and vital signs, as well as 
collecting adverse events continuously  until Month 12. After Month 12 only selected AEs 
(protocol defined AEs) will be collected.
For patients in the secondary follow -up, only selected AEs (protocol defined) will be collected.
For complete details on AE collection, reporting and adverse events of special i nterest, refer to 
Section 8.
For all patients either in the primary  or the secondary  follow -
up, any pregnancies will need to 
be reported and followed -up.

Novartis Confidential Page 122
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
7.2.2.1 Physical Examination
A complete evaluation will generally include the examination of general appearance, skin, neck 
(including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities and vascular and neurological. If indicated based on medical history  and/or 
symptoms, r ectal, external genitalia, breast, and pelvic exams will be performed.
Significant findings that were present prior to the signing of informed consent must be included 
in the Medical History  CRF page. Any lesions, detected during a physical exam at any time-
point that are not detectable by imaging should be recorded on the Tumor Evaluation CRF page 
as a non-targeted lesion and does not need to be recorded on the Adverse Event CRF page. 
Significant new findings, other than new lesions, that begins or worsens after informed consent 
must be recorded on the Adverse Event CRF page.
7.2.2.2 Vital Signs
Vital signs include temperature, blood pressure, pulse, respiratory  rate, and pulse oximetry . 
Pulse oximetry  will be performed onl y at Screening, Day  1 (prior to infusion) through Day  14. 
After the patient has been sitting for five minutes, with back supported and both feet placed on 
the floor, systolic and diastolic blood pressure will be measured using an automated validated 
device, with an appropriately  sized cuff. In cas
e the cuff sizes available are not large enough 
for the patient’s arm circumference, a sphy gmomanometer with an appropriately  sized cuff may 
be used.
Vital signs (temperature, respiration rate, pulse, pulse oximetry ,and blood pressure) will be 
taken prior to, during and immediately  after the infusion and then approximately  every  15 
minutes for one hour and then every  hour for the next two hours, or until these signs are 
satisfactory  and stable .
7.2.2.3 Height and Weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor clothing, 
but without shoes) will be measured according to Table 7-1.
7.2.2.4 Performance status
At visits according to Table 7-1, the ECOG performance scale index will be used to evaluate 
the performance status of the patients.
Table 7-4 ECOG Performance status grade
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office work
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours 
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair
5 Dead

Novartis Confidential Page 123
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
7.2.2.5 Laboratory  evaluations
Laboratory  assessments will be performed according to Table 7-1and Table 7-2. Note : 
Additional assessments should be performed between visits as clinically  indicated and to follow 
AEs or CTL 019 expected events. For all laboratory  assessments that occur on Day 1, these 
should be performed prior to CTL 019 infusion unless indicated otherwi se.
Table 7
-5 Local clinical laboratory  parameters collection plan
Test Category Test Name
Hematology Hematocrit, Hemoglobin, MCHC, MCV, Platelets, Red blood cells, W hite blood cells with 
complete differential (Basophils, Eosinophils, Lymphocytes, Atypical Lymphocytes, 
Monocytes, Neutrophils , Lymphoblasts, Plasma cells, Prolymphocytes, Myelocytes, 
Metamyelocytes, and Promyelocytes)
Chemistry Glucose, Blood Urea Nitrogen (BUN), Creatinine, eGFR, Sodium, Potassium, Calcium, 
Total Protein, Albumin, Total Bilirubin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), 
Magnesium, Phosphorus, LDH,  and Uric Acid
Urinalysis Macroscopic Panel (Dipstick) (Bilirubin, Blood, Glucose, Ketones, Leukocytes esterase, 
Nitrite, pH, Protein, Specific Gravity)
If macroscopic panel is abnormal then perform microscopic panel (Red Blood Cells, W hite 
Blood Cells, Casts, Crystals, Bacteria, Epithelial cells)
Coagulation Prothrombin time (PT) or International normalized ratio (INR), activated Partial 
thromboplastin time (aPTT), fibrinogen, and D -dimer
Pregnancy 
screen for 
WOCBPSerum andurine pregnancy test is required as long as contraception is required. Refer to 
Table 7 -1 and Table 7-2 for the timepoints. 
Influenza Rapid Influenza A & B Test
Viral Serology Cytomegalovirus (CMV), Epstein -Barr Virus ( EBV), Hepatitis C Virus RNA , Hepatitis B 
surface antigen (HbsAg), Hepatitis B surface antibody (HBsAb), Hepatitis B core antibody 
(HBcAb), HIV test (if an initial HIV screening test is positive then a confirmatory HIV test is 
required to be performed as per current local guidelines)
Additional 
assessmentsSerum immunoglobulin levels (IgG, IgA, IgM)
CTL 019 PK will be quantified by q-PCR and flow cytometry  in peripheral blood and bone 
marrow.  
 
 
 Replication competent 
lentivirus (RCL ) will be detected by q-PCR for VSV -Gin peripheral blood. See Table 7-6. If 
negative after the first year, samples will be collected and stored but 
not analy zed unless 
requested for safet y purposes.
Table 7
-6 Central clinical laboratory  parameters collection plan
Test Category Test Name/Method
CD19 testing Immunohistochemistry or flow cytometry
DLBCL and subtype determination Immunohistochemistry
Bone marrow aspirate/biopsy Flow cytometry or immunohistochemistry 

Novartis Confidential Page 124
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Test Category Test Name/Method
RCL (VSV-G) VSV-g q -PCR (whole blood)
Cytokines Serum cytokine panel, PD1, PDL1 (peripheral blood, CSF)
Immunogenicity Incidence and prevalence (pre -existing) of immunogenicity against 
CTL019 (peripheral blood and serum)
CTL019 pharmacokinetics CTL019 PK by q -PCR or flow cyto metry (peripheral blood, bone marrow 
aspirate)
Additional assessments Serum immunoglobulin levels (IgG, IgA, IgM) (Secondary follow -up only)
Refer to the [Laboratory Manual] for more detailed instructions for the collection, handling, 
and shipment of PK samples.
7.2.2.6 Cardiac assessments
7.2.2.6.1 Electrocardiogram (ECG)
A standard 12 lead ECG will be performed at:
Screening
Infusion- Day 1 (prior to infusion)
The date and time of the ECG and the following parameters will be collected and assessed: 
QTcF, PR, QT and QRS interval in msec, heart rate (bpm).
Interpretation of the tracing must be made by a
 qualified physician and documented on the ECG 
CRF page. Each ECG tracing should be labeled with the study  number, patient initials (where 
regulations permit), patient number, date, and kept in the source documents at the study  site. 
Clinically  significant abnormalities present when the patient signed informed consent should 
be report ed on the Medical History  CRF page. Clinically  significant findings must be discussed 
with Novartis prior to enrolling the patient in the study. New or worsened clinically  significant 
findings occurring after informed consent must be recorded on the Advers e Events CRF page.
7.2.2.6.2 Cardiac imaging –MUGA (multiple gated acquisition) scan or 
echocardiogram (ECHO)
An ECHO/MUGA test is required to be completed at screening. Clinically  significant 
abnormalities present when the patient signed the informed consent shoul d be reported on the 
Medical History  CRF page. Clinically  significant findings must be discussed with Novartis 
prior to enrolling the patient in the study . New or worsened clinically  significant findings 
occurring after informed consent must be recorded onthe Adverse Events CRF page. Patients 
must have a left ventricular ejection fraction (LVEF) ≥ 45% to be included into the study .

Novartis Confidential Page 125
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
7.2.3 Cellular Kinetics and Pharmacokinetics
Blood and BM sampling for PK evaluations will be performed at specified time-points. All 
collections of PK blood samples will be recorded on the appropriate PK blood collection CRF 
page. Refer to the [Laboratory  Manual ]for details on sample handling and shipment.
Table 7
-7 CTL019 pharmacokinetics by  q-PCR in peripheral blood collection log
Cycle Day*Scheduled time 
point relative to 
dosingPK DRID 
(CTL019)*PK 
Sample 
No. 
(CTL019)Blood 
Volume 
(mL)
1 W- 3 to D -8 
Enrollment/Pre -
ChemotherapyPre-dose 201 201 6
1 D1 10 minutes ± 5 
minutes post -infusion0.167h post -dose (±5 
min)201 202 6
1 D2 24h (+/- 6h)/D2 201 203 6
1 D4±1d 72hD4 201 204 6
1 D7±1d D7 201 205 6
1 D11±1d D11 201 206 6
1 D14±1d D14 201 207 6
1 D17±1d D17 201 208 6
1 D21±3d D21 201 209 6
1 D28±7d D28 201 210 6
1 M2±14d M2 201 211 6
1 M3±14d M3 201 212 6
1 M6±14d M6 201 213 6
1 M9±14d M9 201 214 6
1 M12±14d M12 201 215 6
1 M18±14d M18 201 216 6
1 M24±14d M24 201 217 6
1 M30±14d M30 201 218 6
1 M36±14d M36 201 219 6
1 M42±14d M42 201 220 6
1 M48±14d M48 201 221 6
1 M54±14d M54 201 222 6
1 M60±14d M60 201 223 6
1 Unscheduled PK 
samples related to CRSa201 2001 6
1 Unscheduled (PK 
samples related to safety 
events, relapse)b201 3001 6
1 Unscheduled (PK 
samples at relapse)c201 6001 6
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
**Additional unscheduled samples may  be collected as needed dependent upon individual patient 
differences in the clinical time -course of CRS, if clinica lly feasible. See Section 7.1.3

Novartis Confidential Page 126
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Cycle Day*Scheduled time 
point relative to 
dosingPK DRID 
(CTL019)*PK 
Sample 
No. 
(CTL019)Blood 
Volume 
(mL)
 
bUnscheduled PK samples related to other non -CRS safety events are uniquely, sequentially 
numbered 3001, 3002, etc.
cIn the event patient relapses, an unscheduled PK sample should be collected along with 
corresponding immunogenicity sample (refer to Table 7 -12and Table 7 -13)
Note: If RCL testing was negative through Month 12, all samples taken after Month 12 will be stored 
forpotential future testing.
Table 7-8 CTL019 pharmacokinetics by  flow cy tometry  in peripheral bloo d 
collection log
Cycle Day*Scheduled time point 
relative to dosingPK DRID 
(CTL019)*PK Sample No. 
(CTL019)Blood 
Volume 
(mL)
1 W- 3 to D -8 
Enrollment/Pre -
chemotherapy 
evaluationPre-dose 201 301 2
1 D1 10 minutes 
± 5 minutes 
post-infusion0.167h post-dose (±5 min) 201 302 2
1 D4±1d 72hD4 201 303 2
1 D7±1d D7 201 304 2
1 D11±1d D11 201 305 2
1 D14±3d D14 201 306 2
1 D17±1d D17 201 307 2
1 D21±3d D21 201 308 2
1 D28±7d D28 201 309 2
1 M2±14d M2 201 3 10 2
1 M3±14d M3 201 311 2
1 M6±14d M6 201 312 2
1 M9±14d M9 201 313 2
1 M12±14d (EOT) M12 201 314 2
1 M18±14d M18 201 315 2
1 M60±14d M60 201 316 2
1 Unscheduled 
PK samples 
related to CRSa201 4001 2
1 Unscheduled 
(PK samples 
related to safety 
events, relapse)
b201 5001 2
1 Unscheduled 
(PK samples at 
relapse)c201 7001 2

Novartis Confidential Page 127
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Cycle Day*Scheduled time point 
relative to dosingPK DRID 
(CTL019)*PK Sample No. 
(CTL019)Blood 
Volume 
(mL)
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
**Additional unscheduled samples may  be collected as needed dependent upon individual patient 
differences in the clinical time -course of CRS, if clinically feasible. See Section 7.1.3
 
 
bUnscheduled anytime PK samples related to other non -CRS safety events will be uniquely, 
sequentially numbered 5001, 5002, etc.
cIn the event patient relapses, an unscheduled PK sample should be collected along with 
corresponding immunogenicity sample (refer to Table 7 -12and Table 7 -13)
Table 7-9 CTL019 pharmacokinetics by q-PCR in bone marro w aspirate 
collection log
To be completed onl y if bone marrow examined
Cycle Day*Scheduled time point 
relative to dosingPK DRID 
(CTL019)*PK Sample 
No. 
(CTL019)Sample 
Volume (mL)
1 W- 8 to W -4 
ScreeningPre-dose/screening 201 401 2
1 M3±14d M3 201 402 2
1 Unscheduled 
(e.g. at time of 
radiological CR, 
related to 
relapse) a201 403 2
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
a.Unscheduled time points begin with 403, 404, 405 series
Table 7-10 CTL019 pharmacokinetics by  flow cy tometry  in bone marro w aspirate 
collection log
To be completed onl y if bone marrow examined
Cycle Day*Scheduled time point 
relative to dosingPK DRID 
(CTL019)*PK Sample 
No. (CTL019)Sample 
Volume (mL)
1 W- 8 to W -4 
ScreeningPre-dose/screening 201 501 2
1 M3±14d M3 201 502 2
1 Unscheduled 
(e.g. at time of 
radiological CR, 
related to 
relapse)a201 503 2
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
a.Unscheduled time points begin with 503, 504, 505 series "

Novartis Confidential Page 128
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 7-11 CTL019 pharmacokinetics by  q-PCR in CSF biopsy or other tissue log
To be completed onl y if CSF collection performed.
Day/ Scheduled Time Point* Sample Volume
W-8 to W -4 Screening 4-8 mL
Unscheduled (e.g. related to relapse) 4-8 mL
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
Table 7-12 Immunogenicity  serum sample collection log
Day/ Scheduled Time Point* Sample volume
W-3 to D -8 Enrollment/Pre -chemotherapy evaluation **
D14±1d **
D28±7d **
M3±14d **
M6±14d **
M12±14d **
Unscheduled (at relapse)*** **
Unscheduled (e.g. related to safety events ) **
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
** Aliquots are derived from the serum cy tokine collections; refer to Table 7 -17.
***In the event patient relapses, an unscheduled immunogenicity sample should be collected along 
with corresponding PK s ample (refer to Table 7 -7, Table 7 -8)
Table 7-13 Immunogenicity  whole blood sample collection log
Day/ Scheduled Time Point Sample volume
W-3 to D -8 Enrollment/Pre -chemotherapy evaluation **
D14±1d **
D28±7d **
M3±14d **
M6±14d **
M12±14d **
Unscheduled (at relapse)***
Unscheduled (e.g. related to safety events ) **
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
 
***In the event patient relapses, an unscheduled immunogenicity sample should be collected along with 
corresponding PK sample (refer to Table 7 -7, Table 7 -8)

Novartis Confidential Page 129
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 7-14  CTL019 Pharmacokinetics (PK),  
 treated patients dur ing CRS
Day/ 
Scheduled 
Time 
Point*/**Dose 
Reference 
IDSample 
NumberSample 
Volume 
(serum) CTL019 
Dose 
Reference 
IDCTL019 
PK b y 
qPCR 
Sample 
Number^Sample 
Volume
(whole 
blood)CTL019 
PK b y 
flow 
cytometry  
Sample 
Number^Sample 
Volume
(whole 
blood)
D1 (5 -15 
minutes post 
infusion)101 1 5 mL 201 -- -- -- --
D1 1h ± 15 
min post 
infusion101 2 5 mL 201 251 2 mL 351 2 mL
D2 ± 2h 101 3 5 mL 201 252 2 mL 352 2 mL
D3 ± 4h 101 4 5 mL 201 253 2 mL 353 2 mL
D7 ± 1d 101 5 5 mL 201 254 2 mL 354 2 mL
D1 (pre -
dose; 
second 
infusion)101 6 5 mL 201 255 2 mL 355 2 mL
D1(5 -15 
minutes post 
second 
infusion)102 7 5 mL 201 -- -- -- --
D2 ± 2h 
from second 
infusion102 8 5 mL 201 256 2 mL 356 2 mL
D3± 4 hours 
(post second 
infusion)102 9 5 mL 201 257 2 mL 357 2 mL
D7±1d (post
second 
infusion)102 10 5 201 258 2 mL 358 2 mL
D1 (5 -15 
minutes pre -
dose; 
additional 
infusion)102 11 5 mL 201 259 2 mL 359 2 mL
D1 (5 -15 
minutes post 
additional 
infusion103 12 5 mL 201 -- -- -- --
D2 ± 2 hours 103 13 5 mL 201 260 2 mL 360 2 mL
D3 ± 4 hours 103 14 5 mL 201 261 2 mL 361 2 mL
D7 ± 1d 103 15 5 mL 201 262 2 mL 362 2 mL
Additional*** 104,105 16, 17, 
18, 19, 
205 mL 201 263, 264, 
265, 2662 mL 363, 364, 
365, 3662 mL
*All measurement times are relative to infusion unless otherwise specified. A serum 
sample collected at D -1 for cytokine analysis (see Table 7 -17would serve as the baseline sample.
**Sampl es may  be collected as needed dependent upon administration of if clinically 
feasible.
Unscheduled CTL019 PK sample collections related to CRS as specified in Table 7 -7will cease once 

Novartis Confidential Page 130
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Day/ 
Scheduled 
Time 
Point*/**Toci Dose 
Reference 
IDToci 
Sample 
NumberToci 
Sample 
Volume 
(serum) CTL019 
Dose 
Reference 
IDCTL019 
PK b y 
qPCR 
Sample 
Number^Sample 
Volume
(whole 
blood)CTL019 
PK b y 
flow 
cytometry  
Sample 
Number^Sample 
Volume
(whole 
blood)
^PK collections for CTL019 measured by qPCR will be numbered starting with 251 series and PK 
collections measured by flow c ytom etry will be numbered starting with a 351 series
 
Table 7- 15  CTL019 PK  treated 
patients during CRS
Day/ 
Scheduled 
Time 
Point*/**Dose 
Reference 
IDSample 
NumberSample 
Volume 
(serum) CTL019 
PK b y 
qPCR 
Sample 
NumberSample 
Volume
(whole 
blood)CTL019 PK 
by flow 
cytometry  
Sample 
NumberSample 
Volume
(whole 
blood)
D1 (5 -15 
minutes post 
infusion)301 401 5 mL -- -- -- --
D1 1 hour ± 
15 min post 
infusion301 402 5 mL 501 2 mL 701 2 mL
D2 ± 2 hours 301 403 5 mL 502 2 mL 702 2 mL
D3 ± 4 hours 301 404 5 mL 503 2 mL 703 2 mL
D7 ± 1d 301 405 5 mL 504 2 mL 704 2 mL
D1 (pre -dose; 
additional 
infusion)301 406 5 mL 505 2 mL 705 2 mL
D1(5 -15 
minutes post 
additional 
infusion)302 407 5 mL -- -- -- --
D2 ± 2 hours 
from 
additional 
infusion302 408 5 mL 506 2 mL 706 2 mL
D3 ± 4 hours 302 409 5 mL 507 2 mL 707 2 mL
D7 ± 1d 302 410 5 mL 508 2 mL 708 2 mL
Additional*** 303, 304 411, 412, 
413, 414, 
4155 mL 509, 510, 
511, 5122 mL 709,710, 
711, 7122 mL
*All measurement times are relative to administration unless otherwise specified. A serum sample 
collected at D1 for cytokine analysis (see Table 7 -17) would serve as the baseline sample.
**Samples may be collected as needed dependent upon administration o  if clinically feasible.
Unscheduled CTL019 PK sample collections related to CRS as specified in Table 7 -7, Table 7 -8, and will 
cease once PK/PD sample collections related to administration commence, if applicable.
 

Novartis Confidential Page 131
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 132
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 133
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 134
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 135
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 136
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
 
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), symptom(s), or medical condition(s) that occur after patient’s signed informed 
consent/assent has been obtained.
Abnormal laboratory  values or test results occurring after informed consent/assent constitute 
adverse events only if they induce clinical signs or symptoms, are considered clinicall y 
significant, require therapy  (e.g., hematologic abnormality  that requires transfusion or 
hematological stem cell support), or require changes in study  medication(s).
8.1.2 Reporting
Adverse events that begin or worsen after informed consent/assent will be recorded in the 
patient’s source documents. New or worsening adverse events prior to starting study 
treatment (i.e. lymphodepleting chemotherap y or the pre -infusion visit if the lymphodepleting 
chemotherap y is not given per Section 6.1.1.1) are required to be recorded in the Adverse Events 
CRF if they  meet one of the following criteria:
All infections
All clinical AEs grade ≥ 3
All laboratory  abnormalities deemed clinically  significant by  the investigator
All AEs related to a study procedure
All AEs leading to stud y discontinuation
All SAEs meeting criteria outlined in Section 8.2.2
Concomitant medications during the pre-screening period will also follow modified reporting 
criteria as described in Appendix 3 .
Once the patient begins lymphodepleting chemotherapy or the pre-infusion visit, all new 
or worsening adverse events, inclu
ding laboratory  abnormalities deemed clinically  significant 
by the investigator, regardless of causalit y will be recorded in the Adverse Events CRF up to 
the Month 12 visit.
Adverse event monitoring should be continued through the Month 60 (EOT) visit. Following 
the Month 12 visit, and through the Month 60 visit , adverse events should only  be reported 
to Novartis and recorded in the Adverse Events CRF if it meets one of the following criteria:
Events leading to death
Events related to a stud y procedure
Infections:
Serious or opportunistic infections that fulfill one of the follo wing criteria:

Novartis Confidential Page 137
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Require anti -infective treatment OR
Lead to significant d isability  or hospitalization OR
Need surgical or other intervention
New incidence or exacerbation of a pre-existing neurologic disorder
New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder
New incidence of other hematologic disorder
Any severe adverse event or condition the investigator believes may  have a reasonable 
relationship to CD19 CART therapy
Positive RCL  test result
Vector insertion site sequencing result with a mono- or oligoclonality  pattern or in a 
location near a known human oncogene
New malignancy  (T-cell & non T -cell), other than the primary  malignancy
Progressive multifocal leucoencephalopathy  (PML)
Hepatitis B reactivation
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underl ying signs and symptoms. When a 
clear diagnosis cannot be identified, each sign or symptom should be reported as a separate 
Adverse Event.
Adverse events will be assessed according to the Medical Dictionary  for Regulatory  Authorities
(MedDRA) and the Common Terminology  Criteria for Adverse Events (CTCAE) version 4.03, 
with the exception of CRS, which will follow Table 6 -1. If CTCAE grading does not exist for 
an adverse event, the severity  of mild, moderate, severe, and life -threatening, corresponding to
Grades 1 - 4, will be used. CTCAE Grade 5 (death) will not be used in this study ; rather, 
information about deaths will be collected though a Death form.
The occurrence of adverse events should be sought by  non-directive questioning of the patient
during the screening process after signing informed consent/assent and at each visit during the 
study . Adverse events also may be detected when they are volunteered by the patient during the 
screening process or between visits, or through physical examina tion, laboratory  test, or other 
assessments. As far as possible, each adverse event should be evaluated to determine:
1.The severit y grade (CTCAE v. 4.03 Grade 1-4)
2.Its duration (Start and end dates)
3.Its relationship to the study  treatment (Reasonable possibility  that AE is related: No,
Yes, investigational treatment, Yes, the study  treatment (non -investigational), Yes, both 
and/or indistinguishable)
4.Action taken with respect to study  or investigational treatment (none, temporaril y 
interrupted, permanentl y discontinued, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown)
7.Whether it is serious, where a serious adverse event is defined as in Section 8.2.1

Novartis Confidential Page 138
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
thera py is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Modified data capture for inpatient/in hospital events
A significant number of CTL 019 treated patients will r equire multiple days of inpatient and/or 
ICU care within 28 days after CTL019 infusion. These adverse events are mostly  due to CRS 
and MAS, although there may be some contribution from the preceding lymphodepleting 
chemotherap y (neutropenia fever, cytopeni as). CRS/MAS toxicity  is an ‘on-target’ effect 
resulting from the expected CTL 019 cell expansion, activation and tumor cell killing.
A typical inpatient or ICU day can generate hundreds of data points and many therapeutic dose 
changes throughout a given day. These inpatient events and days are not scheduled protocol 
defined visits although they are anticipated to occur in some patients. R evised inpatient data 
capture will be utilized for this study  to systematically  collect subsets of patient data to descri be 
the management of safety events associated with CTL 019 therapy  for the purpose of:
1.Adequatel y informing physicians and patients of the expected risks of CTL019 and the 
recommended interventions to manage these risks
2.Health authorit y submission
This is d one through a targeted collection of concomitant medications and laboratory  data and 
CRS CRFs specifically  designed to capture CTL 019-related toxicity , severity , interventions and 
response/resolution following intervention. Details can be found in the CRF Completion 
Guidelines (CCGs) and Appendix 3 and 4.
8.1.3 Laboratory  test abnormalities
8.1.3.1 Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events CRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnorma lities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities that do not meet the definition of an adverse event should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A medication for the lab abnormality may be required b y the protocol 
in which case the lab abnormality  would still, by definition, be an adverse event and must be 

Novartis Confidential Page 139
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
reported as such. Whenever possible, a diagnosis, rather than a symptom should be provided 
(e.g. anemia instead of low hemoglobin).
8.1.4 Adverse events of special interest
An adverse event of special interest (AESI, serious or non-serious ) isone of greater scientific 
and medical concern specific to CTL019. The current defined AESI s for CTL 019 include 
Cytokine Release Sy ndrome, Tumor Ly sis Sy ndrome, Neutropenic fever, Cy topenia >28 day s, 
drop in cardiac ejection fraction, neurotoxicity , hepatic events ( Section 6.3 ) , and infections.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outc omes listed above
Requires inpatient hospitalization or prolongat ion of existing hospitalization
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indicatio n, not associated with any 
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an emergency
 outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a se rious adverse event
All malignant neoplasms (secondary  malignancies, not disease progression of the study 
indication) will be assessed as serious under “medically  significant .”
Progression of the underly ing malignancy  with fatal outcome must be reported as a SAE within 
24 hours of awareness, if the following criteria are met: 
Deaths bey ond 30 day s after CTL019
infusion, if there is a least a possible causality  
to CTL 019
Non-fatal disease progression should not be reported as AE.
8.2.2 Reporting
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has begun study -related treatment (i.e. ly mphodepleting chemotherapy , or pre -CTL019 

Novartis Confidential Page 140
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
infusion visit if no ly mphodepleting chemotherapy  was given) and through the Month 12 visit 
must be reported to Novartis within 24 hours of learning of its occurrence.
8.2.2.1 Screening/pre -treatment
Any SAEs experienced during the screening/pre -treatment phase (from the time of patient 
providing informed consent/assent until the patient begins study -related treatment) should 
ONLY be reported to Novartis and be captured in the CRF and safet y database if the event 
meets at least one of the following criteria:
All events leading to death.
All pulmonary  or cardiac abnormalities
All infections
All events related to a study  procedure
Any AE reportable for this study  period that also meets criteria for serious
Any substantial change in the status of the patient that precludes the patient from 
proceeding to study treatment (e.g. GVHD, rapid progression of malignancy, marked 
decline in performance status)
Any other substantial change in the status of the patient that the investigator deems may  
have a potential impact on the patients during l ymphodepletion and CTL 019 treatment
8.2.2.2 Study -related treatment to Month 12
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has begun study -related treatment (i.e. ly mphodepleting chemotherapy , or pre -CTL019 
infusion visit if no ly mphodepleting chemotherapy  was given) and through the Month 12 visit 
must be reported to Novartis within 24 hours of learning of its occurrence.
8.2.2.3 Month 12 to Month 60
Any SAEs experienced after the Month 12 visit, and through the Month 60 (EOT) visit should 
only be reported to Novartis and recorded in the Adverse Events CRF if it meets one of the 
following criteria:
Events leading to death
Events related to a stud y procedure
Infections:
Serious or opportunistic infections that fulfill one of the following criteria:
Require anti -infective treatment OR
Lead to significant d isability  or hospitalization OR
Need surgical or other intervention
New incidence or exacerbation of a pre -existing neurologic disorder
New incidence or exacerb ation of a prior rheumatologic or other autoimmune disorder
New incidence of other hematologic disorder
Any severe adverse event or condition the investigator believes may  have a reasonable 
relationship to CD19 CART therap y

Novartis Confidential Page 141
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Positive RCL  test result
Vector insertion site sequencing result with a mono -or oligoclonality  pattern or in a 
location near a known human oncogene
New malignancy  (T-cell & non T -cell), other than the primary  malignancy
Progressive multifocal leucoencephalopath y (PML)
Hepatitis B reactivation
In addition, at the specific request of a National Health Authority , the following SAEs will be 
reported in an expedited manner:
Any SAE related to a study  procedure
All occurrences of CRS grade ≥ 3 (to be reported to National Health Authority on a 
monthly  basis)
All occurrences of Neurologic toxicity  ≥ 4
All deaths regardless of attribution following ly mphodepleting chemotherapy  and/or 
CTL 019 infusion
8.2.2.4 Post -treatment protocol
Any SAEs experienced after the Month 60 (EOT) visit should only be reported to Novartis Drug 
Safety  and Epidemiology (DS&E) if the investigator suspects a causal relationship to the study 
treatment. Recurrent episodes, complications, or progression of the initial SAE must be reported 
as follow -up to the original episode w
ithin 24 hours of the investigator receiving the follow -up 
information. An SAE occurring at a different time interval or otherwise considered completel y 
unrelated to a previously  reported one should be reported separatel y as a new event.
In addition, semia nnual and annual evaluations will be performed for up to 15 years from the 
date of infusion on all patients under a separate long term follow -up (LTFU) protocol as 
recommended by health authority  guidance for patients treated with gene therapies. All patie nts 
who either complete or prematurel y discontinue from the study  will be enrolled in this 
destination protocol at the time of study  completion/discontinuation (a separate informed 
consent form will be provided for this protocol; Section 7.1.7).
Information 
about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investiga tor must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis. Detailed 
instructions regarding the SAE submission process and requirements for signatures are to be 
found in the investigator folder provided to each site.
Follow -up information is submitted in the same way as the original SAE Report .Each re-
occurrence, complication, or progr ession of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, and whether the patient 
continued or withdrew from study  participation.

Novartis Confidential Page 142
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
If the SAE is not previously  documented in the [Investigator’s Brochure] or Package Insert 
(new occurrence) and is thought to be related to the Novartis study  treatment, an oncology 
Novartis DS&E department associate may urgently  require further information from the 
investigator for Health Authority  reporting. Novartis may need to issue an Investigator 
Notification (IN), to inform all investigators involved in an y study with the same treatment that 
this SAE has been reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will 
be collected and reported to the competent authorities and relevant ethics committees in 
accordance with Directive 2001/20/EC or as per national regulatory  requirements in 
participating cou ntries.
8.3 Emergency  unblinding of treatment assignment
Not applicable
8.4 Contraception
Thecontraceptive measures outlined in this section for WOCBP and sexually  active males are 
the effective ones and they replace those presented in the Inclusion Criteria section.
WOCBP
Women of child -bearing potential, defined as all women physiologically  capable of becoming 
pregnant, must use highly  effective methods of contraception forat least 12 months following 
CTL 019 infusion and until CAR T cells are no longer present by qPCR on two consecutive tests. 
qPCR test results will be available upon request. Highl y effective contraception methods 
include:
●Total abstinence (when this is in line with the preferred and usual lifest yle of the patient. 
Periodic abstinence (e.g. calendar, ovulation, sy mptothermal, post- ovulation methods) and 
withdrawal are not acceptable methods of contraception
●Female sterilization (surgical bilateral oophorectomy  with or without hy sterectom y), total 
hysterectom y or bi lateral tubal ligation at least six weeks before taking study treatment. In 
case of oophorectom y alone, only when the reproductive status of the woman has been 
confirmed b y follow up hormone level assessment.
●Male sterilization (at least 6 months prior to screening). For female patients on the study , 
the vasectomized male partner should be the sole partner for that patient.
●Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or 
other forms of hormonal contraception that have comparable efficacy  (failure rate <1%), 
for example hormone vaginal ring or transdermal hormone contraception. In case of use of 
oral contraception women should have 
been stable on the same pill for a minimum of 3 
months before enrollment into this study .
NOTE: If local regulations deviate from the contraception methods listed above to prevent 
pregnancy , local regulations apply  and will be described in the ICF.
Sexu ally active males
Sexually  active males must use a condom during intercourse for 12 months after the CTL019
infusion and until CAR T -cells are no longer present by  qPCR on two consecutive tests. qPCR 

Novartis Confidential Page 143
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
test results will be available upon request. A condom isrequired for all sexually  active male 
participants to prevent them from fathering a child AND to prevent delivery of stud y treatment 
via seminal fluid to their partner .
8.5 Pregnancies
To ensure patient safet y, each pregnancy  occurring after signing the informed consent must be 
reported to Novartis within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications. 
Pregnancy  follow up in this study  will end after birth or after any adverse pregnancy  outcome 
associated with the end of the pregnancy . In case of live birth the newborn will be followed up 
until 12 months of age to detect an y developmental issue or abnormalit y that would not be seen 
at birth. Pregnancy  outcomes must also be collected for the female partners of any males who 
received CTL019 in this study . Consent to report information regarding these pregnancy 
outcomes shou ld be obtained from the mother.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to theNovartis Chief Medical Office and Patient Safety  (CMO&PS ). Pregnancy  
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship between the investigational treatment andpregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Repor t Form.
8.6 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [Investigator 
Brochure ]. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.7 Data Monitoring Committee
A data monitoring committee (DMC) will be established prior to the enrollment of the first 
patient. The DMC will be responsible for reviewing the safet y and efficacy  results from the 
interim analy sis as well as overseeing safet y data at regular intervals. Enrollment will not be 
interrupted in between the interim analy sis data cutoff date and a DMC review of the interim 
analysis data and determination on whether to proceed with the study . The DMC will consist of 
members who are not involved in patient recruitment or trial conduct, with at least two 
oncologists (at least one adult hematologist/oncologist) and one biostatistician.
There will be an initial meeting with the DMC to have agreement on their roles and 
responsibilities and potential data format and procedures that will be reviewed during the course 
of the study . The first DMC safety  review meeting will be held when approximately  the first 5 
patients have been treated for at least 1 month or at least 6 months after the first patient is 
enrolle d, whichever occurs first. Subsequent safety reviews will occur every six months, unless 
otherwise requested by the Chairman of the DMC. Additional meetings will be held by DMC 

Novartis Confidential Page 144
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
or sponsor’s requests at the time of some safet y issues occurrence, especially  when serious 
events (e.g., death) occur on the study  or safety  notifications regarding the study  treatment come 
out.
Detailed recruitment status and interim safety reports will be provided to the DMC on a regular 
basis.
Further details regarding the constitution of the DMC and its specific roles will be provided in 
the DMC charter prior to the enrollment of the first patient.
8.8 Steering Committee
The steering committee (SC) will be established comprising investigators participating in the 
trial, Novartis representatives from the Clinical Trial team and not members of the DMC. The 
SC will ensure transparent management of the study  according to the protocol through 
recommending and approving modifications as circumstances require. The SC will review 
protocol amendments as appropriate. Together with the clinical trial team, the SC will also 
develop recommendations for publications of study  results including authorship rules. The 
details of the role of the Steering Committee will be defined in a Steering Committee charter.
8.9 Independent Review Committee (IRC)
An IRC will be established to review data related to disease response assessments during the 
Treatment and Primary  Follow -up Phase and determine response and relapse for the primary  
analysis. An IRC charter will detail the IRC data flow and review process in alignment with the 
response definitions in Section 14.1. Patient management will be based upon local investigator 
assessments. The designation of response and relapse for the primary analysis and other related 
secondary  efficacy  endpoints will be based only on the evaluations made by the IRC. Details 
regarding the constitution of the IRC and its specific roles will be documented in the IRC charter 
agreed upo n between Novartis and the IRC before initiation of any  IRC reviews.
8.10 Follow -up of Secondary  Malignancy
For patients treated with CTL 019, treating physician/ healthcare providers should contact 
Novartis if the patient develops a secondary  malignancy . 
Upon clinical confirmation of a secondary  malignancy , blood samples should be collected for 
CAR -
transgene and RCL. 
Novartis strongl y recommends collection of a portion of a biopsy  (e.g., bone marrow, solid 
tumor) from the secondary  malignancy  (if applicable andpreviously  collected as standard of 
care in diagnosing or treating the secondary  malignancy ) for analysis, such as CAR -transgene 
and RCL . Additional details for sample handling and shipping are outlined in the laboratory  
manual.

Novartis Confidential Page 145
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
9 Data collection and manage ment
9.1 Data confidentiality
Information about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
What protected heal th information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -
up safet y information (e.g. has the subject 
experienced an y new or worsened AEs) at the end of their scheduled study period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Pract ice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessme nts. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor acc ess to all relevant source documents to confirm their 
consistency  with the CRF entries. Novartis monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria and documentation 
of SAEs. A dditional checks of the consistency  of the source data with the CRFs are performed 
according to the stud y-specific monitoring plan.

Novartis Confidential Page 146
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data requi red by the protocol into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully validated secure web-enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they 
have been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the 
dataentered into eCRF is complete, 
accurate, and that entry and updates are performed in a timely  manner.
9.4 Database management and quality  control
For studies using eCRFs, Novartis personnel (or designated CRO) will review the data entered 
by investigational staff for completeness and accuracy . Electronic data queries stating the nature 
of the problem and requesting clarification will be created for discrepancies and missing values 
and sent to the investigational site via the EDC system. Designated investigator site staff are 
required to respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Ther apeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data will be processed centrall y and the results will be sent electronically to 
Novartis (or a designated CRO).
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copies 
of the patient data for archiving at the investigational site.
10 Statistical methods and data analy sis
Data from all participating centers will be combined.
The primary  anal ysis will be performed when 80 patients have received CTL019 infusion in the 
main cohort and completed 3months from study  day 1 infusion or discontinued earlier. Selected 
efficacy  and safet y analysis will be updated annually. A final Clinical Study Report (CSR) will 
be produced once all patients complete the stud y.
10.1 Analysis sets
The anal ysis sets to be used are defined as below. The FAS will be used as the primar y efficacy 
analysis set. The Safety Set will be used for all the safet y analy sis. The Pharmacokinetic 
Analy sis Set (PAS) will be used for the pharmacokinetics anal ysis.
All tables and listings will be presented b y one treatment arm of CTL019.

Novartis Confidential Page 147
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
10.1.1 Screened Set
The Screened Set compri ses all patients who have signed informed consent and screened in the 
study .
10.1.2 Enrolled Set
The enrolled set comprises all patients who are enrolled in this study . Enrollment is defined as 
the point at which the patient meets all inclusion/exclusion criteria , and the patients’ apheresis 
product is accepted for manufacturing.
10.1.3 Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all patients who received an infusion of CTL 019
10.1.4 Safety Set
The Safet y Set comprises all patients w ho received infusion of CTL 019.
10.1.5 Per-Protocol Set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with major requirements of the clinical stud y protocol (CSP).
Major protocol deviations leading to exclusion from the PPS include:
Diagnosis of disease other than DLBCL at baseline;
Missing or incomplete documentation of disease at baseline ;
In addition, patients who receive a dose less than the minimum dose of 1×108 CTL019 
transduced viable T cells will also be excluded. The detailed exclusion criteria of PPS will be 
determined and documented in the study  Report and Analy sis Plan (RAP) prior to primary 
analysis.
10.1.6 Pharmacokinetic analy sis set
The CTL019 pharmacokinetic anal ysis set (PAS) consists of patients in FAS who have at least 
one sample provi ding evaluable pharmacokinetic (PK) data. The PAS will be used for 
summaries (tables and figures) of PK data.
 
 
 
Note that patients may be removed from the estimation of certain PK parameters on an 
individual basis depending on the number of available samples. These patients will be identified 
at the time of the anal yses.

Novartis Confidential Page 148
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
10.2 Patient demographics/other bas eline characteristics
Demographic and other baseline data will be listed by  patient and/or summarized descriptivel y 
by cohort for the FAS. Categorical data will be presented as frequencies and percentages. For 
continuous data, summary statistics will be presented (i.e., mean, median, standard deviation, 
minimum, maximum).
Number and percentage of patients failing prior anti-neoplastic medications/therapies will be 
summarized.
Patients will be classified by  their prior treatment response:
Primary  refractory :Patients who have never achieved CR prior to study
Relapse without HSCT: Patients without SCT, had a CR from other therapy  and relapsed 
prior to the study
Relapse disease after prior autologous SCT
10.3 Treatments (study  treatment, concomitant therapies, 
compliance)
The total cells infused (cells) and total CTL019 transduced viable T cells infused (cells) will be 
listed and summarized by cohort using descriptive statistics. Patients will be categorized as 
below, within or above the prescribed dose range.
Prior and concomitant medications and significant non-drug therapies prior to and after the start 
of infusion will be listed by  patient and summarized by  the Anatomical Therapeutic Chemical
(ATC) term. Transfusion during the study  will be listed.  
10.4 Primary  objective
The primary  objective of the study  is to evaluate the efficacy  of CTL 019 therapy  as measured 
by overall response rate (ORR) rate, which includes complete response (CR) and partial 
response (PR) as determined by  IRC assessment in the FAS for the main cohort .
In addition, sensitivity  analysis will be performed using the local investigator response 
assessments instead of the I RC assessmen
t.
10.4.1 Variable
The primary endpoint is the ORR as determined by IRC assessment. The ORR is defined as the 
proportion of patients with a best overall disease response of CR or PR, where the best overall 
disease response is defined as the best disease response recorded from CTL019 infusion until 
progressive disease or start of new anticancer therapy , whichever comes first.
The overall response at each assessment is determined as in Table 10 -1. For time points when 
both FDG -PET and CT are available, the FDG -PET assessment overrules the CT response.

Novartis Confidential Page 149
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Table 10-1 Overall response assessment
FDG -PET based response CT-based response
CMR/CR Complete Metabolic Response 
(CMR)
(All of the following)Complete Radiologic Response 
(CR)
(Allof the following)
Index 
nodal/extranodal 
(including splenic 
and hepatic 
lesions)Score 1 or 2 with or without a 
residual mass on 5 -PS
Residual masses allowed if no 
PET-avidNodal Disease: ≤ 1.5 cm in LDi
Extranodal Disease: Absent
Non-index
(including splenic 
and hepatic 
lesions)Absent
Spleen Regress to normal
New lesions None None
Bone marrow No evidence of FDG -avid disease 
in marrow. Normal by morphology; 
if indeterminate, IHC/FLO W 
negative.Normal by morphology; if 
indeterminate, IHC/FLO W negative.
PMR/PR Partial Metabolic Response 
(PMR)
(All of the following)Partial Remission (PR)
(All of the following)
Index 
nodal/extranodal 
(including splenic 
and hepatic 
lesions)Score of 3, 4 or 5 with reduced 
uptake compared to baseline with 
respect to SUV intensity or extent. 
This may apply to the specific hot 
spot and/ or overall the subject. It is 
expected that there wil l be residual 
mass(es) present.≥ 50% decrease from baseline in SPD 
of all index lesions
Non-index
(including splenic 
and hepatic 
lesions)No increase
Spleen > 50% decrease from baseline in 
enlarged portion of spleen (value > 13 
cm)
New lesions None None
Bone marrow ●Residual uptake higher than 
uptake in normal marrow but 
reduced compared with baseline
●Persistent focal changes in the 
marrow with nodal response,Not applicable
NMR/SD No Metabolic Response
(NMR)
(All of the following)Stable Disease
(SD)
(All of the following)
Index 
nodal/extranodal 
(including splenic 
and hepatic 
lesions)Score of 3, 4 or 5 with no significant 
change in FDG uptake from 
baseline<50% decrease from baseline in SPD 
of all index lesions
No criteria for PD are met
Non-index
(including splenic 
and hepatic 
lesions)No progression

Novartis Confidential Page 150
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
FDG -PET based response CT-based response
Spleen No progression
New lesions None None
Bone marrow No change from baseline Not applicable
PMD/PD Progressive Metabolic Disease 
(PMD)
(At least one of the following)Progressive disease
(PD)
(At least one of the following)
Index 
nodal/extranodal 
(including splenic 
and hepatic 
lesions)Score of 3, 4 or 5 with increased 
uptake compared to the visually 
determined nadir with respect to 
SUV intensity or extent. This may 
apply to the specific hot spot and/ 
or overall the subject.
and/or
●New FDG -avid foci consistent 
with lymphoma
●Consider biopsy or interval scan 
if etiology of new lesions uncertainPPD Progression:
An individual node/lesion must be 
abnormal with:
●LDi > 1.5 cm AND
● Increase by >= 50% from PPD 
nadir AND
●An increase in LDi or SDi from 
nadir
● ≥ 0.5 cm for lesions ≤ 2.0 cm
● ≥ 1.0 cm for lesions > 2.0 cm
Non-index
(including splenic 
and hepatic 
lesions)Unequivocal Progression
Spleen Progression of existing splenomegaly
New or Recurrent splenomegaly
New lesions Regrowth of previously resolved 
lesions
New node > 1.5 cm in any axis
New extranodal site > 1.0 cm in any 
axis
New extranodal site < 1.0 cm in 
longest axis and 
unequivocal/attributable to lymphoma.
Any size assessable disease 
unequivocal/attributable to lymphoma
Bone marrow New/recurrent FDG -avid foci New/recurrent involvement
†PET 5PS: 1, no uptake above background; 2, uptake mediastinum; 3, uptake > mediastinum but liver; 4, 
uptake moderately > liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake 
unlikely to be related to lymphoma. SPD: Sum of the Products of Diameters; LDI: Longest transverse Diameter 
of a lesion; PPD: Product of perpendicular diame ters
A patient will have a best overall disease response of CRif they had CR as overall disease 
response for at least one of the assessments.
A patient will have a best overall disease response of PRif at least one overall response of PR 
is available (and the patient would not qualify  for CR).
A best overall disease response of SDwill be declared when at least one SD assessment is 
available at least 4 weeks after CTL019 infusion (and the patient would not qualify  for CR or 
PR).
A patient will have a best overall disease response of PDif the progressive disease was observed 
less than 14 weeks after CTL 019 infusion (and the patient does not qualify for CR, PR or SD).

Novartis Confidential Page 151
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
If a patient does not qualify  for CR, PR, SD or PD, then their best disease response will be 
Unknown (UNK).
See Section 14.1 for details of disease response criteria.
10.4.2 Statistical hy pothesis, model, and method of analy sis
The primary  efficacy  analysis will be performed by testing the null hypothesis of ORR being 
less than or equal to 20% against the alternative hypothesis that ORR is greater than 20% at 
overall one -sided 2.5% level of significance, i.e.,
H0: p ≤ 0.2 vs. H a: p>0.2
The ORR will be summarized along with the 2-sided 95% exact Clopper -Pearson confidence 
intervals. The study  will be considered successful if the lower bound of the 2 -sided 95% exact 
confidence interval for ORR is greater than 20%, so that the null hypothesis that the ORR is 
less or equal to 20% can be rejected.
The primary  efficacy  endpoint, ORR will be analyzed based on the data observed in the FAS.
10.4.3 Handling of missing values/censoring/discontinuations
Patients in this study  who are of unknown clinical response will be treated as non-responders. 
See also the Novartis guideline for efficacy  evaluation in DLBCL and FLstudies  
 (Appendix 1 ) for more details.
Other missing data are simply  noted as missing on appropriate tables/listings.
10.4.4 Supportive analy ses
The primary  analysis will also be performed on the Enrolled Set and PPS using the same 
methodology . In addition, analysis will also be performed using all patients who satisfy  all 
clinical eligibility  criteria.
10.4.4.1 Subgroup analy sis
Subgroup anal yses will be performed on the following based on the patient’s baseline status:
Age: < 40 years, ≥40 y ears to <65 y ears, ≥ 65 y ears
Gender: Male, Female
Race: Asian, Black, Caucasian, Native Ame rican, Other, Pacific Islander, Unknown
Ethnicity : Hispanic or Latino, Chinese, I ndian, Japanese, Mixed ethnicity , Other
Prior response status: Primary  refractory , relapse without SCT, relapse after SCT
IP
I at enrollment: <2 risk factors, ≥2 risk factors
Number of prior lines of anti -neoplastic therap y: ≤2 lines, 3 to4 lines, >4 lines
Stage of disease at baseline: I /II, III/ IV.
Subgroup analyses will only be performed if at least 5 
patients are present in each subgroup. 
Some grouping of classes will be cons idered if there are too few patients in some subgroups.

Novartis Confidential Page 152
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
10.5 Secondary  objectives
10.5.1 Key secondary  objective(s)
Not applicable because no formal hypothesis testing is planned other than for the primary 
objective.
10.5.2 Other secondary  efficacy  objectives
IRC assessment will be used in the main analy sis of secondary  endpoints that involve disease 
response.
10.5.2.1 Duration of overall response (DOR)
Duration of response (DOR) applies only to patients whose best overall disease response was 
CR or PR. It is defined as the time from the date of first documented disease response (CR or 
PR) to the date of first documented progression or death due to DLBCL. If a patient has not had 
an event, duration of overall response is censored at the date of the last adequate assessment.
In ca sea patient does not haveprogression or death due toDLBCL prior to data cutoff ,DOR
willbe ce
nsore d at the dat e oft he la stadeq uate assessment on or prior to the earliest censoring 
event . The censoring reason could be:
Ongoing without event
Lost to 
follow -up
Withdrew consent
New anticancer therap y (also see below for handling HSCT)
Event documented after at least two missing tumor assessments
Adequate assessments no longer available
In the main analysis of DOR, death due to reason other than DLBCL  will be considered as a 
competing risk event to other events of interest (progression or death due to DLBCL). In this 
analysis, the median response duration as well as proportion of patients without events 
following response (progression or death due to DLBC L) at 3, 6, 9, 12 months, etc. will be 
presented with 95% confidence intervals using the cumulative incidence function (CIF). 
Distribution of DOR will also be estimated using the Kaplan -Meier method in which death due 
to reason other than DLBCL  will be censored.
As HSCT is an important treatment option in responding patients, it is appropriate to consider 
the date of HSCT as censoring date, instead of censoring at the last tumor assessment date. If a 
patient received HSCT after a CR or PR, relapse or sur vival status after HSCT will be recorded 
on the corresponding follow -
up eCRFs, although data on individual disease response 
components (e.g. CT scan) will not be collected. In such cases, the date of relapse or death (if 
due to DLBCL) after HSCT will be used for the calculation of DOR as a sensitivity  anal ysis.
Distribution of DOR will be estimated using the Kaplan -Meier method and the median response 
duration as well as proportion of patients without event at 3, 6, 9, and 12 months will be 
presented along with 95% confidence interval.

Novartis Confidential Page 153
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
In addition, the DOR may  be separatel y summarized for patients with best overall response of 
CR and those with best overall response of PR.
10.5.2.2 DOR w ill be analy zed by  cohort as w ell as for all treated patients 
combined in FA S.Event free survival (EFS)
Even t freesurvival(EFS) is the time from dateoffirst CTL019 infusion to the earliest of the 
following:
Deathfrom anycause
Disease progression or re lapse
New anticancer therap y for lymphoma, excluding HSCT
Incase apatient does not have any of the above events prior to data cutoff, E FSiscenso redat
thelastadequa te response assessment date on or prior to the earliest censoring event (except 
for HSCT). The censoring reason could be
Ongoing without event
Lost to follow -up
Withdrew consent
HSCT (see below for handling of HSCT)
Event after at least two missing scheduled disease assessment
Adequate assessments no longer available
In the main analy sis of EFS, patients who proceed to HSCT after CTL019 infusion will be censored 
at the time of HSCT. In addition, a sensitivity analy sis of EFS will be performed without censoring 
for HSCT.
The distribution function of EFS will be estimated using the KM method. The median EFS 
along with 95% confidence intervals will be presented if app ropriate.
EFS will be anal yzed by cohort as well as for all treated patients combined in FAS.
10.5.2.3 Progression free survival (PFS)
Progression- free survival (PFS) is defined as the time from the date of first CTL019 infusion to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression- free survival is censored at the date of the last adequate 
assessment.
In ca sea patient does not h aveprogression or death prior to data cutoff ,PFS willbe censore d at
the dat e of the la stadeq uate assessment on or prior to the earliest censoring event . The 
censoring reason could be:
Ongoing without event
Lost to follow -
up
Withdrew consent
New anticancer therap y (see below for handling of HSCT)
Event documented after at least two missing tumor assessments
Adequate assessments no longer available

Novartis Confidential Page 154
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
In the main analy sis of PFS, patients who proceed to HSCT after CTL019 infusion will be censored 
at the time of HSCT. In addition, a sensitivity  analysis of PFS will be performed without censoring 
for HSCT.
PFS will be estimated using the Kaplan -Meier method and the median PFS as well as proportion 
of patients without event at 3, 6, 9, and 12 months will be presented along with 95% confidence 
interval.
PFS will be analy zed by  cohort as well as for all treated patients combined in FAS.
10.5.2.4 Time to response
Time to overall disease response (CR or PR) is defined as the time from the date of CTL 019 
infusion to the date of first documented disease response (CR or PR). The analysis will include 
all responders.
Time to response will be estimated using the Kaplan -Meier method and the median time to 
response will be presented along with a 95% confidence interval.
10.5.2.5 Time to response will be analy zed by cohort as well as for all treated 
patients combined in FA S.Overall survival (OS)
Overall survival (OS) is the time from date of first CTL019 infusion to date of death due to an y 
reason. If a death has not been observed by the date of analy sis cutoff, OS will be censored at 
thedate of last contact.
OS will be assessed in all patients (FAS). The distribution function of OS will be estimated 
using the Kaplan Meier (KM) method. The median OS and the proportion of patients alive at 3, 
6, 12, 18, 24, 36, 48 and 60 months with 95% co nfidence intervals will be presented.
OS will be analy zed by  cohort as well as for all treated patients combined in FAS.
10.5.2.6 Efficacy  in histological and molecular subgroups
ORR, PFS, OS, EFS, and DOR will be descriptively  summarized in histological subty pes (NOS, 
other) and molecular subty pes (GC, ABC and other).
10.5.2.7 Overall response rate in all treated patients
Overall response rate in all treated patients in FAS will be summarized along with the 95% 
confidence interval.
10.5.3 Safety  objectives
10.5.3.1 Analysis set and groupi ng for the analy ses
For all safet y analyses, the safet y set will be used, unless otherwise specified. All listings and 
tables will be presented by one treatment arm of CTL 019.
The overall observation period will be divided into three mutually  exclusive seg ments:

Novartis Confidential Page 155
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Pre-treatment period: from day  of patient’s informed consent to the day  before first 
lymphodepleting chemotherap y dose or the pre -infusion visit if the ly mphodepleting 
chemotherap y is not given.
Lym phodepleting period (note: this period only  applies to patients who received 
lymphodepleting chemotherap y): from the first day of l ymphodepleting chemotherap y
to the day  before infusion of CTL 019, for patients who received infusion, or
to the earlier of date of discontinuation and 30 days after last dose o f lymphodepleting 
chemotherap y for patients who di dn’t receive infusion of CTL 019
Post-infusion period: starting at day  of CTL019 infusion
10.5.3.2 Adverse events (A Es)
Reporting of adverse events will be based on MedDRA and CTCAE version 4.03.
Adverse events that begin or worsen after informed consent should be recorded in the patient ’
s source documents. New or worsening adverse events prior to starting study  treatment (i.e. 
lymphodepleting chemotherap y or the pre -infusion visit if the ly mphodepleting chemotherap y 
is not given per Section 6.1.1.1
) are not required to be recorded in the CRF unless it is an SAE 
meeting criteria outlined inSection 8.1.2 or SAE meeting criteria outlined inSection 8.2.2. 
Once the patient begins lymphodepleting chemotherap y or the pre-infusion visit, all new or 
worsening adverse events will be recorded in the Adverse Event CRF. Summary  tables for 
adverse events will be provided for AEs that started or worsened during the post-infusion period, 
i.e. the CTL 019
-treatment- emergent AEs. In addition, AEs that started or worsened during the 
lymphodepleting period will be summarized for all patients who received lymphodepleting 
chemotherap y.All safety  data (including those from the pre-treatment period) will be listed 
along with the period (as defined in Section 10.5.3.1 ) of the starting date of AE.
The incidence of CTL019 treatment -
emergent adverse events (new or worsening during the 
post-infusion period) will be summarized by primary  system organ class, preferred term, 
severit y (based on CTCAE grades), and relation to study  treatment. A patient with multiple 
CTC grades for an AE will be summarized under the maximum CTC grade recorded for the 
event. The frequency  of Common Toxicity  Criteria (CTC) grade 3 and 4 AEs will be 
summarized separatel y.
Deaths and serious adverse events will be listed by patient and tabulated by primary  system 
organ class and preferred term.
Adverse events of special interest (A ESI)
The current search criteria of AESI are based on limited experience from ongoing clinical 
studies without an accurate assessment of causality . AESI and the search criteria of AESI will 
be updated prior to reporting. AESI that occur within 8 weeks of the CTL019 infusion will be 
summarized by  group term and preferred term.

Novartis Confidential Page 156
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
10.5.3.3 Laboratory  abnormalities
For laboratory  tests covered by the CTCAE, the study ’s biostatistics and reporting team will 
grade laboratory  data accordingl y. For laboratory  tests covered by CTCAE, a Grade 0 will be 
assigned for all non- missing values not graded as 1 or higher. Grade 5 will not be used.
For laboratory  tests where grades arenot defined by CTCAE, results will be graded by the 
low/normal/high classifications based on laboratory  normal ranges.
The following summaries will be generated separately  for hematology  and biochemistry  and 
laboratory  tests:
shift tables using CTCAE grad es to compare baseline t o the worst post -infusion value
for laboratory  tests where CTCAE grades are not defined, shift tables using the
low/normal/high/(low and high)
All laboratory  data will be listed with valued flagged to show the corresponding CTC grades 
and the classifications relative to the laboratory  reference ranges.
 
 
10.5.3.4 Immunogenicity
Humoral immunogenicity  assessment will include evaluation of pre-existing (pre-treatment) 
and post-treatment anti-CTL 019 antibodies and to examine the incidence of immunogenicit y 
with treatment, together with antibody  titers, as a secondary  endpoint. Data may be further 
fractionated to determine proportion of patients who make transient versus sustained antibody 
responses. The assay  for humora l immunogenicity  will be a cell-based assay , detecting 
antibodies that bind to a Jurkat cell line transfected with the CTL 019 construct. This cell line 
stably  expresses the complete CTL 019 sequence and can be used to detect antibodies that bind 
to any  epitope on the extracellular domain of the protein.  
 
 
10.5.3.5 Other safety  data
Vital signs will be collected as clinically  needed. Presence of detectable RCL  will be tested by  
VSV -G at scheduled assessments in Table 7-1 and Table 7-2. All safet y data will be listed.
10.5.3.6 Safety  subgroup analysis
Key safety summaries for adverse events regardless of relationship to study drug by System, 
Organ, Class (SOC) and PT, and adverse events of special interest will be repeated on the Safet y 
Set in the following subgroups:
Age: < 40 years, ≥ 40 y ears to <65 years, ≥ 65 years
Gender: Male, Female
Race: Asian, Black, Caucasian, Native American, Other, Pacific Islander, Unknown

Novartis Confidential Page 157
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Ethnicity : Hispanic or Latin o, Chinese, I ndian, Japanese, Mixed ethnicity , Other
Prior HSCT therap y yes or no
Histological (NOS, other) and molecular subgroups (GC, ABC, other)
The objective of carry ing out these subgroup analy ses is to identify  safety  problems that are 
limited to a subgroup of patients or that are more commonly  observed in a subgroup of patients.
Summary  tables will only be performed if at least 5 patients are present in each subgroup. Some 
grouping of classes will be considered.
Summary  for AE will be separately  performed for each cohort and for all patients combined in 
safet y set.
10.5.4 Pharmacokinetics
CTL 019 concentrations in peripheral blood (and bone marrow and CSF if available) will be 
listed, graphed and summarized by  time points as assessed by  the following:
CTL 019transgene levels as measured by  q-PCR
CTL 019 transduced cells measured b y flow cy tometry  of CD3 -posit ive
 
The PK parameters listed in Table 10-2along with other relevant PK parameters will be 
estimated, if feasible, from the individual concentration versus time profiles using a non-
comp
artmental approach within the modeling program Phoenix®(Pharsight, Mountain View, 
CA) and reported by best response category .The non0- quantifiable concentrations will be 
imputed to zero for PK concentration summaries wand will not be included for estimat ion of 
PK parameters. Results reported but deemed unreliable will be flagged and excluded from the 
summaries and PK parameter derivations.
Table 10
-2 Noncompartmental pharmacokine tic parameters
Parameter Definition
AUC 0 - Tmax The AUC from time zero to T maxin peripheral blood (%*days or days*copies/ µg)
AUC Tmax -28d 
and/or AUCTmax -
84dThe AUC from time Tmax to day 28 and/or AUCTmax -84dor other disease assessment 
days, in peripheral blood (%*days or days*copies/ µg)
AUC 0 -28d 
and/or AUC0 -
84dand M3 The AUC from time zero to day 28 and/or day 84 and or other disease assessment days, 
in peripheral blood (%*days or days*copies/ µg)
Cmax The maximum (peak) observed in perip heral blood or other body fluid drug concentration 
after single dose administratio n(% or copies/ µg)
Tmax The time to reach maximum (peak) peripheral blood or other body fluid drug 
concentration after single dose administration (days)
T1/2 The half -lifeassociated with the elimination phase slope of a semi logarithmic 
concentration -time curve (days) in peripheral blood
Clast The last observed quantifiable concentration in peripheral blood (% or copies/µg)
Tlast The time of last observed quantifiable concentration in peripheral blood (days)

Novartis Confidential Page 158
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Descriptive statistics of PK parameters will be summarized by arithmetic and geometric means, 
standard deviation, CV%, CV% geometric mean minimum, median and maximum. For Tmax 
only minimum, median and maximum will be presented. PK parameters will also be 
summarized by  best overall response.
 
 
 
 
 
If there is sufficient data available additional summaries and/or model -based analy ses relating 
exposure to clinical response, CRS grade or other endpoints of interest may be considered. 
Further details will be provided in the RAP.  
 
 Population PK and/or PKPD methods including covariate anal ysis may  be utilized if 
supported by  the data, and may  be summarized in a report separate from the CSR.
 
 
Descriptive statistics of key PK parameters will be separatel y summarized for each cohort as 
well as for all treated patients in the Pharmacokinetic A nalysis Set.

Novartis Confidential Page 159
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 160
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 161
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
10.7 Interim analy sis
One interim analysis for futility  and overwhelming efficacy  is planned for the study  when 
approximately  50 patients of the planne d 80 (62.5%) in the main cohort have received CTL019 
infusion and the last patient has completed 3 months from study day 1 infusion or discontinued 
earlier. An α-spending function according to Lan -DeMets (O’Brien- Fleming), as implemented 
in EAST 6.3, will be used to construct the efficacy stopping boundary  (Lan and DeMets 1983 ). 
Based on this choice of α
-spending function, if the interim analy sis is performed with 50 
patients, the lower bound of the 2 -sided 99.08% exact confidence interval for ORR will need to 
be greater than 20% to declare statistical significance. As a result, an ORR of 19/50=38% will 
be 
needed to claim success at interim analy sis. At the final analysis when 80 patients are treated 
and followed for at least 3months, 2-sided 95.28% exact CI will be used correspondingl y, 
requiring an ORR of 24/80=30% to claim success.
The futility  stopping boundary  will be determined based on the predicted probability  of success 
at the final anal ysis. Thestudy  may be stopped for futility  if the posterior predictive probability 
of claiming success at the end of the study , i.e. observing at least 24 responders out of 80 total 
patients, is found to be smaller 
than 10% based on the data from interim analy sis.Based on a 
non-informative prior (Beta (1,1)) on the probability  of success, if less than or equal to 12 
responders are observed from 50 
patients in the interim analysis, then the Bayesian predictive 
probability  of observing at least 24 responders from 80 patients at the end of the study  will be 
less than 10%.

Novartis Confidential Page 162
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
In case the actual number of patients included in the interim anal ysis cut -off date is not exactl y 
equal to the planned 50 patients, the efficacy and futility  boundaries will be re -calculated based 
on the actual number of patients using the pre- specified α-spending function and predicted 
probability  of success criteria, respectivel y.
The above decision rules will be used by the DMC, to make recommendations to continue or 
stop the trial. The DMC will also r eview safet y data periodicall y.
The operating characteristics of certain scenarios are summarized in Table 10 -3below.
Table 10-3 Simulated scenarios for interim and final analysis
ScenarioSimulated probability  
(%) to claim success at 
interim analy sisSimulated probability  (%) to 
stop for futility  at interim 
analy sisSimulated probability  (%) to 
claim success at interim o r 
final analy sis
p=0.20 (H 0) 0.3 81.04 2.1
p=0.30 13.86 22.36 52.18
p=0.38 54.49 2.66 93.64
p=0.50 96.60 0.05 99.95
10,000 simulations were performed for each scenario using R 3.0.2.
10.8 Sample size calculation
In two retrospective studies in relapsed and refractory  DLBC L patients receiving 2nd or 3rd 
line therapies, the observed ORR were 14% and 20% ( Seshadri et al 2008 , Elstrom et al 2010). 
In arecent prospective clinical trial with ibrutinib in patients who had a median of 3 prior lines 
of therap y, the ORR in the ABC subty pe was 40% and in the GC subtype 5% leading to an 
overall ORR of 21.7% ( Wilson et al 2012
).
Based on the null hypothesis of ORR ≤ 20% and alternative hypothesis of ORR >20%, 80 
patients in the primary  analysis will provide 94% cumulative power to demonstrate statistical 
significance, using a 2-look Lan-DeMets group sequentia l design with O’Brien -Fleming type 
boundary  and an exact CI at one -sided cumulative 0.025 level of significance, if the underl ying 
ORR is 38%. I n this setting, an ORR of 24/80=30% will be needed to claim success.
Assuming approximately 20% enrolled patients will not be infused due to reasons such as 
manufactory  failure, worsening of patient’s condition, etc., at least 100 patients need to be 
enrolled in the main cohort to ensure 80 
patients are treated and hence will be used for the 
primary  analysis. At least 25 patients in each of the GC and ABC DLBCL subtypes will be 
treated in the main cohort .
10.9 Power for analy sis of key secondary  variables
Not applicable because no formal hypothesis testing is planned other than for the primary 
objective.

Novartis Confidential Page 163
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and I RB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, theinvestigator is required 
to sign a protocol signature page confirming his/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study after providing written (witnessed, where 
required b y law or regulation), I RB/IEC/REB -approved informed consent.
Informed consent must be obtained before conducting an y stud y-specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a subject’s Informed Consent was 
actuall y obtained will be captured in their CRFs.
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission tothe IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnan cy were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
Male participants must be informed that if a female partner becomes pregnant while he is 
enrolled in the study , contact with the female partner will be attempted to request her consent 
to collect pregnancy  outcome information.
11.4 Discontin uation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study  are outlined in Section 4.3.

Novartis Confidential Page 164
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
11.5 Publication of study  protocol and results
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the stud y report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
11.6 Stud y documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a Novartis -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by  applicable law, to copy ) clinical records for the purposes of 
quality  assurance reviews, audits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory  notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study  electronic case report form (eCRF) is the primary  data 
collection instrument for the study. The invest igator should ensure the accuracy, completeness, 
legibility , and timeliness of the data reported in the eCRFs and all other required reports. Data 
reported on the eCRF, that are derived from source documents, should be consistent with the 
source documents or the discrepancies should be explained. All data requested on the eCRF 
must be recorded. Any  missing data must be explained. For electronic CRFs an audit trail will 
be maintained b y the s ystem.
The investigator/institution should maintain the trial docum ents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by applicable 
regulations and/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.

Novartis Confidential Page 165
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by names 
in any documents submitted to Novartis , with the exception of information required to ensure
the chain of identit yof the CTL019 product. This may include name, date of birth, medical 
record number and donor identification number . The level of detail disclosed will follow local 
regulations . Signed informed consent forms and patient enrollment log must be kept strictly  
confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
evaluation of patients at the site - prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the study 
to request approval of a protocol deviation, as no authorized deviations are permitted. If the 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where req uired, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate actio n required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
Novartis should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. UK requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working day
s.

Novartis Confidential Page 166
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
13 References (available upon request)
Aiuti A, Biasco L, Scaramuzza S, et al (2013) Lentiviral hematopoietic stem cell gene therapy 
in patients with Wiskott -Aldrich sy ndrome. Science; 341(6148):1233151
Alizadeh AA, Eisen MB, Davis RE, et al (2000) Distinct types of diffuse large B-cell lymphoma 
identified by  gene expression profiling. Nature; 403: 503-511
Anon (2014) Adult non-hodgkin lymphoma treatment. National Cancer institute Available from: 
cancer.gov/cancertopics/pdq/treatment/adult -
non-hodgkins/HealthProfessional/page1
Anon (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The international 
non-Hodgkin’s ly mphoma pr ognostic factors project. N Engl J Med; 329(14):987 -94
Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherap y. Nature; 
411(6835): 385-389
Barrington SF, Mikhaeel NG, Kostakoglu L, et al (2014) Role of imaging in the staging and 
response assessment of lymphoma: consensus of the international conference on malignant 
lymphomas imaging working group. J Clin Oncol; pii: JCO.2013.53.5229
Bear A, Morgan R, Cornetta K, et al (2012) Replication- competent retroviruses in gene -
modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther; 
20(2):246-249
Biffi A, Bartolomae CC, Cesana D, et al (2011) Lentiviral vector common integration sites in 
preclinical models and a clinical trial reflect a benign integration bias and not oncogenic 
selection. Blood;117(20):5332-9
Biffi A, Montini E, Lorioli L, et al (2013) Lentiviral hematopoietic stem cell gene therapy 
benefits metachromatic leukody strophy . Science; 341 (6148):1233158 -1-1233158 - 11
Bonifant CL, Jackson HJ, Brentje ns RJ et al (2016) Toxicity  and management in CAR Tcell 
therap y. Mol Ther Oncolytics; 3:16011
Botzug K, Schmidt M, Schwarzer A, et al (2010) Stem -cell gene therapy  for the Wiskott-
Aldrich sy ndrome. N Engl J Med; 363(20):1918 -1827
Brentjens R, LaTouche JB, Santos E, et al (2003) Eradication of systemic B-cell tumors by 
geneticall y targeted human T lymphocy tes co-stimulated by CD80 and interleukin -15. Nat. Med; 
9:279 -286
Brentjens R, Yeh R, Bernal Y, et al (2010) Treatment of chronic lymphocy tic leukemia with
geneticall y targeted autologous T cells: case report of an unforeseen adverse event in a phase I 
clinical trial. Mol Ther; 18(4):666-668
Brentjens R, Riviere I, Park JH, et al (2011) Safety  and persistence of adoptively  transferred 
autologous CD19- targete d T cells in patients with relapsed or chemotherapy  refractory  B-cell 
leukemias. Blood; 118(18):4817-28
Cairo MS and Bishop M (2004) Tumor lysis syndrome: new therapeutic strategies and 
classification. Br J Haematol; 127(1):3 -11
Calogero A, DeLeij LFMH, Mulder N, et al (2000) Recombinant T-cell receptors: an 
immunologic link to cancer therap y. J I mmunol; 23(4):393-400

Novartis Confidential Page 167
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Cartier N, Hacein -Bey-Abina S, Bartholomae CC, et al (2009) Hematopoietic stem cell gene 
therap y with a lentiviral vector in X-linked adrenoleukody strophy . Science; 326(5954):818 -823
Cavazzana -Calvo M, Hacein -Bey-Abina S, Fischer A (2010) Ten years of gene therapy : 
thoughts and perspectives. Med Sci; 26(2):115 -118
Chan K (2007) HIV manual 2007: major opportunistic infections- progressive multifocal 
leukoencephalopath y. Available from: info.gov.hk/aids/p df/g190htm/algorithimsindex.htm
Cheson B, Pfistner B, Juweid M, et al (2007) Revised response criteria for malignant lymphoma. 
J Clin Oncol; 25(5):579-586
 
 
Clay  T, Morse M, Lyerl y HK (2002) Redirecting cytotoxic T lymphocy te responses with T-cell 
receptor transgenes. Expert Opin Biol Ther; 2(4):353-360
Cooper L, Topp M, Serrano L M, et al (2003) T -cell clones can be rendered specific for CD19: 
toward the selective augmentation of the graft -versus -B-lineage leukemia effect. Blood 
101:1637 - 1644
Davila ML, Riviere I, Wang X, et al (2014) Efficacy  and toxicity  management of 19- 28z CAR 
T cell therap y in B cell acute lymphoblastic leukemia. Sci Trans Med; 6(224):224ra25
De Velasco G, Krajewski KM, Albiges L,Awad MM, Bellmunt J,et al (2015) The 
heterogeneity  of radiologic response with anti-PD-1/PD -L1 therap y in metastatic Renal Cell 
Carcinoma (mRCC). Cancer Immunol Res. [Epub ahead of print]
Di Bisceglie AM, Lok AS, Martin P, et al (2015) Recent US Food and Drug Administration 
warnings on hepatitis B reactivation with immune -suppressing and anticancer drugs: just the 
tip of the iceberg? Hepatology  61(2):703 -11.
Donahue RE, Kessler SW, Bodine D, et al (1992) Helpe r virus induced T cell lymphoma in 
nonhuman primates after retroviral mediated gene transfer. J Exp Med; 176:1125 -1135
Dudley  M, Wunderlich J, Robbins P, et al (2002) Cancer regression and autoimmunity  in 
patients after clonal repopulation with antitumor l ymphocy tes. Science; 298:850 -854
Dudley  M, Wunderlich J, Yang J et al (2005) Adoptive cell transfer therapy  following non-
myeloablative but l ymphodepleting chemotherapy for the treatment of patients with refractory  
metastatic melanoma. J Clin Oncol; 23(10) :2346 -57
Dummer W, Niethammer AG, Baccala R, et al (2002) T cell homeostatic proliferation elicits 
effective antitumor autoimmunity . J Clin I nvest; 110(2):185-192
Elstrom RL, Martin P, Ostrow K, et al (2010) Response to second -line therap y defines the 
potential for cure in patients with recurrent diffuse large B -cell lymphoma: implications for the 
development of novel therapeutic strategies. Clin Lymphoma M yeloma Leuk; 10(3):192 -196
Eshhar Z, Waks T, Bendavid A, et al (2001) Functional expression of chimeri c receptor genes 
in human T cells. J I mmunol Methods; 248:67 -76
Fearon D and Carroll M (2000) Regulation of B lymphocy te responses to foreign and self-
antigens b y the CD19/CD21 complex. Annu Rev I mmunol; 18:393 -422

Novartis Confidential Page 168
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Finney  H, Lawson A, Bebbington C, et al (1998) Chimeric receptors providing both primary 
and costimulatory signaling in T cells from a single gene product. J I mmunol; 161:2791 -2797
Finney  H, Akbar A, Lawson A (2004) Activation of resting human primary  T cells with 
chimeric receptors: costimulatio n from CD28, inducible, costimulator, CD134 and CD137 in 
series with signals from the TCR zeta chain. J I mmunol; 172:104 -113
Friedberg JW (2011) Relapsed/refractory  diffuse large B -cell lymphoma. Hematology  AM Soc 
Hematol Educ Program. 2011:498-505
Friedma n DL, Whitton J, Leisenring W, et al (2010) Subsequent neoplasms in 5- year survivors 
of childhood cancer: the Childhood Cancer Survivor Study . J Natl Cancer Inst; 102(14):1083-
95. [Fulbright JM, Raman
Friedmann -Morvinski D, Bendavid A, Waks T, et al (2005) Redirected primary  T cells 
harboring a chimeric receptor require costimulation for their antigen -specific activation. Blood; 
105:3087-3093
Fu K, Weisenburger DD, Choi WW, et al (2008) Addition of rituximab to standard 
chemotherap y improves the survival ofboth the germinal center B-cell-like and non-germinal 
center B -cell-like subt ypes of diffuse large B
-cell ly mphoma. J Clin Oncol; 16(28):4587 -4594
Gaspar HB, Parsley  KL, Howe S, et al (2004) Gene therapy  of X-linked severe combined 
immunodeficiency  by useof a psuedoty ped gammaretroviral vector. Lancet; 364(9452):2181-
2187
Ghielmini M, Vitolo U, Kimby  E, et al (2013) ESMO guidelines consensus conference on 
malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular 
lymphoma (FL) and c hronic ly mphocy tic leukemia (CLL). Ann Oncol; 3:561 -576
Gilbert MJ (2017) Severe Neurotoxicity  in the Phase 2 Trial of JCAR015 in Adult B-ALL 
(ROCKET Study ): Analy sis of Patient, Protocol and Product Attributes. Societ y for 
Immunotherap y of Cancer's (SITC) , 32nd Annual Meeting, National Harbor MD, 08 -12 –Nov -
2017
Gisselbrecht C, Glass B, Mounier N et 
al (2010) Salvage regimens with autologous 
transplantation for relapsed large B-cell ly mphoma in the rituximab era. J Clin Oncol; 28(27): 
4184-4190
Goldrath AW , Bevan MJ (1999) Selecting and maintaining a diverse T -cell repertoire. Nature; 
402(6759):255 -
262
Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T- cell receptor chimeric 
molecules as functional receptors with antibody -type specificit y. Proc Natl Acad Sci USA; 
86(24):10024-10028
Gross G, Eshhar Z (1992) Endowing T cells with antibody  specificit y using chimeric T cell 
receptors. FASEB J; 6:3370-3378
Grupp SA, Kalos M, Barrett D, et al (2013) Chimeric antigen receptor -modified T cells for 
acute lymphoid leukemia. N Engl J Med; 368(16):1509 -1518
Hacein -Bey-Abina S, vonKalle C, Schmidt M, et al (2003) LMO2-associated clonal T cell 
proliferation in two patients after gene therap y for SCI D-X1. Science 302:415 -419

Novartis Confidential Page 169
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular 
classification of diffuse large B-cell lymphoma by immunohistochemistry  using a tissue 
microarray . Blood; 103(1):275-282
Hombach A, Heuser C, Abken H (2002) The recombinant T cell receptor strategy : insights into
structure and function of recombinant immunoreceptors on the way towards an optimal receptor 
design for cellular immunotherap y. Curr Gene Ther; 2:211 -226
Hoofnagle J (2009) Reactivation of hepatitis B. Hepatology ; 49: S156- S165
Howe SJ, Mansour MR, Schwar zwaelder K, et al (2008) Insertional mutagenesis combined 
with acquired somatic mutations causes leukemogenesis following gene therapy  of SCID-X1 
patients. J Clin I nvest; 118(9):3143 -3150
Johnston PB, Wiseman GA and Micallef IN (2008) Positron emission tom ograph y using F -18 
fluorodeox yglucose pre-and post-autologous stem cell transplant in non-Hodgkin’s lymphoma. 
Bone Marrow Transplant; 41(11):919
-925
June CH (2007) Adoptive T cell therap y for cancer in the clinic. J Clin Invest; 117(6):1466-
1476
June C, Blazar B, and Riley  J  (2009) Engineering lymphocy te subsets: tools, trials and 
tribulations. Nat Rev I mmunol; 9:705 -716
Kaech SM and Ahmed R (2001)] Memory  CD8+ T cell differentiation: initial antigen encounter 
triggers a developmental program in naïve cell s. Nat I mmunol; 2(5):415- 422
Kimura M, Yamaguchi M, Nakamura S, et al (2007) Clinicopathologic significance of loss of 
CD19 expression in diffuse large B- cell ly mphoma. Int J Hematol; 85(1):41 -8
King C, Ilic A, Koelsch K, et al (2004) Homeostatic Expansion of T Cells during Immune 
Insufficiency  Generates Autoimmunity . Cell; 117(2):265 -277
Klebanoff CA, Khong HT, Antony  PA, et al (2005) Sinks, suppressors and antigen presenters: 
how lymphodepletion enhances T cell-mediated tumor immunotherap y. Trends Immunol ; 
26(2):111-117
Kochenderfer JN, Dudley  ME, Feldman SA, et al (2012) B-cell depletion and remissions of 
malignancy  along with cytokine -associated toxicity  in a clinical trial of anti-CD19 chimeric -
antigen -receptor -transduced T cells. Blood; 119(12):2709-20
Kohn DB, Dotti G, Brentjens R (2011) CARS on track in the clinic. Mol Ther; 19(3):432 -436
Kolb HJ, Schattenberg A, Goldman JM, et al (1995) Graft -versus- leukemia effect of donor 
lymphocy te transfusions in marrow grafted patients. Blood; 86(5):2041-50
Krau se A, Guo HF, LaTouche JB, et al (1998) Antigen -dependent CD28 signaling selectivel y 
enhances survival and proliferation in genetically  modified activated human primary  T 
lymphocy tes. J Exp Med; 188(4):619-626
Lamers CH, Sleijfer S, Vulto A, et al (2006) T reatment of metastatic renal cell carcinoma with 
autologous T-lymphocy tes genetically  retargeted against carbonic anhydrase ix: first clinical 
experience. J Clin Oncol; 24(13):20e -22e
Lan KKG, Demets DL. (1983) Discrete sequential boundaries for clinical trials, Biometrika 70, 
659-63

Novartis Confidential Page 170
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Laport G, Levine B, Stadtmauer E, et al (2003) Adoptive transfer of costimulated T cells 
induces lymphocy tosis in patients with relapsed/refractory non-hodgkin lymphoma following 
CD34 (+) -selected hematopoietic cell transplanta tion. Blood; 102(6):2004 -
2013
Ledbetter J, Rabinovitch P, June C, et al (1988) Antigen- independent regulation of cytoplasmic 
calcium in b cells with a 12- kDa b -cell growth factor and anti -CD19. Proc Natl Acad Sci USA; 
85:1897-1901
Lenz G, Wright GW, Emre NC, et al (2008) Molecular subty pes of diffuse large B-cell 
lymphoma arise by  distinct genetic pathway s. Proc Natl Acad Sci USA; 105(36):13520 -13525
Levine B, Humeau L, Boyer J, et al (2006) Gene transfer in humans using a conditionally 
replicating lentivir al vector. Proc Natl Acad Sci USA; 103(46):17372-17377
Maher J, Brentjens R, Gunset G, et al (2002) Human T-lymphocy te cytotoxicity  and 
proliferation directed b y a single chimeric TCR zeta/ CD28 receptor. Nat Biotechn; 20:70-75
Maude SL, Frey N, Shaw PA, et al (2014) Chimeric antigen receptor T cells for sustained 
remissions in leukemia. N Engl J Med; 371(16)1507-17
Maurer MJ, Ghesquières H, Jais JP, et al (2014) Event -free survival at 24 months is a robust 
end point for disease -related outcome in diffuse large B-cell lymphoma treated with 
immunohistochemistry . J Clin Oncol; 32(10):1066 -1073
Maus MV, Grupp SA, Porter DL, et al (2014) Antibody -modified T cells: CARs take the front 
seat for hematologic malignancies. Blood; 123(17):2625-35
McGarrity  G, Hoyah G,Winemiller A, et al (2013) Patient monitoring and follow -up in 
lentiviral clinical trials. J Gene Med; 15(2):78 -82
Mellman I, Coukos G, and Dranoff G (2011) Cancer immunotherap y comes of age. Nature; 
480(7378):480 -9
Milone M, Fish J, Carpenito C, et al (2009) Chimeric receptors containing CD137 signal 
transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy 
in vivo. Mol Ther Nucleic Acids; 17(8):1453 -1464
Mohanlal R, Qiu Y, Zheng M et al (2016) Long -Term Safety  Follow -Up of Subjects Previously  
Treated with Non-Replicating Retroviral Vector -Based Gene Therapies. Mol Diagn Ther; 
20(6):591-602
Moller MB, Chridtensen BE, Pedersen NT (2003) Prognosis of localized diffuse large B-cell 
lymphoma in y ounger patients. Cancer; 98(3 ):516 -521
Montini E, Cesana D, Schmidt M, et al (2006) Hematopoietic stem cell gene transfer in a tumor -
prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol; 
24(6):687-696
Mullaney  BP, Pallavicini MG (2001) Protein-protein interactions in hematology  and phage 
display . Exp Hematol 29(10):1136-1146
Neelapu SS, Tummala S, Kebriaei P, et al (2018) Chimeric antigen receptor T-cell therap y -
assessment and management of toxicities. Nat Rev Clin Oncol; 15(1):47 -62
Palmer DC, Balasubramaniam S, Hanada KI, et al (2004) Vaccine -Stimulated, Adoptively 
Transferred CD8+ T Cells Traffic Indiscriminatel y and Ubiquitously  while Mediating Specific 
Tumor Destruction. J I mmunol; 173(12):7209 -7216

Novartis Confidential Page 171
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Patel A, Yapali S, Lok A (2015) Admissions for hepatitis B reactivation in patients receiving 
immunosuppressive therapy  remain unchanged from 1999 to 2014. Hepatol I nt 10(1):139 -46.
Persons DA and Baum C (2011) Solving the problem of γ-retroviral vectors containing long 
terminal repeats. Mol Ther;19(2):229-231
Perillo RP, Martin P, Lok AS (2015) Preventing hepatitis B reactivation due to 
immunosuppressive drug treatments. JAMA; 313(16):1617-1618
Pinthus JH, Waks T, Kaufman -Francis K, et al (2003) Immuno -gene therapy  of established 
prostate tumors using chimeric receptor -redirected human ly mphocy tes. Cancer Res; 63:2470 -
2476
Porter D, Levine B, Bunin N, et al (2006 )A phase 1 trial of donor lymphocy te infusions 
expanded and activated ex vivo via CD3/CD28 combination. Blood; 107(4):1325 -1331
Porter D, Levine B, Kalos M, et al (2011) Chimeric antigen receptor -modified T cells in chronic 
lymphoid leukemia. N Engl J Med; 365(8):725- 733
Pule M, Finney  H, Lawson A (2003) Artificial T- cell receptors. C ytotherapy ; 5(3):211 -226
Rapoport AP, Stadtmauer EA, Aqu i NA, et al (2005) Restoration of immunity  in ly mphopenic 
individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med; 11(11):1230-
1237
Roessig C, Scherer SP, Baer A, et al (2002) Targeting CD19 with genetically  modified EBV -
specific human T lymphocy tes. Ann Hematol; 81(2 Suppl):42S -43S
Ruella MJ, Barrett DM, Fraietta JA, et al (2018) Induction of resistance to chimeric antigen 
receptor T cell therapy  by transduction of a single leukemic B cell. Nature medicine, 24(10), 
1499–1503
Russell JA, Walley  KR, Singer J, et 
al (2008) Vasopressin versus norepinephrine infusion in 
patients with septic shock. N Engl J Med; 358(9):877 -887
Sadelain M, Riviere I, Brentjens R (2003) Targeting tumours with genetically  enhanced T 
lymphocy tes. Nat Rev Cancer ; 3:35 -45
Sant M, Allemani C, Tereanu C (2010) Incidence of hematologic malignancies in Europe by 
morphologic subt ype : results of the HAEMACARE project. Blood;116(19):3724-3734
Schambach A, Bohne J, Baum C, et al (2006) Woodchuck hepatitis virus post-transcriptional 
regulatory  element deleted from X protein and promoter sequences enhances retroviral vector 
titer and expression. Gene Ther; 13(7):641-645
Schambach A, Zychlinski D, Ehrnstroem B, et al (2013) Biosafet y features of lentiviral vectors. 
Hum Gene Ther; 24(2):132 -142
Scholler J, Brady T, Binder -Scholl G, et al (2012) Decade -Long safety  and function of 
retroviral -modified chimeric antigen receptor T cells. Sci Transl Med; 4(132ra53):1-7
Sehn L H (2012) Paramount prognostic factors that guide therapeut ic strategies in diffuse large 
B-cell ly mphoma. Hematology  Am Soc Hematol Educ Program; 2012:402-409
Serrano L, Pfeiffer T, Olivares S, et al (2006) Differentiation of naïve cord-blood T cells into 
CD19- specific cytolytic effectors for post transplantation adoptive immunotherap y. Blood; 
107(7):2643-2652

Novartis Confidential Page 172
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Seshadri T, Stakiw J, Pintilie M, et al (2008) Utility  of subsequent conventional dose 
chemotherap y in relapsed/refractory  transplant -eligible patients with diffuse large B-cell 
lymphoma failing platinum- based salvage chemotherap y. Hematology; 13(5):261 -266
Stamenkovic I and Seed B (1988) CD19, the earliest differentiation antigen of the B cell lineage, 
bears three extracellular immunoglobulin- like domains and an epstein -barr virus -related 
cytopla smic tail. J Exp Med; 168:1205 -1210
Stein S, Ott MG, Schultze- Strasser S, et al (2010) Genomic instability  and myelod ysplasia with 
monosomy  7  consequent to EVI1 activation after gene therapy  for chronic granulomatous 
disease. Nat Med; 16(2):198 -204
Sulliva n KM, Storb R, Buckner CD, et al (1989) Graft -versus- host as adoptive immunotherapy 
in patients with advanced hematologic neoplasms. N Engl J Med; 320(13):828-834
Surh CD, Sprent J (2000) Homeostatic T cell proliferation: how far can T cells be activated to 
self-ligands? J Exp Med; 192(4):F9 -F14
Tedder T, Isaacs C (1989) Isolation of cDNAs encoding the CD19 antigen of human and mouse 
B lymphocy tes. A new member of the immunoglobulin superfamily . J Immunol; 143(2):717-
717
Tey SK (2014) Adoptive T-cell therap y: adverse events and safet y switches. Clin Transl 
Immunology ; 3(6):e17
Themis M, Waddington SN, Schmidt M, et al (2005) Oncogenesis following delivery  of a 
nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther; 12(4):763 -771
Thieblemont C, Briere J, Mounier N, et al (2011) The germinal center/activated B- cell 
subclassification has a prognostic impact for response to salvage therap y in relapsed/refractory 
diffuse large B -cell l ymphoma: a bio -CORAL  study . J Clin Oncol; 29(31):4079 -87
Tilly  H, Vitolo U, Walewski J, et al (2012) Diffuse large B-cell lymphoma (DLBCL): ESMO 
clinical practice guidelines for diagnosis, treatment and follow -up. Ann Oncon 23(Suppl7):vii 
78-82
van Stipdonk MJ, Lemmens EE, and Schoenberger SP (2001) Naïve CTL s require a single brief 
period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol; 
2(5):423
-429
Wang GP, Levine BL, Binder GK, et al (2009) Analy sis of lentiviral vector integration in HIV+ 
study  patients receiving autologous infusions of gene modified CD4+ T cells. Mol Ther; 
17(5):844-850
 
Willemsen RA, Weijtens MEM, Ronteltap C, etal (2000) Grafting primary  human T 
lymphocy tes with cancer -specific chimeric single chain and two chain TCR. Gene Ther; 
7:1369 -1377
Wilson WH, Jung SH, Porcu P, et al (2012) A Cancer and Leukemia Group B multi- center 
study  of DA-EPOCH -rituximab in untreat ed diffuse large B-cell lymphoma with analysis of 
outcome by  molecular subty pe. Haematologica; 97(5):758-765

Novartis Confidential Page 173
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Wilson WH, Gerecitano JF, Goy  A, et al (2012) The Bruton’s t yrosine kinase (BTK) inhibitor, 
ibrutinib (PCI -32765), has preferential activity  in theABC subty pe of relapsed/refractory  de 
novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open -label, 
phase study . Blood;120:Abstract 686.
Zaiss AK, Son S, Chang LJ (2002) RNA 3’readthrough of oncoretrovirus and lentivirus: 
implications for vector safety and efficacy . J Virol; 76(14):7209 -7219

Novartis Confidential Page 174
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
14 Appendices

Novartis Confidential Page 175
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 176
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 177
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 178
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 179
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 180
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 181
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 182
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 183
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 184
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 185
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 186
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 187
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 188
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 189
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 190
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 191
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 192
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 193
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 194
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 195
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201

Novartis Confidential Page 196
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
14.2 Appendix 2: Eligibility  based on serologic markers for hepatitis B 
infection
Test Results
HBsAg + - - - -
HBcAb Any + + - -
HBsAb Any - + + -
Eligibility Not Eligible Not Eligible Not Eligible Eligible Eligible
HBsAg positive: Indicates active infection and/or chronic active and potential for reactivation 
with fulminant hepatitis. These patients are not eligible for this trial.
Anti -HBs positive as the only positive marker : Protective – Indicates vaccination . These 
patients are eligible for this trial.
Anti -HBc positive (with or without HBsA bpositive) : Indicates prior infection and the 
possibility  of recrudescent hepatitis B (including flare with acute liver failure). These patients 
are also at risk for viral reactivation. Thes e patients are not eligible for this trial.
14.3 Appendix 3: CTL019 modified data reporting –Treatment and 
Primary  Follow Up Phase
This guidance is used to determine whether or not an AE, SAE, Concomitant medication, or 
Laboratory  result has to be recorded in the CRF during the relevant study  period. Before using 
this guidance, the investigator should determine whether or not an adverse event is serious using 
the criteria found in the protocol Section 8, and then use the applicable row of this guidance to 
determine whether or not that event is to be recorded in the CRF.

Novartis Confidential Page 197
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
14.3.1 Adverse event (AE) and serious adverse event (S AE) reporting
Pre-treatment period
(ICF to LD chemo/pre -infusion visit)Treatment Period
(Starting from LD chemo/pre -
infusion visit)Post -treatment Period
Through Month 12 Visit After Month 12 Visit, through Month 60
Non-serious Adverse 
Events (AE)Modified:
●All infections
●All laboratory abnormalities deemed 
clinically significant by the investigator
●All clinical AEs grade ≥ 3
●All AEs related to a study procedure
●All AEs leading to study discontinuationAll, including all laboratory 
abnormalities deemed clinically 
significant by the investigatorModified –Whether serious or non -serious, report 
following:
●Events leading to death
●Related to a study procedure
●Infections
●Serious or opportunistic infections that fulfill one of 
the following criteria: Require anti -infective treatment 
OR Lead to significant disability or hospitalization OR 
Need surgical or other intervention
●New incidence or exacerbation of a pre -existing 
neurologic disorder
●New incidence or exacerbation of a prior 
rheumatologic or other autoimmune disorder
●New incidence of other hematologic disorder
●Any severe adverse event or condition the 
investigator believes may have a reasonable 
relationship to CD19 CART therapy
●Positive RCL tes t result
● Vector insertion site sequencing result with a mono-
or oligoclonality pattern or in a location near a known 
human oncogene
●New malignancy (T -cell & non T -cell), other than the 
primary malignancy
●Progressive multifocal leucoencephalopathy ( PML)
●Hepatitis B reactivationSerious Adverse 
Events (SAE)Modified:
●All events leading to death
●All events related to a study procedure
●Any AE reportable for this study period that 
also meets criteria for serious
● All pulmonary or cardiac abnorm alities
●All infections
●Any substantial change in the status of the 
patient that precludes the patient from 
proceeding to study treatment (e.g. GVHD, 
rapid progression of malignancy, marked 
decline in performance status)
●Any other substantial change i n the status 
of the patient that the investigator deems may 
have a potential impact on the patients during 
lymphodepletion and CTL019 treatmentAll

Novartis Confidential Page 198
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
14.3.2 Concomitant medication and laboratory  reporting
Pre-treatment period
(ICF to LD chemo/pre -infusion visit)Treatment Period
(Starting from LD chemo/pre -infusion visit, 
through Month 12 )Post -treatment Period
(After Month 12, through Month 60 )
Inpatient/ICU OR Outpatient Inpatient/ICU Outpatient Inpatient/ICU OR Outpatient
Concomitant 
medicationsModified:
Drugs:
Record allof the following medications:
●Corticosteroids (including prophylactically for blood product 
administrations, physiologic replacement doses, high or stress 
doses, etc.)
●Anti-seizure medications
●Allopurinol, or non -allopurinol alternatives
●Rasburicase
●Immunoglobulin therapy
●Any medication given therapeutically for an SAE
● Vasopressors and cardiac inotropic agents (see below)
● Narcotics and sedatives (see below)
●Antineopla stic therapies (e.g. lymphodepleting chemotherapy)
●Related to an AE or SAE defined as reportable for this period
Vasopressors and cardiac inotropic agents:
●For dose, record only maximum daily rate (e.g. µg/kg/hr, mg/hr, 
etc.)
Narcotics and sedatives:
●For dose, record only total daily dose
Blood products (e.g. red cells, platelets, FFP, cry oprecipitate):
●Record allblood products, including prophylaxis
Electroly te & vitamin replacement:
●Record all electrolyte replacement if given for a clinically 
significant electrolyte disturbance and list these as an adverse 
event (AE).All Modified:
●Related to an AE or SAE defined as reportable for 
this period
●Mutagenic agents (including cytot oxic drugs)
● Radiation & antineoplastic therapy (including SCT)
●Immunoglobulin therapy
● Immunosuppressive agents (including dose of 
steroids higher than physiologic replacement therapy 
doses of steroids (< 12 mg/m2/day hydrocortisone or 
equivalent)
●Investigational therapy

Novartis Confidential Page 199
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Pre-treatment period
(ICF to LD chemo/pre -infusion visit)Treatment Period
(Starting from LD chemo/pre -infusion visit, 
through Month 12 )Post -treatment Period
(After Month 12, through Month 60 )
Inpatient/ICU OR Outpatient Inpatient/ICU Outpatient Inpatient/ICU OR Outpatient
●Do notrecord prophylactic use of electrolyte or vitamin 
replacements
●Do notrecord total parenteral nutrition (TPN) on concomitant 
medication CRF
Fluids:
●Do notrecord fluid boluses and maintenance fluids
Antibiotics:
Record all antibiotics starting from day of infusion , even if given 
prophylactically
Laboratory 
dataModified:
●Record allscheduled labs (per Visit Evaluation Schedule)
●Record allresults (scheduled or unscheduled) for: LDH, Uric 
acid,  and fibrinogen (related to CRS/TLS/MAS)
●Record all other laboratory values if they are ≥ Grade 3
●For laboratory abnormalities reportable as AE/SAE, record 
laboratory results that support the event (scheduled or 
unscheduled)
● For any AE/SAE that may be caused by a laboratory 
abnormality, the laboratory value(s ) (any grade) must also be 
recorded (e.g. “muscle cramps” potentially caused by 
hypokalemia)
● Laboratory abnormalities that are not clinically significant 
and treated prophylactically are NOT to be recorded (e.g. 
maintenance electrolyte replacement, plate lets given without 
clinical bleeding)All Modified:
●Record allscheduled labs (per Visit Evaluation 
Schedule)
●Record allresults (scheduled or unscheduled) for: 
LDH, Uric acid,  and fibrinogen (related to 
CRS/TLS/MAS)
●Record all other l aboratory values if they are ≥ 
Grade 3
●For laboratory abnormalities reportable as AE/SAE, 
record laboratory results that support the event 
(scheduled or unscheduled)
● For any AE/SAE that may be caused by a 
laboratory abnormality, the laboratory value(s) (any 
grade) must also be recorded (e.g. “muscle cramps” 
potentially caused by hypokalemia)
● Laboratory abnormalities that are treated 
prophylactically are NOT to be recorded (e.g. 
maintenance electrolyte replacement, platelets 
given without clinical blee ding)

Novartis Confidential Page 200
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
14.4 Appendix 4: CTL019 modified data reporting –Secondary  Follow Up Phase
Adverse Events/ Serious Adverse Events Concomitant Medications
●New incidence or exacerbation of a pre -existing neurological disorder
●New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder
● New incidence of other hematologic disorders
● Any severe adverse event or condition the investigator believes may have a reasonable relationship to 
CTL019 therapy
●Any severe adverse event or condition that is unexpected
●Positive RCL test result
● Vector insertion site sequencing result with a mono-or oligoclonality pattern or in a location near a known 
human oncogene
●New malignancy (T -cell & non T -cell), other than primary malignancy
●Progressive multif ocal leukoencephalopathy (PML)
●Hepatitis B reactivation●Intravenous Immunoglobulin
14.5 Appendix 5 :Liver event and Laboratory trigger Definitions and Follow -up Requirements
14.5.1 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY TRIGGERS ALT or AST > 5 x ULN
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBIL > 3 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and TBIL > 2 × ULN [mainly 
conjugated fraction] without notable increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, abdomina l pain, 
nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity*
If ALT or AST abnormal at baseline .                                                                ALT or AST > 3x baseline or > 300 U/L (whichever occurs first)

Novartis Confidential Page 201
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
14.5.2 Follow Up Requirements for Liver Laboratory  Triggers - ALT, AST, TBL
ALT TBL Liver Sy mptoms Actions
ALT increase without bilirubin increase:
If normal at baseline:
ALT > 3 x ULNNormal
For participants with 
Gilbert’s syndrome: No 
change in baseline TBLNone No change to study treatment
Measure ALT, AST, ALP, GGT, TBIL, INR, albumin, CK, 
and GLDH in 48 -72 hours.
Follow -up for symptoms. If elevated at baseline:
ALT > 2 x Baseline 
or > 300 U/L (whichever occurs ﬁrst)
If normal at baseline:
ALT > 5 x ULN
for more than two
weeksNormal
For 
participants with
Gilbert’s
syndrome: No
change in
baseline TBLNoneInterrupt study drug
Measure ALT, AST, ALP, GGT, TBIL, INR, albumin, CK, 
and GLDH in 48 -72 hours.
Follow -upfor symptoms.
Initiate close monitoring and workup for competing 
etiologies.
Study drug can be restarted only if another etiology is 
identi ﬁed and liver enzymes return to baseline.If elevated at baseline:
ALT > 3 x
baseline
or > 300 U/L (whichever occurs ﬁrst) for 
more than two weeks
If normal at baseline:
ALT > 8 x ULNNormal None
ALT increase with bilirubin increase:
If normal at baseline:
ALT > 3 x ULNTBL > 2 x ULN
(or INR > 1.5) for 
participants with Gillbert’s 
syndrome: Doubling of 
direct bilirubinNone Interrupt study drug
Measure ALT, AST, ALP, GGT, TBIL, INR, albumin, CK, 
and GLDH in 48 -72 hours.
Follow -up for symptoms.If elevated at baseline:
ALT > 2 x
baseline

Novartis Confidential Page 202
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
ALT TBL Liver Sy mptoms Actions
or > 300 U/L (whichever occurs ﬁrst) Initiate close monitoring and workup for competing 
etiologies.
Study drug can be restarted only if another etiology is 
identi ﬁed and liver enzymes return to baseline.If normal at baseline:
ALT > 3 x ULNNormal or elevated Severe fatigue, 
nausea, vomiting, right 
upper quadrant pain
If elevated at baseline:
ALT > 2 x
Baseline or > 300 U/L (whichever 
occurs first).
14.6 Append ix 6: Specific Renal Alert Criteria and Actions and Event Follow -up
14.6.1 Specific Renal A lert Criteria and A ctions
Renal Event Actions
Confirmed serum creatinine increase 25 –49% Consider causes and possible interventions
Follow up within 2 -5 days
Serum creatinine increase ≥50% +
OR if <18 years old, eGFR ≤35 mL/min/1.73 m2Consider causes and possible interventions 
Repeat assessment within 24 -48 hours if possible 
Consider drug interruption or discontinuation unless other causes are diagnosed 
and corrected
Consider patient hospitalization and specialized treatment
New onset dipstick proteinuria ≥ 3+ OR
(Spot) urinary protein-creatinine ratio (PCR) ≥ 1g/g (or mg/ mmoL equivalent as 
converted by the measuring laboratory)Consider causes and possible interventions 
Assess serum albumin & serum total protein
Repeat assessment to confirm 
Consider drug interruption or dis continuation unless other causes are diagnosed 
and corrected

Novartis Confidential Page 203
Amended Protocol Version 06 (Clean) Protocol No. CCTL019C2201
Renal Event Actions
New onset hematuria ≥3+ on urine dipstick Assess & document 
Repeat assessment to confirm 
Distinguish hemoglobinuria from hematuria 
Urine sediment microscopy 
Assess serum creatinine
Exclude infection, trauma, bleeding from the distal urinary tract/bladder, 
menstruation 
Consider bleeding disorder
+Corresponds to KDIGO criteria for Acute Kidney I njury
14.6.2 Follow up of renal events
Assess, document and record in the appropriate CRF
Urine d ipstick and sediment microscopy evidence of DIN: crystals, red blood cells (dysmorphic/glomerular vs. non -dysmorphic/non -glomerular), white blood cells, 
tubular epithelial cells
Blood pressure and body weight
Serum creatinine, BUN, electrolytes (sodium, potassium, phosphate, calcium), bicarbonate and uric acid
Urine output
Review and record possible contributing factors to the renal event (co -medications, other co -morbid conditions) and additional diagnostic procedures (MRI etc.) in the 
CRF.
Monitor pat ient regularly (frequency at investigator’s discretion) until: 
Event resolution: serum creatinine within 10% of baseline or PCR <1 g/g or albumin -creatinine ratio <300 mg/g)
or
Event s tabilization: serum creatinine level with ± 10% variability over last 6 months or PCR stabilization at a new level with ± 50% variability over last 6 months
Analysis of urine markers in samples collected over the course of the renal event
